








ANTI CANCER EFFECTS OF COMBINED 
GAMMA-TOCOTRIENOL AND 13-CIS RETINOIC 










Thesis submitted to The University of Nottingham  
for the degree of Doctor of Philosophy  
 
 








High-risk neuroblastoma mainly affects young children and is known to be 
resistant to treatment (surgery and chemotherapy) which is often attributed to 
amplified MYCN. Overexpressed Bcl-2 protein is also frequently a feature of 
neuroblastoma tumours. 13-cis retinoic acid (13cRA) is used as a differentiation 
agent in the final, maintenance stage of therapy to reduce recurrence of 
malignant tumours. However, response to this treatment is still not optimal due 
to side effects and treatment failure. Gamma-tocotrienol (γT3) has been found 
to induce apoptosis in neuroblastoma cells by binding to the BH3 groove of the 
Bcl-2 protein. It has also been investigated for its synergistic effects when used 
in combination with other drugs. This study had several aims. First, to explore 
the potential for a synergistic effect of γT3 and 13cRA used in combination for 
neuroblastoma, in vitro and in vivo. The mechanism of action by which γT3 acts 
in neuroblastoma will also be investigated. We investigated the effect of γT3 
and/or 13cRA treatment on SH-SY5Y and SK-N-BE(2) cell lines and found that 
while individual treatments produced significant reduction in cell viability and 
increase in cell death, the addition of γT3 reduced the IC50 of 13cRA by more 
than half in both cell lines. Combination index values of <1 indicate that the 
combination of γT3 and 13cRA is synergistic. In the in vivo work, we found that 
the combination of γT3 and 13cRA significantly reduced tumour volume 
compared to other treatments (p≤0.05), including the specific Bcl-2 inhibitor, 
ABT-263. Annexin-FITC/PI flow cytometry showed increased population of 
apoptotic cells in the γT3 combination group in both cell lines, although it was 
not statistically significant compared to other treatment groups. Finally, protein 
expression studies were conducted using Bcl-2, Bcl-xL, MYCN, caspases-3 and 
-9 and p53. No conclusive changes were found when compared to other 
treatment groups from both in vitro and in vivo samples. In conclusion, the 
combination of γT3 and 13cRA showed significant anti-tumour effects on 
neuroblastoma, in vitro and in vivo. So, γT3 could potentially be used in 
combination with 13cRA, in a clinical setting. Further work is needed to confirm 
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Neuroblastoma is a paediatric solid tumour that originates from the neural crest 
and is divided into categories ranging from low to high risk (Cheung & Dyer, 
2013). While low-risk neuroblastoma tumours may spontaneously regress, high-
risk neuroblastoma is resistant to first line treatments (Pinto et al., 2015; Cheung 
& Dyer, 2013). Survival outcome worsens with increasing age. For example, 
stage 2 and 3 patients below 18 months of age had a statistically higher event 
free survival (EFS) than those aged 18 months or older (88% ± 1% vs. 69% ± 
3%) Another main risk factor of high-risk neuroblastoma is an increased 
expression of the MYCN gene, which is linked to treatment resistance (Cohn et 
al., 2009).  
In an attempt to reduce relapse rate in high-risk neuroblastoma treatment, 
clinicians have introduced the use of 13-cis retinoic acid (13cRA) or isotretinoin 
as a differentiation agent (Matthay et al., 2009). Initial studies showed a 3.7 year 
event-free survival rate of 29 ± 7% in high risk neuroblastoma patients receiving 
13cRA after chemotherapy compared to 11 ± 4% in patients receiving 
chemotherapy alone, p = 0.019 (Matthay et al., 1999). However, in a follow-up 
study, the 5-year event free survival rate was 42 ± 5% vs for patients who were 
given 13cRA compared to 31 ± 5% in those that were not. This difference was 
not significant (Matthay et al., 2009). Therefore, further improvements to 13cRA 
therapy in high risk neuroblastoma need to be made.  
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Another possible mechanism in the resistance of neuroblastoma tumours to 
treatment is an overexpression of Bcl-2. The Bcl-2 gene is increased in 
neuroblastoma compared to normal tissues and other cancers (Lamers et al., 
2012; Goldsmith et al., 2010). It has been suggested that the combination 
treatment of a Bcl-2 inhibitor with retinoic acid may show improvement 
compared to retinoic acid alone as a differentiation treatment (Niizuma et al., 
2006).  There are currently several synthetic Bcl-2 inhibitors available: ABT-
737, ABT-263 and ABT-199 (Oltersdorf et al., 2005; Tse et al., 2008; Souers et 
al., 2013). They have been extensively studied and shown to have high affinity 
to Bcl-2 protein, although to different degrees.   
Gamma-tocotrienol (γT3) is one of eight natural isomers of vitamin E, divided 
equally between tocotrienols and tocopherols (Aggarwal et al., 2010). 
Tocotrienols have demonstrated effects treating and preventing numerous 
disease states, including cardiovascular disease, diabetes, neurodegenerative 
diseases, bone metabolism and exposure to ionising radiation (Wong et al., 
2012b; Kulkarni et al., 2012; Singh, Beattie & Seed, 2013). While tocotrienol 
has shown effects against cancer, a precise mechanism of action has still not yet 
been confirmed for neuroblastoma, and furthermore, central nervous system 
(CNS) cancers such as neuroblastoma are vastly under-represented in literature 
concerning the anti-tumour effects of tocotrienols (Sailo et al., 2018).  
Additionally, tocotrienols have been shown to work synergistically with other 
drug treatments. Tocotrienol rich fraction and tamoxifen in MCF7 and MDA-
MB-435 breast cancer cells showed anti-proliferative and synergistic effects 
(Nesaretnam et al., 2012) and more recently, a paper published results of the 
synergistic actions of γT3 and hydroxyl-chavicol, a plant extract, on 3 different 
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grades of glioma cell lines (Abdul Rahman et al., 2014). When combined with 
jerantinine A, γT3 also demonstrated synergistic effects in the treatment of 
U87MG glioblastoma cells (Abubakar et al., 2017). The combination of γT3 and 
6-gingerol (6G) also showed a synergistic effect on HT-29 and SW837 colorectal 
cancer cell lines (CI = 0.89 ± 0.02 and CI = 0.79 ± 0.10) (Yusof et al., 2015). 
While there is still little research on the effects of tocotrienols on CNS cancers, 
a recent study has shown a novel mechanism of action of γT3 in neuroblastoma 
as a BH3 mimetic targeting the BH3 hydrophobic groove in the Bcl-2 protein 
(Tan et al., 2016). The researchers found that γT3 reduced cell viability and 
induced cell death in SH-SY5Y neuroblastoma cells. Treatment with γT3 also 
depolarised the mitochondrial membrane potential, enabling release of 
cytochrome c to the cytosol and increasing the activities of caspases-9 and -3, 
but not caspase-8. Treatment with Bax and caspase-9 inhibitors also blocked the 
effects of γT3. Finally, they showed that γT3 binds at the hydrophobic groove 
(BH3 domain) of Bcl-2 using in silico docking, while in a binding assay a shift 
in fluorescence readings showed that γT3 competed with a fluorescent probe to 
bind at the hydrophobic groove. 
There is still room for improvement in the treatment for high risk neuroblastoma 
(Peinemann et al., 2015). As suggested by Niizuma et al. (2006), an adjunct to 
the post-consolidation stage to overcome treatment resistance in high risk 
neuroblastoma that targeted Bcl-2 pro-survival proteins may enhance the action 
of the current retinoic acid used in clinical therapy, 13cRA. Furthermore, γT3 
has demonstrated synergy with other compounds, and has shown significant 
anti-proliferative effects on SH-SY5Y neuroblastoma cells as a single agent (Tan 
et al., 2016).  
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Therefore, using the study by Tan et al., (2016) as a foundation, we would like 
to further study the effects of γT3 on neuroblastoma, and it will be important to 
do so with a model that better represents high risk neuroblastoma with MYCN 
overexpression. Additionally, a known Bcl-2 inhibitor could be used to compare 
effects of γT3 both as single treatments and in combination. Finally, in order to 
best understand the effect of γT3 in a complex system, an in vivo model will be 
required. While in vitro studies give good indications of drug activity, an in vivo 
model will represent the interactions within a human body better than cell lines.  
 
1.2 HYPOTHESIS 
Based on the current, available literature, we hypothesise that γT3 has significant 
anti-tumour effects on neuroblastoma. We hypothesise that it binds to the 
hydrophobic groove of the Bcl-2 protein, initiating the intrinsic apoptosis 
cascade. Additionally, we predict that combination drug treatment will show a 
synergistic effect and show similar, although less significant anti-tumour effects 
compared to the Bcl-2 inhibitor ABT-263.  
 
1.3 AIMS & OBJECTIVES 
 
1.3.1 General aims 
To confirm that γT3 binds to the BH3 domain of the Bcl-2 protein, and whether 
that binding is able to trigger the apoptosis signalling cascade, consequently 
reducing the tumour size of a neuroblastoma ectopic xenograft in a nu/nu Nude 
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Mouse Crl/NU-Foxnlnu (albino) model. We also want to confirm if the 
combination of γT3 and 13cRA is synergistic. 
 
1.3.2 Specific objectives 
1. To determine the exact effect of γT3 on cell viability and cell death, as a 
single agent, in combination with 13cRA, and in comparison to the Bcl-
2 inhibitor, ABT-263 in normal MYCN expressing SH-SY5Y cell line 
and MYCN overexpressing SK-N-BE(2) cell line.  
2. To confirm, using flow cytometry and FITC Annexin/PI staining, if cell 
death post-treatment with γT3 is caused by apoptosis. Also to compare 
level of apoptosis (if any) between single γT3, 13cRA and ABT-262, and 
13cRA combinations with either γT3 or ABT-263.  
3. To investigate anti-tumour effects of 13cRA and γT3 as single agents or 
of 13cRA combinations with either γT3 or ABT-263 in a nude mouse 
model, and monitor tumour volume manually (callipers) and PET scan. 
4. To confirm that action of γT3 is caused by apoptosis by measuring 
protein levels of Bcl-2, Bcl-XL, caspase-3, caspase-9, and p53 in in vitro 
and in vivo samples, post-treatment.  
5. To investigate if MYCN protein expression in in vitro and in vivo 








2.1.1 General overview 
Neuroblastoma is the most common cancer diagnosed before the age of one 
(Teitz et al., 2011). In Malaysia, the disease is the fourth most common 
childhood cancer, with a rate of 4.9 per million of childhood cancer cases (Lim, 
2002) and in Singapore, a neighbouring country, the disease was fifth most 
common of childhood cancers and recorded to have an incidence of 8.8 per 
million (Tan & Ha, 2005). In the United States, neuroblastoma is the third most 
common childhood cancer (7%) (Ward et al., 2014) and it accounts for 8% of 
paediatric cancers in Japan (Nakagawara et al., 2018) and 7.7% of cases in 
Europe (Gatta et al., 2014). It is extremely rare in adults, with only ~4% of cases 
occurring ≥ 20 years of age (Esiashvili et al., 2007).  
Neuroblastoma tumours develop during embryogenesis and are thought to arise 
from a precursor cell in the neural crest committed to the sympatho-adrenal 
lineage. The neural crest is a structure that is only present in embryos, and cells 
that develop there go on to develop into multiple cell types and tissues, including, 
but not limited to, melanocytes, adrenal medulla and neurons of the peripheral 
nervous system. Primary tumours are commonly found in the paraspinal 
sympathetic ganglia (~60%) and adrenal medulla (~30%), while the remainder 
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arise from the sympathetic ganglia in the head/neck, chest and pelvis (Cheung & 
Dyer, 2013; Louis & Shohet, 2015; Maguire, Thomas & Goldstein, 2015).  
Common presenting signs and symptoms of neuroblastoma include an enlarging 
abdominal mass, pallor, fever, weight loss and bone/joint pain. Some patients 
also present with paraneoplastic syndromes such as opsoclonus-myoclonus and 
severe, chronic watery diarrhoea (Ng et al., 1999; Maguire, Thomas & 
Goldstein, 2015).  
The median age of diagnosis is approximately 18 months (Brodeur, 2003) and 
survival outcome was found to worsen with increasing age. For example, stage 
2 and 3 patients below 18 months of age had a statistically higher event free 
survival (EFS) than those aged 18 months or older (88% ± 1% vs. 69% ± 3%) 
(Cohn et al., 2009). Additionally, relative survival statistics (net survival 
measure representing cancer survival in absence of other causes of death) in a 5 
year follow up after diagnosis from the US National Cancer Institute’s 
Surveillance, Epidemiology, and End Results (SEER) programme covering the 
years between 1973 and 2002, showed 85.6% relative survival in infants (<1 
year old) compared to only 38.4% in adults (≥20 years) (Esiashvili et al., 2007).  
Unlike many cancers, neuroblastoma is rarely familial, affecting less than 1% of 
all cases (Schleiermacher, Janoueix-Lerosey & Delattre, 2014). In those rare 
cases, two genes, anaplastic lymphoma receptor tyrosine kinase (ALK) and 
paired-like homeobox 2b (PHOX2B) are associated with ~80% of cases of 
familial neuroblastoma, with the majority (~75%) of these attributed to ALK 
(Brodeur & Bagatell, 2014; Schleiermacher, Janoueix-Lerosey & Delattre, 
2014).  ALK is involved in the regulation of proliferation and differentiation of 
8 
 
the neural crest, while PHOX2B is also associated with differentiation and 
development of the autonomic neurons that arise from the neural crest (Cheung 
& Dyer, 2013). Neuroblastoma tumour formation is more likely attributed to 
somatic genetic alterations, as shown by the limited familial genetic 
predispositions. One of the most relevant genetic alterations, MYCN 
amplification, will be further discussed in Section 2.1.2.  
Like many other cancers, there are different risk stages in neuroblastoma. Some 
cases of neuroblastoma regress spontaneously with no treatment needed and 
survival rates of up to 90% in low risk neuroblastoma cases have been reported 
(Yalçin et al., 2013). However, this feature of neuroblastoma may in fact 
contribute to some under-reporting of cases in developing countries where 
extensive scanning of young children is not common (Shuangshoti et al., 2012; 
Ng et al., 1999). The majority of studies on neuroblastoma prevalence, treatment 
and outcomes have mostly been conducted in North America, Europe, Japan and 
Australia (Cohn et al., 2009).  
Unfortunately, far lower survival rates are reported in high risk neuroblastoma 
cases, with a less than 50% 5-year event-free survival rate (Cohn et al., 2009) 
and 5-year overall survival of only up to 59%, and this with the most intensive 
treatment protocol (Yalçin et al., 2013). For the purpose of this literature review, 
event-free survival can be defined as the time to the occurrence of a particular 
event, such as tumour progression, secondary tumour development, or death 
from any cause, while overall survival is the time until a patient dies from any 
cause, not only related to the cancer and treatments (Yalçin et al., 2013).   
9 
 
The following section will explore neuroblastoma stage classification in further 
detail, including the different requirements for each risk stage and a discussion 
on specific risk factors such as MYCN expression.   
 
2.1.2 Neuroblastoma classification 
According to the International Neuroblastoma Risk Group (INRG) 
classification, there are four stages of neuroblastoma; with some cases on the 
lowest end of the scale able to spontaneously regress and on the other end of the 
scale, the most aggressive form of neuroblastoma considered “high-risk”, where 
very intensive treatment is necessary (Cohn et al., 2009; National Cancer 
Institute, 2014). These four groups can be further divided into sixteen subgroups, 
determined according to a variety of diagnostic factors, such as age, 
histopathology and biology of tumour and whether or not it has metastasised. 
There are a total of six specific prognostic risk factors, with four outlined in 
Table 2.1. The other two risk factors are: histologic category and ploidy (with 
diploid increasing risk group vs hyperdiploid) (Cohn et al., 2009; Pinto et al., 
2015).  Table 2.1 is a modified version of the original INRG Consensus Pre-
treatment Classification schema, which was constructed based on analyses of 
8800 children diagnosed with neuroblastoma between 1990 and 2002 from 
North America, Australia, Europe and Japan (Cohn et al., 2009). 
One current issue with reporting the stages of neuroblastoma advancement is 
that there are classification variations due to slightly different definitions 
depending on the clinician’s risk group parameters. This can change depending 
on region (Cohn et al., 2009; Yalçin et al., 2013) as well as when the diagnosis 
10 
 
occurred, as many revisions have been made over the decades since the 
development of the Evans staging system in 1971 (Sokol & Desai, 2019).  
The INRG Staging System is the most recently defined and has slowly been 
adopted globally as the common staging system, over the International 
Neuroblastoma Staging System (INSS). However, due to the currently evolving 
nature of staging classification, and therefore changing criteria for trial inclusion, 
it is difficult to evaluate all neuroblastoma studies equally. (Park et al., 2013; 
Peinemann et al., 2015). One specific factor that has caused some issues with 
reporting is a change in cut off age from 12 months to 18 months, for inclusion 
in the high risk neuroblastoma group. So, there was possible inclusion of patients 
from what is now considered intermediate risk included in the high risk cohort, 
which distorts the data and makes it difficult for future researchers to compare 
and utilise those reports (Yalçin et al., 2013). 
However, all the different risk group parameters do agree on several risk factors. 
One of which is MYCN gene amplification being not only an indicator of high 
risk neuroblastoma, but also a general predictor of poor disease prognosis at all 
stages and a high chance of recurrence (Park et al., 2013; Cohn et al., 2009; 
International Society of Paediatric Oncology Europe Neuroblastoma, 2014). 
Anything from a quarter to a third of neuroblastoma tumours found in human 
patients are known to possess MYCN amplification (Teitz et al., 2011; Tang et 
al., 2006). As seen in INRG Stage L1 in Table 2.1, presence of MYCN 
amplification alone is sufficient to upgrade the pre-treatment risk group from 
“very low” to “high” risk.  
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Table 2.1 International Neuroblastoma Risk Group (INRG) Consensus Pre-
treatment Classification Schema, adapted from original version 
published by the INRG Task Force. Abbreviations: L1, localised 
tumour confined to one body compartment and with absence of 
image-defined risk factors (IDRF); L2, locoregional tumour with 
presence of one or more IDRFs; M, distant metastatic disease 
(except stage MS); MS, metastatic disease confined to skin, liver 
and/or bone marrow in children <18 months of age; NB, 
neuroblastoma; NA, not amplified; Amp, amplified; VL, very 
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One of the first reports regarding the significance MYCN gene amplification was 
a study of 89 patients with untreated neuroblastoma tumours (Seeger et al., 
1985). The researchers showed tumours classified as INSS Stage 4 progressed 
most quickly and overall, the results gave a strong indication that aggressiveness 
of neuroblastoma tumour progression is connected to the amplification of 
MYCN. In addition, they identified the absence of gene amplification at the 4S 
stage in the INSS classification, now a commonly known feature of INSS Stage 
4S.  
Unfortunately, directly focusing on MYCN as a treatment target has proven 
problematic due to several reasons. One reason is that Myc protein does not have 
intrinsic enzymatic activity, thus cannot be directly targeted by small molecule 
inhibitors like many other oncoproteins. Additionally, the same form of Myc is 
expressed in both normal and cancer cells (as well as other kinases associated 
with its activities), albeit in different quantities, so excessive toxicity is another 
problem with any Myc inhibitors (Fletcher & Prochownik, 2015).   
The status of 11q chromosome is another known, unfavourable biological factor 
that is taken into account when assessing the risk group of neuroblastoma at 
diagnosis (Cohn et al., 2009). Also known as 11q loss of heterozygosity (LOH), 
11q aberration has a significant correlation with advanced stage disease, where 
p = 0.042 (Guo et al., 1999). As observed in Table 2.1, the presence of an 11q 
aberration reduces the favourability of the diagnosis, such as at Stage L2, where 
presence of 11q aberration in a child <18 months elevates the risk group from 
low to intermediate, however, not to the same extent of just the presence of 
MYCN amplification elevating the risk group from very low to high at Stage L1.  
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2.1.3 Current treatments 
Treatment for neuroblastoma is generally dependent on risk category where in 
the lowest risk cases, patients can simply be monitored because the tumour may 
regress without treatment. High risk neuroblastoma, which is the focus of this 
research project, has a more complex treatment plan which can include some, if 
not all, of the following: surgery, high dose chemotherapy, stem cell rescue, 
radiotherapy, immunotherapy and finally, differentiation therapy, using cis-
retinoic acid (International Society of Paediatric Oncology Europe 
Neuroblastoma, 2014; National Cancer Institute, 2014). Figure 2.1 shows a 
summary of high risk neuroblastoma treatment.  
13-cis-retinoic acid (13cRA) is administered at a high dose, with a pulsed 
frequency (160 mg/m2/day in 2 divided doses for 14 out of every 28 days) for 
post-consolidation (maintenance) therapy in high risk neuroblastoma (Matthay 
et al., 1999). This dosing schedule was based on in vitro studies that showed that 
drug action was reliant on optimal 13cRA plasma levels, which could be 
achieved this way, while limiting dose-dependent side effects (Matthay, 2013; 





Figure 2.1 Summary of high-risk neuroblastoma treatment. COJEC-
cisplatin, vincristine, carboplatin, etoposide, cyclophosphamide; 
N7-cyclophosphamide, doxorubicin & vincristine/cisplatin & 
etoposide. (International Society of Paediatric Oncology Europe 
Neuroblastoma, 2014; Pinto et al., 2015) 
However, treatment for high-risk cases is still far from optimal, in part due to the 
intensity and multiple stages of treatment. There are numerous side effects and 
complications associated with treatment for high risk neuroblastoma, some of 
which are briefly described here – general nausea and vomiting, dose-limiting 
myelosuppression from etoposide (Paediatric Formulary Committee, 2014); in 
addition to mucositis and longer hospitalisation, busulfan/melphalan treatment 
needs close monitoring for pulmonary damage and hepatotoxicity (Park et al., 
2013); dose-limiting pain associated with anti-GD2 monoclonal antibody 
therapy (Cheung & Dyer, 2013) and dose related mucotaneous toxicity, skin 
dryness and cheilitis from 13-cis retinoic acid (Reynolds et al., 2003).  
Furthermore, many neuroblastoma patients still encounter treatment resistance. 
While improvements have been made to high risk neuroblastoma treatment over 
the last few decades, there is still a portion of patients who have a poor survival 
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either experienced disease progression or did not respond to induction 
chemotherapy. Candidates recruited for this trial were infants below one year of 
age with MYCN amplification (Canete et al., 2009).  
Clinical trials have been conducted in order to optimise high-risk neuroblastoma 
treatments. A Cochrane Review on treatment for high-risk neuroblastoma in 
children evaluated three randomised controlled trials (RCT) that focused on 
high-dose chemotherapy, also known as myeloablative therapy, and stem cell 
transplantation (Yalçin et al., 2013). In total, 739 children were studied in this 
evaluation. Unfortunately, the investigators were unable to make 
recommendations on an optimal treatment programme due to incomplete or 
statistically insignificant data. They found that while there was a statistically 
significant difference in overall survival when comparing myeloablative therapy 
to conventional chemotherapy or no treatment, there was no more statistically 
significant difference once additional follow up data was added to the analyses. 
Only the difference in event-free survival remained statistically different. The 
researchers attributed the statistical insignificance largely due to methodological 
limitations, such as the lack of standardised staging systems (i.e. parameters for 
the categorisation of risk group varied from study to study), a change in cut off 
age for high risk disease, and insufficient data.  
A similar problem emerged when Cochrane evaluated another set of high-risk 
neuroblastoma studies, this time evaluating efficacy and adverse events of 
13cRA post-consolidation therapy with high-dose chemotherapy followed by 
bone marrow transplantation, compared to placebo or no therapy for high risk 
neuroblastoma patients (Peinemann et al., 2015). The details of this review will 
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be discussed in further detail in the following Section 2.1.3.1, but in concluding 
the review, Peinemann et al. (2015) theorised that the many changes in 
treatments and risk classifications contributed to their inability to properly assess 
the significance of the treatments in trials.  
 
2.1.3.1 Retinoic acid and neuroblastoma 
Retinoic acid (RA) is a known, potent differentiation inducer for human cancer 
cells, including neuroblastoma, and in vitro, has been shown to significantly 
reduce MYCN RNA expression during active treatment and more than 60 days 
after treatment removal. There are two families of retinoic acid receptor: RA 
receptor (RAR) and retinoid X receptor (RXR), and each can be further divided 
into α, β and γ. RA binds to these receptors, and they have been found to be 
expressed in most neuroblastoma lines and primary tumours (Reynolds et al., 
2003).  
All-trans-retinoic acid (ATRA) and 13-cis-retinoic acid (13cRA) are two 
common clinically used RA isomers, although 13cRA is the isomer that is used 
in neuroblastoma post-consolidation treatment. 13cRA was found to produce 
higher drug levels than ATRA in a phase I trial, and additionally, a self-induced 
increase in rate of ATRA metabolism was found (Reynolds et al., 2003). 
Drawing on earlier work that presented the ability of retinoids, including 13cRA 
(shown in Figure 2.2), to induce differentiation in neuroblastoma cells, 
researchers demonstrated in a trial that the addition of 13cRA was beneficial to 
patients following chemotherapy or bone marrow transplantation. Of the patients 
who received 13cRA, 46 ± 6 percent had an event free survival rate 3 years post 
17 
 
randomisation versus 29 ± 5 percent of patients who did not receive 13cRA (p = 
0.027) (Matthay et al., 1999). However, in a follow-up study by the same 
research group, the 5-year event free survival rate was 42 ± 5% vs for patients 
who were given 13cRA compared to 31 ± 5% in those that were not. This 
difference was not significant (p = 0.1219) (Matthay et al., 2009). Matthay et al. 
(2009) also found an increase in 5-year overall survival when comparing 13cRA 
post-consolidation treatment to no further treatment: 50 ± 5% vs 39 ± 5%. 
Unfortunately, this was not significant (p = 0.1946).  
As mentioned in Section 2.1.3, a Cochrane Review evaluating efficacy and 
adverse events of 13cRA post-consolidation therapy with high-dose 
chemotherapy followed by bone marrow transplantation, compared to placebo 
or no therapy for high risk neuroblastoma patients, searched several electronic 
databases covering a period of nearly 70 years, trial registries, conference 
proceedings and references from recent reviews with no limit on publication year 
and language. Only one randomised controlled trial (RCT) that met all the 
parameters in the Cochrane methodology was identified: the previously 
mentioned study by Matthay et al. (2009) (Peinemann et al., 2015). The analysis 
found no statistical difference in overall survival and event-free survival between 
the groups in the RCT. While the retinoic acid group showed a higher five-year 
overall survival rate than the no further treatment group (59% vs 41%), this 
difference was also not statistically significant. The lack of statistical difference 
was attributed to a low power, and further issues such as changes in risk 





Figure 2.2 Chemical structure of 13-cis-retinoic acid (PerkinElmer 
Informatics, 2019; Hadjidaniel & Reynolds, 2010). 
 
2.1.3.2 13-cis-retinoic acid and other drugs 
It is interesting to note that while 13cRA has shown some benefit when given as 
post-consolidation therapy to eliminate residual disease, an in vitro study 
demonstrated its antagonism of cytotoxic agents commonly used in induction 
and consolidation stages of high risk neuroblastoma therapy. The study showed 
that overlapping treatment of 13cRA and cytotoxic agents used in induction 
chemotherapy for high-risk neuroblastoma treatment, such as cisplatin and 
doxorubicin, increased the expression of anti-apoptotic Bcl-2 family proteins, 
which was detrimental to the action of the cytotoxic agent. However this 
antagonistic action was considered consistent with the action of retinoic acid to 
differentiate tumour cells into mature cells, which naturally have a higher 
threshold for apoptotic death (Pinto et al., 2015; Hadjidaniel & Reynolds, 2010).  
Reassuringly, while 13cRA may have antagonistic properties when combined 
with cytotoxic agents such as cisplatin and doxorubicin, there are other agents 
that have shown synergy when used together with 13cRA in the treatment of 
cancer.  
Milanovic et al. (2015) concluded that 13cRA was synergistic when used with 
thalidomide in vitro on glioblastoma cell lines (U251 and U343) and when used 
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in vivo in subcutaneous xenografts in nude mice, caused significant tumour 
growth inhibition. Additionally, they found that the addition of thalidomide 
suppressed genes associated with treatment resistance in glioblastoma that were 
usually induced by treatment with 13cRA (IL-8, HILDPA, IGFBPA, and 
ANGPTL4). It should be noted however, that the paper did not publish 
quantitative results of synergy.  
Tolfenamic acid (TA), a small molecule non-steroidal anti-inflammatory drug, 
was found to significantly inhibit cell viability (p<0.0001) when used in 
combination with 13cRA when compared to individual treatments in an in vitro 
study using neuroblastoma cell lines (LA1-55n and SH-SY5Y), although 
synergy was only quantitatively demonstrated in SH-SY5Y cell lines (Shelake 
et al., 2015). They also found a decrease in Sp1 and survivin expression and an 
increase in apoptotic markers, Annexin-V positive cells, caspase-3 and -7 
activity, and c-PARP levels and a downregulation of Akt and ERK1/2 when 
combination treatment was used.  
The use of 13cRA in the treatment of neuroblastoma still appears to be limited. 
The same Cochrane Review researchers performed an update search two years 
after their original paper, but did not find any additional studies that met their 
criteria  (Peinemann et al., 2017). Additionally, resistance to RA treatment has 
now been observed and linked to lower 5-year overall survival rates (Waetzig et 
al., 2019).   
Nevertheless, there are some potential routes to overcome the treatment 
drawbacks. As demonstrated by Shelake et al. (2015), it could be feasible to add 
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an adjunct drug to the 13cRA post-consolidation treatment to overcome 
treatment resistance, thus enhancing treatment effectiveness.  
And although not directly studying 13cRA, Niizuma et al. (2006) found that 
treatment with the retinoic acid isomer, ATRA, slightly induced accumulation 
of anti-apoptotic Bcl-2 in a neuroblastoma cell line (NB-39-nu), which normally 
has low expression of Bcl-2. They also examined the effect of enforced 
expression of Bcl-2 in another naturally low Bcl-2-expressing neuroblastoma 
cell line (CHP134), and found that caspase-3 activated apoptosis was inhibited 
when the cells were treated with ATRA, thus rendering the treatment ineffective. 
A possible adjunct to counteract the anti-apoptotic actions of Bcl-2 may improve 
the actions of retinoic acid differentiation on cancer cells.  
We hypothesise, based on previous work completed by Tan et al. (2016), that a 
vitamin E isomer, γ-tocotrienol (γT3), might be a potential candidate for this 
adjunct treatment. Their work showed that γT3 was able to induce apoptosis in 
human neuroblastoma cells (SH-SY5Y). The study showed that apoptosis was 
induced via the intrinsic pathway due to increased caspase-9 activity in γT3-
treated cells, as well as increased cell viability when a Bax inhibitor was added. 
Furthermore, molecular docking analysis suggested that γT3 binds to the 
hydrophobic groove of Bcl-2, while a binding assay showed that γT3 competed 
with a fluorescent probe to bind at the same groove.  
The following section will discuss γ-tocotrienol and evaluate available literature 
on its background, possible mechanisms, and advantages and disadvantages.   
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2.2 VITAMIN E  
Vitamin E is the name given to a large group of natural and synthetic 
hydrophobic substances, which were first identified as “factor X”, an essential 
dietary factor for fertility in rats (Evans & Bishop, 1922). Shortly after that, the 
chemical structure and antioxidant activity of vitamin E was discovered, leading 
to research into this particular property of vitamin E which continues on till the 
present day (Zingg, 2007).  
The two naturally-occurring members of the vitamin E family are tocopherol and 
tocotrienol. They each have four isomers– α, β, γ and δ. Tocopherol and 
tocotrienol are structurally very similar and only differ in terms of saturation, 
with tocotrienols having an unsaturated isoprenoid side chain in place of the 
saturated phytyl tail on tocopherol. Additionally, tocopherols possess 3 chiral 
centres, as indicated in Figure 2.3 (Kannappan et al., 2012; Cardenas & Ghosh, 
2013). Figure 2.3 shows structural representations of all eight isomers. 
Tocopherol is far more easily and widely available than tocotrienol. It is present 
in common components of the human diet, such as vegetable oils including 
soybean, corn and sesame, as well as in nuts (Ju et al., 2010). One of the best 
sources of γT3 is the Elaeis guineensis tree, where crude palm oil is extracted 
from its fruit. Up to 800mg/kg of tocotrienols, mostly composed of  γ- and α-
tocotrienol, can be extracted from this source (Sen, Khanna & Roy, 2006). Other 
good sources of tocotrienols include rice bran oil, with about 450mg/kg (Ahsan 
et al., 2014) and cereal grains, such as oats, barley and rye, but in trace amounts 
(Theriault et al., 1999; Ju et al., 2010). Compared to tocopherol sources, 
tocotrienol sources are not widely consumed.  
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With regards to vitamin E pharmacokinetics, alpha-tocopherol transfer protein 
(α-TTP) facilitates the transport of α-tocopherol (αT) in the liver, which is then 
secreted into the blood. Mice that were α-TTP-/- consistently recorded lower 
levels of αT in organs and blood plasma than wild-type mice, both on a normal 
diet and even when fed αT supplements (Lim & Traber, 2010). In a small study 
of 10 healthy men and women, detectable concentrations of tocotrienols, 
including γT3, were found in blood plasma after supplementation with 
tocotrienol rich fraction (TRF) containing 70% tocotrienols. However, levels of 
αT were still significantly higher than that of tocotrienols (30.13 ± 2.91 μM to 





Figure 2.3 Vitamin E isoforms. Structural differences between tocopherol 
and tocotrienol; chiral centres are indicated by small arrows, and 
methyl groups on the chromonal head that determine α, β, γ and 
δ isoforms are indicated in the key as either R1 or R2. Also shown 
are the saturated tocopherol (farnesyl) and unsaturated 
tocotrienol (phytyl) tails and unsaturated bonds on phytyl tails are 
shown in blue. (PerkinElmer Informatics, 2019; Cardenas & 




Tocopherols are known to have a higher bioavailability, with higher detected 
plasma concentrations, than tocotrienols. When administered orally, tocopherols 
have both a longer circulation time and better distribution (Fu et al., 2014). Much 
of vitamin E research has focused on α-tocopherol (Cardenas & Ghosh, 2013; 
Kannappan et al., 2012); one possible reason being that α-tocopherol was the 
first vitamin E isomer recognised (Ahsan et al., 2014) and another being that it 
is more readily available than tocotrienols in common components of the human 
diet, such as vegetable oils (Ju et al., 2010). 
Unfortunately, large clinical trials in the last decade demonstrated a lack of 
significant clinical improvement influenced by tocopherol. These results have 
been compiled and reviewed in recent years (Cardenas & Ghosh, 2013; Ling et 
al., 2012).  
The SELECT (Selenium and Vitamin E Cancer Prevention Trial) clinical trial 
showed the possibility of a higher risk of prostate cancer with α-tocopherol 
instead of a reduction, as was originally hypothesised (Klein et al., 2011). The 
SELECT trial investigated the long term effects of selenium and vitamin E on 
35533 relatively healthy men in over 400 centres in the USA, Canada and Puerto 
Rico. The men were randomly assigned to control, selenium only, vitamin E (α-
tocopherol) only, both, or control groups. The trial was run over almost three 
years and the main outcome measure was prostate cancer incidence. The 
unfortunate conclusion of the SELECT trial was that dietary supplementation 
with vitamin E (α-tocopherol) significantly increased the risk of prostate cancer 
among healthy men.  
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The Women’s Health Study (WHS) showed that taking 600IU of natural source 
vitamin E (α-tocopherol) on alternate days did not give an overall benefit for 
cardiovascular disease (CVD) or cancer (Lee et al., 2005). The blinded study 
looked at nearly 40000 healthy American women aged at least 45 years old. The 
women were sorted into a vitamin E or a placebo group and the study took place 
between 1992 and 2004. Endpoints were the occurrence of a cardiovascular 
event, e.g. myocardial infarction, or the occurrence of one of the following 
cancers: breast, lung and colon. The WHS researchers concluded by cautioning 
against vitamin E supplementation for CVD or cancer prevention.  
 
2.2.2 Tocotrienol 
Contrary to tocopherol, tocotrienol has recently been found to possess more 
promising therapeutic abilities than expected, leading researchers to shift their 
focus to tocotrienol. This is despite the superior bioavailability and easy dietary 
availability of tocopherols (Theriault et al., 1999; Sen, Khanna & Roy, 2006; 
Wong & Radhakrishnan, 2012). Some studies have used tocotrienol rich 
fractions (TRFs), others used pure tocotrienol homologues, while some used 
both (Theriault et al., 1999; Sen, Khanna & Roy, 2006; Kannappan et al., 2012).  
An important consideration is that the proportions of tocotrienol homologues in 
a TRF vary depending on the batch (Fu et al., 2014) and despite their structural 
similarities, individual tocotrienol homologues may have very different targets 
and actions from each other (Nesaretnam, 2008; Kannappan et al., 2012).  
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Similar to the clinical effects, pharmacokinetics of tocotrienols are lesser studied 
than tocopherols. Both tocopherols and tocotrienols are known to be transported 
in plasma and to tissues using a tocopherol transportation protein (TTP) (Fu et 
al., 2014). However, when administered together, levels of tocopherols are 
found to be higher, due to tocopherols more successfully competing with 
tocotrienols for uptake by TTPs. An in vivo study comparing uptake of α-
tocopherol and α-tocotrienol showed decreased levels of tocotrienol when co-
administered with tocopherol compared to administration alone (Khanna et al., 
2005). The study noted that tocotrienols have an 8.5-fold less affinity to TTP 
than tocopherols. However, the same study also found that in TTP knockout 
mice, tocotrienols were found to be significantly higher in some tissues than 
tocopherols. These results lead to researchers to hypothesise a possible TTP-
independent pathway.  
Despite over two decades of increased interest in vitamin E, there has not yet 
been a clinical trial using tocotrienol on the same large scale as the SELECT or 
the WHS trials. However, there are many preclinical studies currently ongoing 
and promising data has been published, some of which may eventually lead to 
large-scale human studies. 
For example, Ghosh et al., (2009) found that γT3 acted as a radioprotector in 
CD2F1 mice, preventing radiation-induced neutropenia and thrombocytopenia. 
The mice were given subcutaneous injections of γT3 at different doses and at 
different intervals prior to irradiation. They found that 200 mg/kg, 24 hours prior 
to irradiation gave the optimum results. During the course of that investigation, 
total white blood cell (WBC) and absolute neutrophil counts (ANC) were seen 
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to increase after subcutaneous γT3 injection into mice. A further investigation 
into the effects of γT3 on the hematopoietic system showed that many cytokines 
and chemokines, such as the haematopoietic growth factors granulocyte-colony 
stimulating factor (G-CSF) and numerous interleukins, were significantly 
elevated 12 to 24 hours post γT3 dose (Kulkarni et al., 2012). These levels were 
elevated with and without radiation. The investigators concluded that the 
induction of G-CSF by γT3 might play a role in preventing radiation-induced 
neutropenia and thrombocytopenia and that there is potential for future studies 
in humans. 
Other small trials have proven promising, such as a recent Phase 2, double-blind 
randomised study investigating protective effects of palm oil vitamin E 
tocotrienols on brain white matter, that studied a cohort of 121 volunteers in 
Malaysia (Gopalan et al., 2014). The primary outcome measure was the 
regression of white matter lesion (WML) load in the brain (numbers and size) as 
WMLs can be considered indicative of increased risk of or even a subclinical 
infarct. The study concluded that mixed tocotrienols were found to reduce the 
progression of WMLs; this was based on 2 years of MRI scans and blood 
samples.  
With regards to cardioprotection, some human studies were reported in a review, 
although all were small, with most having less than 50 participants and the 
largest reported with 81 participants (Meganathan & Fu, 2016). Results were 
mixed, sometimes even contradictory and some of the major drawbacks include 
failure to report exact composition and purity of tocotrienol fractions (as most 
studies used TRFs). However, the many cardioprotective effects of tocotrienols 
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in vivo were discussed in a review (Aggarwal et al., 2010). This review evaluated 
numerous investigations and found that tocotrienols mainly work by affecting 
lipid metabolism, in particular cholesterol biosynthesis. They also demonstrate 
positive effects on blood pressure, as well as antioxidant and anti-inflammatory 
activity, which included protective effects in diabetes mellitus.  
Tocotrienols have been shown to work synergistically with other drug 
treatments. A review paper mentioned that treatment with tocotrienol rich 
fraction and tamoxifen in MCF7 and MDA-MB-435 breast cancer cells showed 
anti-proliferative and synergistic effects (Nesaretnam et al., 2012) and more 
recently, a paper published results of the synergistic actions of γT3 and hydroxyl-
chavicol, a plant extract, on glioma cell lines (Abdul Rahman et al., 2014). The 
study treated 1321N1 (Grade II), SW1783 (Grade III) and LN18 cell lines with 
single or combination treatments and found that sub-lethal combination doses 
demonstrated moderate to strong synergistic interactions in all 3 cell lines. 
Annexin FITC staining showed increased apoptosis after 24 hours combined 
treatments. Abubakar et al. (2017) also published findings regarding the 
synergistic effect of γT3, this time when combined with a natural plant product, 
jerantinine A.  Treatment of U87MG glioblastoma cells at low concentrations 
showed potent antiproliferative effects and led to a reduction on the new half 
maximal inhibitory concentration of γT3. The mechanisms of γT3 in this study 
are discussed in Section 2.2.1.1. Another study, this time on colorectal cancer, 
using the combination of γT3 and 6-gingerol (6G) showed a synergistic effect 
on HT-29 and SW837 cell lines (CI = 0.89 ± 0.02 and CI = 0.79 ± 0.10) (Yusof 




2.2.1.1 Tocotrienol targets in cancer  
As mentioned earlier, tocotrienol has been found to act on numerous molecular 
targets. As shown in Figure 2.4, there are some drugs already on the market that 
target the same targets as tocotrienols. However, while these drugs have single 
targets, tocotrienols have multiple targets. In some cases, a single target 
approach is desirable in order to reduce side effects, but at the same time, a multi-
target drug approach may be useful to overcome resistance to drug treatments 
(Ramsay et al., 2018). 
It should be noted that much of current research publications regarding effects 
of tocotrienols on cancer has focused on the most common cancers: breast 
cancer, followed by colorectal, liver, pancreatic and prostate cancer (Sailo et al., 
2018; Aggarwal et al., 2019). However, much less research has investigated the 
action of tocotrienols on other cancers. In a recent review paper discussing the 
potential of tocotrienols as cancer therapeutics, only 3 out of 133 papers 
referenced in the paper discussed cancers originating from the central nervous 









A study to investigate cytotoxicity and apoptotic activity of tocotrienol isomers 
found that α-, γ- and λ-tocotrienol inhibited growth of grade IV glioblastoma 
(U87MG) cell lines in a concentration- and time-dependent manner. The cells 
were also shown to have apoptotic morphological changes such as condensation 
of chromatin and cellular blebbing; flow cytometry later confirmed apoptosis by 
showing cell accumulation at the pre-G1 stage. Furthermore, ELISA showed that 
cytochrome c release was significantly higher in the tocotrienol-treated groups 
than untreated groups (p<0.05) and western blotting demonstrated visibly lower 
levels of Bax protein expression in treated cells than untreated cells (Lim et al., 
2014). 
A few years later, the same research group investigated the effects of combining 
lower concentrations of γ-tocotrienol with a natural plant extract (Jerantinine A) 
on the same U87MG cell line, in order to minimise toxicity of Jerantinine A. 
They concluded that the combination with Jerantinine A increased the potency 
of γ-tocotrienol to induce apoptosis and this was via the death receptor and 
mitochondrial pathways (Abubakar et al., 2017).  
In contrast, there are numerous studies regarding the effects of tocotrienols on 
breast cancer. Sailo et al. (2018) compiled evidence of tocotrienol effects on 
breast cancer, and amongst the proposed mechanisms of action are suppression 
of HMGR, ER, PI3K/Akt/mTOR, NF-κB, PARP, c-myc, COX2, cyclin D1 and 
CDK-2, -4, -6; while elevating Bcl-xL, TGF-β, Fas, and JNK. Some 
investigations showed multiple molecular targets while others only investigated 
one target.  
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Nesaretnam et al. (2004)  injected athymic nude mice with MCF-7 breast cancer 
cells and then fed mice orally with TRF for 20 weeks. After 20 weeks, there was 
a significant delay in onset, incidence and size of tumours in TRF-fed mice 
compared to controls. Additionally, a cDNA array analysis found that interferon-
inducible transmembrane protein-1 (IFITM1) gene and CD59 glycoprotein 
precursor gene, both involved in the immune system, were significantly up-
regulated, while the c-myc gene, from the family of MYC proto-oncogenes, was 
significantly downregulated in tumours from TRF-fed mice. The expression of 
c-myc is often overexpressed or aberrant in many breast cancers and this was the 
focus of an in vitro study on two breast cancer cell lines (Parajuli, Tiwari & 
Sylvester, 2015). Mouse mammary +SA epithelial cell line and human MCF-7 
mammary cancer cell lines showed anti-proliferative effects after treatment with 
γT3. The investigators also carried out western blot and qPCR and found rather 
than directly targeting c-myc, γT3 acted on targets involved in the stabilisation 
and degradation of c-myc, such as reduction in phosphorylated-c-myc-serine 62, 
increase in phosphorylated-c-myc-threonine 58 levels, reduced 
PI3K/Akt/mTOR and Ras/ MEK/Erk mitogenic signalling, cyclin D1 and cyclin-
dependent kinase 4 levels, and increased p27 levels.  
In another in vitro study, Ahmed, Alawin & Sylvester, (2016) investigated the 
suppression of the canonical Wnt/β-catenin signalling pathway, involved in cell 
proliferation and stem cell maintenance, in breast cancer cells. They found 
evidence that γT3 caused a dose-responsive inhibition of MDA-MB-231 and T-
47D cell proliferation, as well as a dose- responsive decrease in the levels of Wnt 
ligands Wnt3a and Wnt5a/b, which are usually very low in normal cells but are 
high in breast cancer cells. High levels of Wnt can ultimately lead to 
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overexpression of Wnt target genes such as c-myc, which are involved in survival 
and proliferation of cancer cells (Laezza et al., 2012). 
The effect of TRF and tamoxifen was also investigated in humans. A 5-year 
double-blinded, placebo-controlled pilot trial recruited 240 women with stage I 
or II breast cancer and gave them a daily dose of either TRF and tamoxifen or in 
the control group, placebo and tamoxifen. At the end, although there was a 60% 
reduction in risk of mortality due to breast cancer in the intervention group, this 
was not statistically significant (p = 0.27) (Nesaretnam et al., 2010).  
The action of tocotrienols on prostate cancer has also been heavily investigated. 
Yap et al. (2008) found that γT3 had the most potent anti-proliferative effect on 
prostate cancer (PCa) cells. After observing activation of pro-caspases and the 
presence of sub-G1 cell population, they found that cell death was caused by 
suppression of NF-kB, EGF-R and Id family proteins (Id1 and Id3), all pro-
survival genes. The study also indicated that γT3 was induced by the JNK-
signalling pathway, as the effects of γT3 were partially blocked by a JNK 
specific inhibitor (SP600125).  
Another study on prostate cancer also showed that γT3 suppressed the NF-κB–
mediated inflammatory pathways linked to tumorigenesis (Kunnumakkara et al., 
2010). The investigators showed that γT3 alone and in combination with 
gemcitabine had an anti-proliferative and pro-apoptotic effect on prostate cancer 
cell lines in vitro and in vivo. Treatment with γT3 on prostate cancer cell lines 
resulted in downregulation of anti-apoptotic proteins Bcl-2, cIAP-1 and survivin, 
as well as suppression of proliferative proteins cyclin D1, c-myc, and COX-2. 
MIA PaCa-2 cells were stably transfected with luciferase and orthotopically 
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implanted into male athymic nu/nu mice. Bioluminescence imaging was used to 
monitor tumour growth throughout the study and they showed that tumour 
volume in the combination group was significantly lower than individual 
treatments and control (p < 0.001). Finally, through HPLC, they also determined 
that a substantial amount of intact γT3 (94.12 ng/g) was present in tumour 






Apoptosis is a process in which cells undergo programmed cell death, in order 
to eliminate unwanted cells. Those cells may be unwanted for a variety of 
reasons, including intracellular damage, malfunctioning cells and infected cells.  
Apoptosis, or altruistic cell suicide, is a normal and important homeostatic 
mechanism in tissues of multicellular organisms. There are two commonly 
known pathways to initiate apoptosis – one is the extrinsic, the other the intrinsic. 
Figure 2.5 is a simplified summary of the two pathways, showing the various 
components involved in the process. Although both pathways end in apoptosis 






Figure 2.5 Summary of pathways to apoptosis: on the left, the intrinsic 
(mitochondrial) pathway is initiated by stressors such as cytokine 
deprivation, intracellular damage or oncogenes. On the right, the 
extrinsic (death receptor-mediated) pathway is activated by the 
binding of a death receptor ligand to a death receptor, to begin a 
cascade where caspase 8, activates the same effector caspases 
(3,6 and 7) as the intrinsic pathway; in some cells it also activates 
the intrinsic pathway via tBid (Ashkenazi et al., 2017; Czabotar 
et al., 2014; Lamers et al., 2012; Adams & Cory, 2007).  
In the intrinsic pathway, apoptosis takes place due to the activation of effector 
caspases 3, 6 and 7 by caspase 9. This happens when cytochrome c is released 
from the intermembrane space of the mitochondria during mitochondrial outer 
membrane permeabilization (MOMP), which occurs due to oligomerization of 
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Bcl-2 associated X protein (Bax) and Bcl-2 antagonist killer 1 (Bak). 
Cytochrome c then forms a complex with apoptotic protease-activating factor 1 
(APAF1) and 2’-deoxyadenosine 5’-triphosphate (dATP), which recruits and 
activates caspase 9 from procaspase 9. After that, caspase 9 activates procaspases 
3 and 7 to form caspases 3 and 7, which then cause apoptosis. Additionally, as 
cytochrome c is released from the mitochondria, so is another substance called 
second mitochondria-derived activator of caspase (SMAC). SMAC releases 
caspase 3 by inhibiting X-linked inhibitor of apoptosis (XIAP), which, when 
uninhibited, inhibits the caspases and blocks apoptotic signalling (Fesik, 2005; 
Czabotar et al., 2014; Ashkenazi et al., 2017).  
The extrinsic pathway, also seen in Figure 2.5, is activated when a death receptor 
ligand binds to a death receptor on the cell membrane, triggering the release of 
caspase 8 inside the cytoplasm, which in turn activates the same caspases 3, 6 
and 7 as mentioned in the intrinsic pathway. Caspase 8 can also affect the 
intrinsic pathway, by way of activating Bax/Bak via tBid (Fesik, 2005; Lamers 
et al., 2012; Czabotar et al., 2014).  
The tumour suppressor protein p53 is also known to activate apoptosis, as a 
response to cellular stress, including DNA damage and oncogene activation, and 
is encoded by the TP53 gene. In an unstressed state, p53 protein levels in cells 
are low, but when stressors such as DNA damage, activation of oncogenes or 
nutrient suppression occur, p53 proteins accumulates in the cell. One of the 
effects of the accumulation of p53 in cells is apoptosis.  
According to the review by Aubrey et al. (2018), p53 can influence both the 
intrinsic and extrinsic apoptosis pathways. P53 can induce apoptosis-promoting 
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factors such Bax, Bid and Apaf1 and specific death receptors. Cytoplasmic or 
mitochondrial p53 can promote the direct activation of Bax (Thornborrow et al., 
2002), neutralise pro-survival Bcl-2 proteins such as Bcl-2 (Bommer et al., 
2007), and increase concentration of death receptors (Müller et al., 1998). 
However, it is not simply accumulation of p53 that leads to apoptosis. The 
review went on to discuss further mechanisms of p53, however some of those, 
such as oligomerisation status of p53 and induction of MOMP are currently only 
proposals, and beyond the scope of this literature review.  
The TP53 gene is known to be mutated in about half of human cancers (Aubrey 
et al., 2018), and while in neuroblastoma, TP53 gene mutations are rare to 
uncommon (< 2% in primary tumours, < 15% in relapse) (Van Goethem et al., 
2017),  there is amplification and increased expression of MDM2, which results 
in increased Mdm2, a p53 inhibitor protein involved in the feedback loop that 
governs p53 accumulation (Van Maerken et al., 2009).  A study by (Van 
Goethem et al., 2017) found that co-treatment of a panel of neuroblastoma cell 
lines and orthotopic tumours with the Bcl-2 inhibitor venetoclax (discussed 
further in Section 2.3.1.1) and the Mdm2 antagonist idasanutlin showed a 
synergistic action to inhibit cell proliferation and tumour growth, and increased 
action of caspases-3 and -7, compared to individual treatments. In conclusion, 
the study demonstrated that targeting Bcl-2 and p53 (via Mdm2 antagonist) was 




2.3.1 Bcl-2 protein family 
The causes of disrupted apoptosis that can lead to cancer can be summarised into 
five main groups: impaired death receptor signalling (Fulda et al., 1998; 
Reesink-Peters et al., 2005), defects or mutations in p53 (Vikhanskaya et al., 
2007; Slatter et al., 2011; Avery-Kiejda et al., 2011), reduced expression of 
caspases (Devarajan et al., 2002; Fong et al., 2006; Shen et al., 2010), increased 
expression of inhibitor of apoptosis proteins (IAPs) (Lopes et al., 2007; Small et 
al., 2010) and disrupted balance of Bcl-2 protein members (Goolsby et al., 2005; 
Miquel et al., 2005). Other researchers have also noted that overexpression of 
Bcl-2 family proteins was a feature of many cancers (Kelly & Strasser, 2011; 
Czabotar et al., 2014).  
B-cell lymphoma 2 (BCL2) is a gene family responsible for encoding over 20 
proteins responsible for the regulation of the intrinsic apoptosis pathway 
(Ashkenazi et al., 2017). The proteins encoded by BCL2 can be grouped 
according to function: BH3-only proteins, pro-survival proteins and pro-
apoptosis proteins (Table 2.2).  
Table 2.2 Summary of selected Bcl-2 family proteins and their roles in 
programmed cell death (Czabotar et al., 2014).  






Bad, Bim, Puma, Noxa, 




Mcl-1, A1, Bcl-B 




The BH3-only proteins are pro-apoptotic and have two possible mechanisms, 
either neutralising pro-survival Bcl-2 family proteins or directly activating Bax 
and Bak, which are both pro-apoptotic proteins. A homologous BH3 region 
comprising nine amino acids is shared by the BH3 proteins and is essential for 
their actions. Different BH3-only proteins have different affinities for binding to 
Bcl-2 family pro-survival proteins – some bind selectively, such as Bad and 
Noxa, while others, such as Bim and tBid, bind to all pro-survival proteins. Bax 
and Bak are activated when intracellular steady state levels of BH3 proteins 
increase (Doerflinger, Glab & Puthalakath, 2015; Czabotar et al., 2014).   
Bcl-2 is a member of the Bcl-2 family proteins, with an anti-apoptotic role. It 
shares structural homology in the Bcl-2 homology (BH) 1, 2, 3, and 4 domains 
with the other pro-survival proteins. All 6 pro-survival proteins have similar 
structures, they are globular and comprise of a helical bundle folding to surround 
a central hydrophobic core helix. This folding forms a groove which can then 
interact with the BH3 domain of the pro-apoptotic proteins (Czabotar et al., 




Figure 2.6 Structures of anti-apoptotic Bcl-2 family members (A) and some 
of the BH3 peptide complexes formed (B). These proteins have 
two hydrophobic core α-helices surrounded by 6–7 amphipathic 
α-helices, a flexible N-terminal loop (shown with ‘N’), a C-
terminal transmembrane domain (shown with ‘C’) and a surface 
hydrophobic groove, which is the binding region for α-helical 
BH3 domains. Green indicates hydrophobic residues, while black 
brackets indicate BH3 binding grooves. Helical peptides are 
shown in pink (Bak and Bad) and blue (Bid). (Walensky, 2006).  
 
To briefly describe its actions, Bcl-2 is involved in the intrinsic pathway of 
apoptosis. Bcl-2 binds to Bax and Bak proteins in the outer mitochondrial 
membrane, and in so doing, the pore formation that would allow the release of 
caspase-activating proteins in the cytosol and that eventually leads to apoptosis 
is prevented (Lamers et al., 2012; Hata, Engelman & Faber, 2015). For more 
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detail, a review by Czabotar et al. (2014) discussed 3 models for the interactions 
between the Bcl-2 family proteins to control apoptosis. In the direct activation 
model, BH3-only proteins directly activate Bax and Bak, while pro-survival 
proteins engage the BH3-only proteins, so preventing their action. In the indirect 
model, pro-survival proteins bind to any Bax or Bak molecule that becomes 
activated (exposes its BH3 domain). Finally, in the unified model, both direct 
and indirect activation theories are combined, suggesting that pro-survival 
proteins sequester both BH3-only proteins as well as activated Bax or Bak. 
An earlier in vitro study found that BCL2 gene expression was connected with 
an ability to avoid cell death, as well as a possible avenue to develop drug 
resistance. Researchers found that increased BCL2 expression in certain cell 
lines were resistant to common cytotoxic treatments, such as cisplatin and 
etoposide (Dole et al., 1994).  
Neuroblastoma tumours are known to express higher levels of BCL2 RNA and 
Bcl-2 protein, compared to other tumours and healthy tissues (Lamers et al., 
2012; Goldsmith et al., 2012). Silencing BCL2 in neuroblastoma cell lines, 
which had high BCL2 expression, lead to apoptosis, although a cell line with 
already low BCL2 expression, SKNAS, was unaffected by the silencing (Lamers 
et al., 2012). Other studies using Bcl-2 inhibitors also showed that the level of 
BCL2 expression determines the efficacy of the Bcl-2 antagonist. ABT-737 was 
found to be most effective in vivo against Bcl-2 dependent SMS-SAN 
xenografts, compared to xenografts that were less dependent on Bcl-2 
(Goldsmith et al., 2012), while the higher drug concentrations of the Bcl-2 
inhibitor ABT-199 (venetoclax) were needed to achieve therapeutic effects in 
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cells with low BCL2 expression levels in another study (Van Goethem et al., 
2017).  
 
2.3.1.1 Drugs targeting Bcl-2 proteins 
Once the Bcl-2 protein was identified as a potential target, development of 
selective Bcl-2 antagonists, or more specifically, BH3 mimetics, began. ABT-
737, ABT-263 and ABT-199 were three such drugs to selectively target Bcl-2 
(Figure 2.7) (Oltersdorf et al., 2005; Tse et al., 2008; Souers et al., 2013). While 
small molecules targeting other members of the Bcl-2 family, such as Bcl-XL 
and Mcl-1 have been synthesised (Ashkenazi et al., 2017), this review will focus 




Figure 2.7 Chemical structures of the BH3 mimetics ABT-737, ABT-263 
and ABT-199 (PerkinElmer Informatics, 2019). 
 
ABT-737 is a small molecule inhibitor of anti-apoptotic proteins Bcl-2, Bcl-XL 
and Bcl-w. It was identified using ‘SAR by NMR’, which is a high throughput 
method to screen and identify potential of small molecules in a chemical library, 
according to protein-ligand interactions, and the most suitable chemical 
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modified and synthesised using structure-based design. However, two major 
drawbacks to this inhibitor include lack of oral formulation as well as a major 
side effect of thrombocytopenia, seen in in vivo models (Oltersdorf et al., 2005).  
ABT-263 (navitoclax) was used in this study as a known inhibitor of Bcl-2 
family proteins. It is the orally bioavailable version of ABT-737 which also has 
improved affinity to Bcl-2, thus reducing side effects such as thrombocytopenia 
as seen in in vivo studies (Tse et al., 2008). Its properties and actions have been 
tested on other cancer xenograft models, such as small cell lung cancer (SCLC) 
(Shoemaker et al., 2008) and non-Hodgkin’s lymphoma (Ackler et al., 2012). 
Additionally, ABT-263 is being investigated in several Phase I and/or Phase II 
clinical trials, both as a single agent and in combination (Delbridge et al., 2016). 
A panel of 11 SCLC in vitro and in vivo models was evaluated with ABT-263 
as a single agent. They found that the most sensitive cell lines had higher 
expression of Bcl-2 and other family member proteins such as Bcl-xL and Bim 
or lower levels of Mcl-1. They also found in that in one tumour xenograft model 
(H1048 human SCLC cell line, known to be resistant to ABT-263), after a dose 
of 100 mg/kg/day for 21days, tumour volume was significantly reduced (p < 
0.01) and comparable to treatment with etoposide. Furthermore, western blotting 
showed that Bcl-2 levels in H1048 were significantly higher compared to vehicle 
control, which is comparable to another model, H1963 (human SCLC cell line), 
which known to be highly sensitive to ABT-263.  
In xenograft models of diffuse large B-cell lymphoma (DoHH-2, SuDHL-4), 
mantle cell lymphoma (Granta 519) and Burkitt’s lymphoma (RAMOS), ABT-
263 was added to the bendamustine with or without rituximab treatment that is 
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already in use clinically (Ackler et al., 2012). The results showed that the 
combination of bendamustine and ABT-263 significantly inhibited tumour 
growth in all xenografts versus treatment alone. They concluded that addition of 
ABT-263 to bendamustine with rituximab might be a potential future 
combination strategy for treatment of non-Hodgkin’s lymphoma. 
ABT-199 (venetoclax) has been shown to be more selective to Bcl-2 than other 
members of the Bcl-2 protein family, such as Bcl-xL and Bcl-w (Ki = <0.01 nM 
compared to Ki = 48 nM and Ki = 245 nM, respectively), and binding to Mcl-1 
is not detectable. Similar to ABT-263, ABT-199 is an orally administered drug, 
but the higher degree of selectivity means that side effects, in particular 
thrombocytopenia, are only evident at much higher doses, (EC50 = 5.5 μM 
compared to EC50 = 0.083 μM with ABT-263) (Vandenberg & Cory, 2013; 
Souers et al., 2013). 
ABT-199 underwent several Phase I, II and III trials, for various lymphomas and 
leukaemia  (Delbridge et al., 2016), and between 2016 and 2019, gained 
approval from the US Food and Drug Administration for use in various types of 





Finally, an orally available Bcl-2 inhibitor called S55746 (Figure 2.8) was shown 
to be effective against a panel of non- Hodgkin lymphoma cell lines and in vivo 
in subcutaneous Acute Lymphoblastic Leukaemia (ALL) and Diffuse Large B-
Cell Lymphoma (Toledo) xenografts in SCID/beige mice, with Casara et al., 
(2018) observing apoptosis through externalization of phosphatidylserine, 
caspase-3 activation and PARP cleavage in cell lines, while caspase-3 activity 
was found to be up to 28 times higher than in vehicle control mice. Tumour 
volume was significantly lower (p < 0.05) in both xenograft models when treated 
as a single agent at the lowest doses compared to vehicle only control. 
Additionally, ex vivo results showed that apoptosis was induced in primary 
Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma patient samples. 
 




Following is a table with a summary of the four Bcl-2 inhibitors discussed above: 




Targets Other remarks References 
ABT-737 i.p. injection 
Bcl-2, Bcl-XL, 
Bcl-w, Mcl-1 
Major drawback: severe thrombocytopenia 
side effect detected in in vivo studies 





Bcl-2 (Bcl-XL & 
Bcl-w, but less 
than ABT-737), 
Mcl-1 
Design based on ABT-737; reduced side 
effects due to improved Bcl-2 infinity. 
Tested on SCLC, non-Hodgkin’s 
lymphoma. Promising in vivo results alone 
or in combination treatments. 
Tse et al. (2008); Shoemaker et al. (2008); 





Fewer side effects than ABT-263. 
Underwent Phase I, II & III trials for 
lymphomas and leukaemia. USFDA 
approval for use in leukaemias in 2019. 
Souers et al. (2013); Vandenberg & Cory 
(2013) 
S55746 oral Bcl-2 
Promising in vitro and in vivo studies for 
haematological tumour growth. 





2.4 GAMMA-TOCOTRIENOL AND SH-SY5Y  
Then et al (2009) showed that gamma-tocotrienol (γT3) in high doses (≥ 100µM) 
has a stronger pro-apoptosis tendency than alpha-tocopherol (αT) by increasing 
expression of proteins involved in the apoptosis pathway: p38 and p53 MAPK 
and reducing the Bcl-2/Bax ratio (Then et al., 2009). γT3 showed pro-apoptotic 
effects on human DS neurons instead of protective effects as originally 
predicted, however this was seen in cells that were pre-treated with γT3 and then 
exposed to hydrogen peroxide (Then et al., 2012). Later, the same research group 
used molecular docking studies and binding assays (Figure 2.9) to show that γT3 
induced apoptosis by active ligand binding to the BH3 domain of the BCL-2 
protein, which is a pro-apoptotic domain (Tan et al., 2016).   
 
Figure 2.9 Results of in silico docking (a) and binding assays (b). γT3 fits in 
the hydrophobic groove (BH3 domain) of Bcl-2 (a), while in the 
binding assay (b), the addition of γT3 caused a shift in 




Based on their findings, the researchers proposed a mechanism of action, as seen 
in Figure 2.10. As shown in Figure 2.9a, γT3 is able to bind to the pro-apoptotic 
groove of Bcl-2, allowing Bax/Bak to permeabilize the outer mitochondrial 
membrane and release cytochrome C from the mitochondrial pores. The cascade 
following that eventually leads to apoptosis. Figure 2.9b shows a shift in 
fluorescence reading when γT3 is added to Bcl-2, compared to Bcl-2 alone.  
 
 
Figure 2.10 Proposed mechanism of action of gamma-tocotrienol, based on 
the results obtained from the study by Tan et al. (2016). The γT3 
molecule competitively binds to the BH3 domain in Bcl-2, which 
can be present in higher than normal levels in neuroblastoma (and 
other cancers) and prevents apoptosis. Binding to Bcl-2 allows 
Bax/Bak to oligomerize for mitochondrial outer membrane 
permeabilization, thus leading to cytochrome c release from the 
mitochondrion, which eventually results in apoptosis. 
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As discussed in Section 2.3.1.1, Bcl-2 is a viable drug target in anticancer 
treatment. Additionally, based on the synergistic actions of the Bcl-2 inhibitor 
ABT-263, as well as tocotrienol, there is a possibility that γT3 may also enhance 
the action of 13cRA. This enhancement could lead to either dose reduction or 
increased effectiveness of the current dose. Furthermore, 13cRA has been shown 
to act synergistically with other drugs (Shelake et al., 2015; Milanovic et al., 
2015) and there is a possibility that targeting Bcl-2 may help overcome treatment 
resistance (Niizuma et al., 2006). ABT-263 has been found to work 
synergistically with all cytotoxic drugs in the neuroblastoma treatment protocol 
except cisplatin in one cell line (Lamers et al., 2012), as well as bendamustine 
and bendamustine-rituximab in haematological tumours (Ackler et al., 2012). 
Guthrie et al. (1997)mentioned that tocotrienol increased the potency of 
tamoxifen in MCF-7 breast cancer cells and more recently, a study showed 
results of the synergistic actions of γT3 and hydroxyl-chavicol, a plant extract, 
on glioma cell lines (Abdul Rahman et al., 2014).  
Therefore, based on what we know about current neuroblastoma treatments and 
their drawbacks, as well as the work done by Tan et al. (2016) to identify Bcl-2 
inhibition as a mechanism of action of γT3 in neuroblastoma, we would like to 
further investigate the potential of γT3 as an adjunct to 13cRA during the post-
consolidation stage of high-risk neuroblastoma therapy using in vitro and in vivo 
studies. As stated in the previous section, we will accomplish that with cell 
viability and cell death assays, analyse apoptosis with flow cytometry and 
Annexin-FITC/PI staining, and using a neuroblastoma nude mouse model, 
investigate anti-tumour effects of γT3. Finally, expression of relevant proteins 
will be evaluated using both in vitro and in vivo samples.   
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The experiments here can be broadly divided into in vitro and in vivo work, and 
were chosen to fulfil the aims and objectives of this research project. In vitro 
work used two neuroblastoma cell lines, SH-SY5Y and SK-N-BE(2), as they 
represent different stages of neuroblastoma, while in vivo work utilized nude 
mice with SH-SY5Y ectopic tumours.  
The aim of the in vitro study was to test whether a combination of 13-cis-retinoic 
acid (13cRA) and gamma-tocotrienol (γT3) inhibits neuroblastoma cell growth 
more effectively than individual treatments. We also wanted to confirm that cell 
death was caused by apoptosis, and to investigate the hypothesis that the Bcl-2 
protein was a target of γT3.   
To investigate the first aim, we performed cell viability and cell cytotoxicity 
assays to elucidate effective doses (IC50) of γT3 and 13cRA. We also 
investigated ABT-263 as a comparison with known Bcl-2, anti-tumour activity 
(Oltersdorf et al., 2005). We then performed the same assays on combined 
treatments to see if there was an improvement in IC50 values compared to 
individual treatments.  
In order to confirm that cell death was caused by apoptosis, we carried out flow 
cytometry with Annexin V-FITC/PI, with both individual and combined 
treatments, on both cell lines. Western blot tested expression of several proteins, 
Bcl-2, p53 and MYCN, and compared their relative expression on treated 









The aim of the in vivo study (Figures 3.2 and 3.3) was to test whether γT3 is able 
to inhibit growth of an ectopic NB xenograft alone, in comparison to 13cRA and 
also whether the combination with 13cRA has a better effect than individual 
treatments. We also wanted to determine the mechanism of action of γT3, based 
on earlier computer models that predicted that Bcl-2 was the target, using 
molecular studies such as western blot. ABT-263, a synthetic Bcl-2 inhibitor, 
also known as navitoclax, will be used as a comparison to γT3, due to extensively 
documented mechanism of action indicating a high affinity to Bcl-2, as well as 
oral route of administration. All 3 pilot studies are summarised in Figure 3.2. 
First, we wanted to optimise the tumour growth protocol, in particular number 
of cells injected, time taken for palpable tumour growth and PET scan 
parameters and workflow. That study was run concurrently with the non-tumour 
bearing drug tolerability study where we checked if drug doses and vehicles were 
tolerated by the mice. Finally, results for the first 2 parts of the pilot study were 
used to run the tumour bearing toxicity study. Tumour growth protocol was 
finalised and drug doses were deemed non-toxic to mice. A tumour bearing 
toxicity study was carried out to ensure that there were no adverse effects to 
tumour bearing test mice. Any final adjustments to the study protocol would be 
made here.   
Mice with ectopic SH-SY5Y tumours were treated with individual and combined 
treatments, and tumour size measured manually and also with positron emission 
tomography (PET) scan. Then, protein from tumours were extracted and western 
blot was used to determine and compare levels of the following proteins: Bcl-2, 








Figure 3.3 Flow chart summary of in vivo main study and western blot 
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3.2 IN VITRO EXPERIMENTS 
 
Two human neuroblastoma cell lines were chosen for this: SH-SY5Y (ATCC 
CRL-2266) and SK-N-BE(2) (ATCC CRL-2271). SH-SY5Y cells have a single 
copy of MYCN and SK-N-BE(2) have more than 100 copies, i.e. SK-N-BE(2) 
are MYCN-amplified, while SH-SY5Y are not (Baj & Tongiorgi, 2009) and so 
were chosen to represent different risk categories of clinical neuroblastoma 
(Cohn et al., 2009).     
It should also be noted that although γT3 has been shown to have apoptotic 
effects on cancer cell lines, including neuroblastoma cell lines (Tan et al., 2016), 
it was shown to only have a toxic effect on non-cancerous cells at high 
concentrations, for example on primary rat astrocytes above 200µM (Mazlan et 
al., 2006) and primary rat cerebellar neurons above 100µM (Then et al., 2009). 
The highest concentration of γT3 used in the in vitro investigations was only 
30µM.  
 
3.2.1 General cell culture 
SH-SY5Y human neuroblastoma cells (CRL-2266) were donated by our 
collaborators at the Department of Biochemistry, UKM and SK-N-BE(2) human 
neuroblastoma cells (CRL-2271) were purchased from American Type Culture 
Collection (ATCC; USA).  
Both cell lines were grown in Dulbecco’s Modified Eagle’s Medium (DMEM) 
and Ham’s F-12 (Sigma, USA) at a 1:1 ratio, supplemented with 10% fetal 
bovine serum (Sigma, USA) and 50 µg/mL gentamicin (Sigma). 2mM L-
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glutamine and 100 µg/mL non-essential amino acid (Sigma) were also added to 
the complete culture medium. Cell lines were maintained at 37°C in a humidified 
incubator supplied with 5% CO2. Medium was changed every four days, and if 
they were not used for assays, cells were passaged/split when they reached 70 to 
80% confluence.  
To detach adherent cells in T25 flasks, cells were rinsed twice with 3 mL sterile, 
1x phosphate buffered saline (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 
1.8 mM KH2PO4) (PBS) and then incubated at 37ºC for 5 minutes in 500 µL of 
2.5g/l Trypsin/1mmol/l EDTA solution (Nacalai Tesque, Japan). Then, trypsin 
was neutralised with an equal volume of complete culture medium before cells 
were pelleted using 5810R Refrigerated Centrifuge (Eppendorf, Germany) and 
supernatant removed. Subsequently, cells were resuspended in culture medium 
before either being counted and then transferred to plates or flasks.  
Cell counting was performed after cells were pelleted and then resuspended in 5 
mL culture medium. 10 µL of cell suspension was gently mixed with 40 µL 1x 
trypan blue (Nacalai Tesque, Japan) in a microcentrifuge tube (1 in 5 dilution).  
10 µL of this mixture was added to each of two chambers of a glass 
haemocytometer, under a glass coverslip, using capillary action. Cells were 
viewed using a TS100 Eclipse microscope (Nikon, Japan). Live, unstained cells 
in each quadrant of each chamber (4 x 2 chambers = 8) were counted using a 
hand tally counter and live cell estimate was calculated as below: 
 
 [(No. of cells Chamber 1 + No. of cells Chamber 2 ÷ 8) × Vol. original cell suspension
 × dilution 




For cryopreservation, cells were stored in 5% DMSO and 95% complete culture 
medium (in aliquots of 500 µL per 1.5 mL cryovial). Cells were first stored in -
20ºC for 1 hour before transfer to -80ºC overnight. Then, frozen cells were 
transferred to the liquid nitrogen tank for long term storage. To thaw frozen cells, 
cryovials containing frozen cells were retrieved from liquid nitrogen storage, 
then immediately warmed in a 37ºC water bath until almost completely thawed. 
Cells were gently mixed with a 1 mL pipette in the cryovial before transfer to 
4.5 mL warm, complete culture medium in a T25 cell culture flask. Cells were 
allowed to attach overnight, and then DMSO-containing medium was replaced 
with fresh, complete culture medium the following day.  
 
3.2.2 Preparation of test reagents 
Pure γT3 (Davos, Singapore), a highly viscous substance, was dissolved in 100% 
ethanol to make a 0.5 M stock solution, which was stored at -20 ºC. A 0.02 M 
stock solution (diluted in ethanol) was stored at 4 ºC. and the evening before 
treating cell lines with γT3, the 0.02 M stock solution was incubated overnight 
at 37 ºC together with 100% fetal bovine serum (Sigma) at a 3:4 ratio of γT3 to 
FBS. Then, γT3 was further diluted to 100 times the final concentration with 
complete culture medium containing 50% ethanol before addition to cells to 
make up the final concentration (Then et al., 2012).  
13cRA powder (Sigma, USA) was dissolved in DMSO to make a 100 mM stock 
solution, stored at -20 ºC. This was later dissolved, again in DMSO, to a 4 mM 
stock solution, stored at 4 ºC, which was subsequently diluted in complete 
culture medium.  
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ABT-263 powder (Toronto Research Chemicals Inc., Canada) was similarly 
dissolved in DMSO to make a 100 mM stock solution stored at -20 ºC, which 
was further diluted in DMSO to make a 4 mM stock solution (stored at 4 ºC) 
which was then diluted to final concentrations in complete culture medium.  
 
3.2.3 Treatment groups 
Treatment groups for the cell viability and cell cytotoxicity assays are 





Figure 3.4 Treatments for SH-SY5Y and SK-N-BE(2) cell lines (MTS and 
LDH assays) 
 
In the individual treatment stage, both cell lines were treated with a dose range, 
in order to identify the IC50. Once that value was calculated, the IC25 was 
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calculated, and added to the dose range of another treatment, to see how, or if, 
the combination was able to reduce the original IC50.  
For example, the IC50 values of γT3 and 13cRA to treat the SH-SY5Y cell line 
were identified. Then, the IC50 value of γT3 was divided to obtain the IC25, in 
order to have a sub-optimal treatment dose. This IC25 dose of γT3 was then added 
to the dose range of the 13cRA treatment, to see if the IC50 value of 13cRA 
reduced (Abubakar et al., 2017).  
 
3.2.4 Cell viability assay 
We measured cell viability using the MTS assay, which uses the tetrazolium 
compound, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium (MTS) and an electron coupling reagent, phenazine 
ethosulfate (PES). NADPH or NADH in metabolically active cells convert the 
tetrazolium compound to a soluble, purple formazan compound. The amount of 
purple formazan product is directly proportional to the number of living cells 
present and can be measured at 490 nm wavelength (Promega, 2012).  
SH-SY5Y or SK-N-BE(2) cells (2 x 104 cells per well) were seeded in a flat-
bottomed 96-well plate and allowed to grow in complete culture medium 
containing 10% FBS. After 48 hours, medium in wells was replaced with fresh 
medium containing 1% FBS and no gentamicin along with treatments as 
described in Section 3.2.3. After 24 hours’ incubation (Tan et al., 2016), cell 
viability was measured with the CellTiter 96® AQueous One Solution Cell 
Proliferation Assay (MTS) (Promega, USA). 20µL of CellTiter 96 reagent was 
added to each well and incubated in dark conditions at 37ºC for 4 hours. Then, 
absorbance at 490nm was measured using a VarioskanFlash reader (Thermo 
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Scientific, USA) and the accompanying SkanIt Software (Thermo Scientific, 
USA).  
To calculate cell viability, first, absorbance values were corrected by deducting 
background absorbance. Average absorbance of blanks (no cells, medium only, 
performed in triplicate) was deducted from all other absorbance values. Then 
percentage cell viability of sample cells was calculated as follows: 
 
Cell viability (%) =
Absorbance of treated sample
Absorbance of untreated sample
 × 100 
 
3.2.5 Cell cytotoxicity assay  
To evaluate cell death, a lactate dehydrogenase (LDH) release assay kit (Takara 
Bio Inc, Japan) was used. This assay measures LDH activity in the cell culture 
supernatant by reducing NAD+ to NADH (conversion of lactate to pyruvate 
using LDH catalysis). At the same time, diaphorase catalyst transfers H+ from 
NADH to tetrazolium salt, which then reduces to a red formazan product, which 
can be measured quantitatively with absorbance. Increase in LDH activity, 
which is released when cell membrane is damaged, is directly correlated with 
the amount of formazan product formed (Fotakis & Timbrell, 2006).   
Following treatments, as described in Section 3.2.3, as well as 2% Triton-X (high 
control), plates were spun at 140 x g for 5 minutes, then 50µL supernatant was 
carefully transferred from each well to a new 96-well plate. The transferred 
supernatant was mixed with an equal volume of reaction mixture 
(diaphorase/NAD+ and iodotetrazolium chloride/sodium lactate, 1:45 ratio) and 
then this mixture was incubated at room temperature in dark conditions. After 
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30 minutes, absorbance at 490 nm and 610 nm was measured, again, using the 
Varioskan Flash reader and SkanIt Software.  
Average absorbance values (n=3) were calculated and then percentage 
cytotoxicity was calculated as below, using the other absorbance values: 
Cytotoxicity (%) =
exp. value − no treatment control
TritonX value − no treatment control
× 100 
 
3.2.6 Combination Index analysis 
There are several ways to investigate the pharmacological interactions between 
drug combinations, including isobologram, which is a graphical representation, 
and combination index (CI), which is a quantitative representation (Wali & 
Sylvester, 2007). Here, we have decided to use CI, the quantitative 
representation.  
The combination index (CI) value indicates whether the combined treatment is 
synergistic (CI = <1), antagonistic (CI = >1) or additive (CI = 1), and CI can be 
worked out using the following equation: 
Combination index (CI) = dx/Dx + dy/Dy 
Where dx = IC50 of compound X in combination, Dx = IC50 of compound X alone, 
dy = IC50 of compound Y in combination, Dy = IC50 of compound Y alone (Chou, 
2006).  
We determined the effect of combining treatments with the CI method. First, 
IC50 values of individual and combination treatments were determined using 
non-linear regression curve fit analysis on GraphPad Prism 7.03 Software 
(GraphPad Software Inc., USA), using results obtained from the cell viability 
assay (section 3.2.4). Then, these IC50 values were analysed with CompuSyn 
software (Chou, 2006) to calculate the CI of each drug combination, in order to 
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quantitatively measure the pharmacological interaction between combined 
treatments.  
 
3.2.7 Flow cytometry 
Annexin V-FITC was used to detect and quantify apoptosis in SH-SY5Y and 
SK-N-BE(2) cells after undergoing treatment. Annexin V is a protein which 
binds preferentially to phosphatidylserine (PS). PS is one of the phospholipids 
present on the inner surface of the plasma membrane, and is only exposed to the 
external cellular environment in events such as early apoptosis, where it 
translocates to the outer layer, or in late apoptosis or necrosis, where the 
membrane loses integrity and Annexin V can bind to PS still located on the inner 
surface. Labelling Annexin V with a fluorochrome such as fluorescein 
isothiocyanate (FITC) allows its detection and thus, quantification by the flow 
cytometer (Koopman et al., 1994; Wilkins et al., 2002). Propidium iodide (PI) 
is also used in this assay, to differentiate between early and late 
apoptosis/necrosis, as PI is excluded by viable cells (with intact cell membrane), 
while the membranes of dead cells or those in late apoptosis are permeable to PI, 
thus allowing staining of nucleic acids that resulted from DNA degradation 
(Riccardi & Nicoletti, 2006). Cells that are viable are both Annexin V and PI 
negative, while cells in early apoptosis are Annexin V positive, but PI negative. 
Cells in late apoptosis or necrosis are both Annexin V and PI positive.  
SH-SY5Y or SK-N-BE(2) cells were cultured in 6-well plates, with 3.2 x 105 
cells per well, in 10% FBS-containing cell culture medium. Two wells were used 
for each treatment group. Cells were allowed to grow for 48 hours before 
medium was discarded and each well rinsed once with 300 μL warm PBS. 
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Treatments were added in 1% FBS-containing cell culture medium according to 
the following groups in Table 3.1.  
 
Table 3.1:  Flow cytometry treatment groups 















SH-SY5Y - 15 8.5 19.5 8.5 + 15 
19.5  
+ 15 
       






Following a 24-hour exposure to treatments, medium from wells were 
transferred to 15 mL falcon tubes. Wells were rinsed with 300 μL warm PBS 
and then cells detached as per section 3.2.1, except that 250 μL trypsin was used 
instead of 500 μL. After trypsin was neutralised, cells were transferred to the 
aforementioned falcon tubes containing the corresponding supernatant, and then 
cells were centrifuged at 350 x g for 5 minutes, room temperature. Supernatant 
was discarded and pellet was resuspended in fresh, room temperature PBS and 
then centrifuged again using previous settings. Supernatant was discarded again 
and then pellet was resuspended in 5 mL room temperature PBS. Cells were then 
filtered using a 40 μm cell strainer (Corning, USA) to ensure a uniform, single 
cell suspension and then cells were counted, as per section 3.2.1. After cells were 
counted, they were diluted in cold (4ºC) PBS to a concentration of 1 x 107 
cells/mL, for each treatment group.   
Cells were then immediately stained using the FITC Annexin V Apoptosis 
Detection Kit I (BD Pharmingen, USA), according to the manufacturer’s 
protocol. Cells were washed twice in cold PBS and then resuspended in 1X 
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Binding Buffer, containing 0.1 M Hepes/NaOH (pH7.4), 1.4 M NaCl, 25 mM 
CaCl2, (component no. 51-66121E, provided in kit) to a concentration of 1 x 106 
cells/mL. From this, 100 μL (1 x 105 cells) was transferred to a 1.5 mL Eppendorf 
tube. Three more Eppendorf tubes, each containing 100 μL solution, were 
prepared as controls for compensation controls and quadrants.  
In the first tube, 5 μL of FITC Annexin V (component no. 51-65874X, provided 
in kit) and 5 μL Propidium Iodide, PI (component no. 51-66211E, provided in 
kit) was added, the tube gently vortexed and incubated for 15 minutes at room 
temperature in the dark. For each treatment group the controls for compensation 
used were: unstained cells, cells stained with FITC Annexin V only (no PI), and 
cells stained with PI only (no FITC Annexin V). Nothing further was added to 
the second tube, 5 μL FITC Annexin V was added to the third tube and 5 μL was 
added to the fourth tube. After incubation, 400 μL of 1X Binding Buffer was 
added to each tube, and then samples were analysed using the BD Accuri C6 
Flow Cytometer and the BD Accuri Software (BD Biosciences, USA).  
 
3.2.8 Western blot 
3.2.8.1 Cell culture 
SH-SY5Y or SK-N-BE(2) cells (1.67 x 106 ) were seeded in T25 flasks and 
allowed to grow for 48 hours in 10% FBS-containing cell culture medium, as 
described in section 3.2.1. After 48 hours, medium in wells was replaced with 
fresh medium containing 1% FBS and no gentamicin along with same treatment 
doses, as described in Table 3.1. Cells were exposed to drug treatments (and no 
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treatment control) for 24 hours, and then protein was extracted for use in western 
blot, as described in section 3.2.8.2. 
 
3.2.8.2 Protein extraction and quantification for cell lines 
After 24 hours treatment, cells in T25 flasks were transferred to 15 mL falcon 
tubes and centrifuged at 130 x g, 4°C for 5 minutes. Supernatant was discarded, 
and then pellets washed in 5 mL ice cold PBS and centrifuged again, at 2500 x 
g, 4°C for 5 minutes. Supernatant was again discarded and washed for the last 
time in 5 mL ice cold PBS and centrifuged as before.  
After the final wash, supernatant was removed and the cell pellet was 
resuspended in 50 μL of cold radioimmunoprecipitation assay (RIPA) buffer, 
containing 10μL/mL each of Halt Protease and Phosphatase Inhibitor Cocktail 
100X and 0.5M EDTA (Thermo Scientific, USA). Cell lysate was then 
transferred to a 1.5 mL tube and kept on ice for 30 minutes, vortexing 
occasionally. After that, samples were centrifuged at 14000 x g, 4°C for 15 
minutes. Supernatant containing total protein lysates was then transferred to a 
fresh 1.5 mL tube and stored at -80°C.  
Protein quantification was performed using Bradford reagent (Sigma, USA). A 
protein standard was made using bovine serum albumin (BSA) (Affymetrix, 
USA) diluted in ultrapure water. The stock concentration was 1mg/mL, and this 
was further diluted to the following concentrations: 0.05, 0.1, 0.2, 0.4, 0.6 and 
0.8 mg/mL. 5 μL of each protein standard concentration was added in triplicate 
to 250 μL Bradford reagent (as per manufacturer instructions). RIPA buffer was 
diluted 1:1 in ultrapure water and 5 μL of this was used, again in triplicate as 
previously described, to compensate for background in protein samples. 
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Absorbance of blank (ultrapure water only) samples were also used to 
compensate for background readings. 1 μL of each protein sample was added to 
4 μL ultrapure water, to make 5 μL sample for use with Bradford reagent. Each 
sample was tested in triplicate. Protein quantification was carried out in 96 well 
plates and after addition of samples and Bradford reagent, absorbance was 
measured using a plate reader (BioTek Instruments, USA) using 595 nm 
wavelength.  
 
3.2.8.3 SDS-Page and Western Blotting 
Expression levels of proteins involved in apoptosis signalling were studied with 
both in vitro and in vivo samples. For in vitro samples, proteins studied were: 
Bcl-2, p53, and MYCN. β-actin was used as a loading control.  
After determination of total protein concentration (Section 3.2.8.2), samples 
containing 20 μg of total protein was heated for 5 minutes at 95°C together with 
4X sample-loading buffer (240 mM Tris-HCl pH 6.8, 8% w/v SDS, 40% v/v 
glycerol, 0.04% bromophenol blue, 5% w/v 2-mercaptoethanol) in a 3:1 ratio, 
and then cooled before being loaded into 12% SDS-polyacrylamide gels (Table 
3.2). To monitor protein migration and band separation, BLUeye Prestained 
Protein Ladder (GeneDireX, Taiwan) was also loaded in one well on each gel. 











Ultrapure water 1.28 mL 700 μL 
30% acrylamide/bis-acrylamide (29:1) 
solution 
1.6 mL 170 μL 
1.5 M Tris-HCl, pH 8.8 1.04 mL - 
1.0 M Tris-HCl, pH 6.8 - 130 μL 
10 % SDS 40 μL 10 μL 
10 % APS 40 μL 10 μL 
TEMED 1.6 μL 1 μL 
Total volume 4 mL 1 mL 
 
Gels and filter pads (Bio-Rad, USA) were soaked in Bjerrum-Schafer-Nielsen 
buffer (For 1 L: 48 mM Tris, 39 mM glycine, 10% methanol, 1.3 mM SDS) for 
15 minutes. Polyvinylidene fluoride (PVDF) membranes (Membrane Solutions, 
USA) were soaked in methanol for 1 minute, rinsed in ultrapure water for 5 
minutes, and then soaked in cold Bjerrum-Schafer-Nielsen buffer for 10 minutes. 
A semi-dry blotting system, the Pierce G2 Fast Blotter (Thermo Scientific, USA) 
was used to transfer proteins from gel to PVDF membrane. Gels, filter pads and 
PVDF membranes were stacked on the Fast Blotter, which was run for 50 
minutes, at 10 V, 1.0 A.  
Following protein transfer to PVDF membrane, membranes were soaked in the 
rapidly reversible protein stain, Ponceau S solution (0.1% w/v Ponceau S in 5% 
acetic acid, ultrapure water), for 1 minute, to detect presence and location of 
bands, in order to check protein transfer. Membranes were then rinsed in 
ultrapure water several times to remove pink Ponceau S stain.  
For detection of desired bands, membranes were blocked with 5% BSA 
dissolved in Tris-buffered saline, TBS (15.2 mM Tris-HCl, 4.6 mM Tris base, 
150.6 mM NaCl) for 1 hour at room temperature, then washed in TBST (TBS, 
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0.1 % Tween-20) for 5 minutes, three times and incubated overnight with 
primary antibody, diluted at a 1:1000 ratio in 5% BSA/TBST (see Table 3.3 for 
full list and details) at 4°C, with gentle agitation. Primary antibody dilution ratios 
were determined using the manufacturer’s recommended ratio of 1:1000 and 
then titrating with ratios of 1:500, 1:1000, 1:2000 and 1:4000.  
The following day, membranes were washed with TBST for 5 minutes, five 
times. Then, membranes were incubated in the corresponding secondary 
antibody, diluted at a 1:5000 ratio in 5% BSA/TBST (see Table 3.3 for full list 
and details) for 1 hour at room temperature, with gentle agitation. Secondary 
antibody dilution ratios were determined in a similar manner to the primary 
antibodies, but using ratios of 1:2500, 1:5000 and 1:10000. Secondary antibodies 
were conjugated with horseradish peroxidase (HRP), and therefore, after 1 hour, 
membranes were washed as after primary antibody incubation and one final 
wash in TBS for 5 minutes, before addition of Pierce™ ECL Western Blotting 
Substrate (Thermo Scientific) for 1 minute in dark conditions. Then, membrane 
was scanned using the Chemidoc MP Imaging System (Biorad) and protein 




Table 3.3 List of antibodies used for western blot (in vitro protein samples). 












Elabscience, Taiwan 42 kDa 1:1000 
Bcl-2 Elabscience, Taiwan 26 kDa 1:1000 
NMYC Elabscience, Taiwan 45 kDa 1:1000 














3.3 IN VIVO MOUSE MODEL 
 
Animal studies are essential to improve our understanding of the mechanisms of 
diseases, leading to improvements in prevention, diagnosis and treatment. In 
cancer research, animal, or in vivo studies explore both fundamental and 
translational theories and understanding (Workman et al., 2010; Gargiulo et al., 
2012). Rodents, specifically mice, are the most common model in cancer 
research; in 2008, 96.8% of animals used for cancer research in the UK were 
mice (Workman et al., 2010). 
There are two main models available for cancer research: autochthonous tumour 
models and transplantation tumour models. Autochthonous tumour models use 
animals that possess genetic changes that make them more susceptible to tumour 
development. There is now an increasing range of specific tumour models 
available, which are created by either inducing expression of oncogenes or 
inactivating tumour-suppressor genes. Transplantation tumour models involve 
transplanting and growing tumour cells in mice. If the tumour cells are not of 
rodent origin, e.g. human tumour cells, then immunodeficient mice are used to 
prevent rejection (Workman et al., 2010).  
An in vivo model can be a necessary step in cancer research as the fundamental 
interactions between drug, disease, and the rest of the body can be complex. 
Furthermore, such studies are usually required by regulatory authorities before 
proceeding to human investigations, in order to better judge the risks of any new 
interventions (Workman et al., 2010). The promising apoptotic effect of γT3 on 
SH-SY5Y cells was demonstrated by a recent, in vitro study which also 
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suggested that this is accomplished when γT3 binds to the hydrophobic groove 
of the Bcl-2 protein (Tan et al., 2016).  
Our in vivo study was guided by a similar study published by researchers who 
induced neuroblastoma tumours in nude mice, in order to observe the effects of 
combination treatment of retinamide and genistein (Karmakar et al., 2011). We 
used this paper as a reference for the final methodology which was approved by 
both the Animal Welfare and Ethical Review Body (AWERB) of The University 
of Nottingham and the Animal Ethics Committee of Universiti Kebangsaan 
Malaysia (UKM).  
 
3.3.1 Ethics approval 
The use of the animals, the protocol for their care, as well as the study protocol 
used was reviewed and approved by both the Universiti Kebangsaan Malaysia 
Animal Ethics Committee (UNMC/2015/THEN SUE-MIAN/25-MAR./663-
JUNE-2015-JUNE-2017) and the University of Nottingham Animal Welfare and 
Ethics Review Board (UNMC0003).  
 
3.3.2 Animals 
Male mice [strain: nu/nu nude mouse Crl/Nu-Foxnlnu (albino)] were obtained 
from Biolasco, Taiwan and Charles River, China, and housed at UKM.  Mice 
used for the tumour optimisation stage were supplied by Biolasco, Taiwan but 
subsequent batches (of the same strain) were obtained from Charles River, 
China, due to supply changes by the local distributor.  
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The study was conducted at the same facility and mice were housed in IVCs with 
a 12 hours light, 12 hours dark lighting cycle. The room was air-conditioned with 
a temperature range of 20-22°C. Mice were housed in groups of four during the 
procedure (tail mark identification), with irradiated bedding, and provided with 
autoclaved nesting materials and environmental enrichment. Mice were offered 
sterile irradiated PicoLab Rodent Diet 20 (LabDiet USA, product code 5053) 
and autoclaved water ad libitum. Mice were allowed to acclimatise for 7 to 10 
days before any interventions commenced. 
 
3.3.3 Monitoring 
In addition to PET/CT scanning and use of Vernier callipers to monitor tumour 
size in tumour-induced mice, all mice were observed daily for signs of adverse 
effects. This included recording daily weights, as well as monitoring and 
recording food and water intake. Tumour bearing mice were observed for 
potential adverse effects specifically related to the tumour initiation, such as 
restricted movement due to tumour size. The full list of possible adverse effects 
can be seen in Appendix A.  
 
3.3.4 Positron emission tomography (PET) scan 
Positron emission tomography (PET) is a non-invasive imaging method that 
detects and measures positron emissions of radionuclides in vivo. In the case of 
this project, PET imaging was combined with computed tomography (CT) for 
anatomical reference. The radionuclide we used was 18-flurodeoxyglucose (18-
FDG), which is a glucose molecule labelled with the radioactive 18F molecule. 
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As tumours (and xenografts) are known to exhibit higher glucose uptake than 
many normal cells, injection of 18-FDG to a xenograft model causes an 
accumulation of positron emissions at the site of the xenograft, which can be 
detected by a PET scan (Koba, Jelicks & Fine, 2013). Combining PET scan with 
computed tomography (CT) provides a direct anatomical image of the test 
animal (Koba, Jelicks & Fine, 2013).  
Training to operate the G8 PET/CT Preclinical Imaging System was provided 
by Perkin Elmer. A PET scan protocol was developed based on the training.  
Anaesthesia of 3% isoflurane and 100% oxygen inhalation was initiated by an 
induction chamber, then mice were transferred to an imaging cassette on a 
docking station, which continued to deliver anaesthesia and also contained a 
heating pad, in order to maintain mouse body temperature. The depth of 
anaesthesia was monitored by a toe pinch to verify no response before tracer 
injection.  
A trained technician calibrated and calculated the 18-FDG dose, before injecting 
into mouse via intraperitoneal injection by a trained technician. Dose range was 
25 to 75 μCi, and dose was allowed to equilibrate in mouse for 45 minutes before 
scanning. Following the injection, the syringe was placed back in the dose 
calibrator to calculate the residual dose remaining in the syringe and recorded. 
A whole body emission scan will be performed from the head to lower abdomen 
with a total acquisition time of 10 minutes, followed by CT scan. Initial dose, 
residual dose and administered dose was recorded. 
Images were reconstructed using 3D Maximum Likelihood Estimation Method 
(MLEM) algorithms. Regions of interest (ROIs) were manually placed on each 
transverse section of the body. The software (VivoQuant; inviCRO, USA) 
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utilizes the initial, residual and administered doses, along with the known half-
life of the isotope, to convert ROIs into percent injected dose values. 
 
3.3.5 Tumour optimisation study 
3.3.5.1 Animals 
This study used eight mice that were obtained, housed, fed and monitored as 
stated in Section 4.2.3. Mice were allowed to acclimatise for 7 to 10 days before 
tumour induction was initiated. 
 
3.3.5.2 Tumour induction 
The SH-SY5Y neuroblastoma cell line (CRL-2266) was cultured, detached and 
counted as per the protocol in Section 3.2.1. A total of 6 x 106 cells in 100µL of 
a 1:1 mixture of complete culture medium and Matrigel was implanted in four 
mice by subcutaneous injection on the right flank of each mouse, using a sterile 
1 mL syringe (Terumo, Japan) and 18G needle (Terumo, Japan). (Karmakar et 
al., 2011). The remaining four mice were implanted with 4 x 106 cells. Mice 
were sedated with isoflurane anaesthesia during all injection procedures. Mouse 
conditions (appearance, weight, tumour growth, behaviour) were monitored 
daily for a period of 14 days.  
 
3.3.5.3 Tumour growth monitoring 
Palpable tumours were expected to develop within 6 to 8 days for mice 
administered 6x106 cells (Karmakar et al., 2011), but ended up taking 10 to 14 
days. Mice were considered ready for treatment when tumours reached a volume 
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of about 1cm3 although final size was ultimately dependent on the growth curve 
and how long the study could run before the size was reached. For external 
calliper measurements, the two longest perpendicular axes in the x/y plane of 
each xenograft tumour were measured to the nearest 0.1cm, by the same person. 












In addition to callipers, mice were imaged with PET scan twice: prior to tumour 
induction and at the end of the study when Vernier callipers indicated the tumour 
size was ready for treatment. 
 
3.3.5.4 Termination 
Mice were terminated at the end of the study by cervical dislocation. Then, 
tumours were removed, weighed and snap frozen in liquid nitrogen, before being 
transferred to a -80ºC freezer for storage.   
 
3.3.6 Drug tolerability study 
The tolerability study had two parts: the first, involving non-tumour bearing 
mice ran concurrently with the tumour optimisation study. The second part, 
carried out in tumour bearing mice, ran after the tumour initiation protocol was 
optimised and doses (frequency and combinations) were confirmed to be 
tolerated by non-tumour bearing mice. Additionally, due to a concern by the 
AWERB regarding bone fractures as an adverse effect of 13cRA treatment 
(Hixson et al., 1979), particular care was taken to monitor CT images of 13cRA 






3.3.6.1 Animals  
The pilot study used 20 mice that were obtained, housed, fed and monitored as 
stated in Section 3.3.2. Mice were allowed to acclimatise for 7 to 10 days before 
any interventions were initiated. 
 
3.3.6.2 Treatment preparation and administration 
All drug treatments were suspended in vitamin E stripped palm oil (gift from 
Malaysian Palm Oil Board, Bangi). Volume of each drug dose was 100µL, i.e. 
volume of single drug doses were 100µL and combination drug doses were 
200µL. Drug treatments were freshly prepared daily from stock solutions 
(Section 3.2.2) according to doses described in Table 3.4, and immediately 
administered to mice using autoclaved 20 G gavage needles or sterile 20G 
flexible plastic feeding tubes (both Instech Laboratories Inc, USA) and 1 mL 
syringe (Terumo, Japan).  
 
3.3.6.3 Non-tumour bearing study 
Mice were randomly divided into five groups, and treated as summarised below: 




Vitamin E stripped palm oil (γT3, 13cRA & ABT-263 
vehicle), PO, weekly on 5 consecutive days, 4 weeks. 
Group 2 
(N=2) 
53mg/kg 13cRA, PO, weekly on 5 consecutive days, 2 weeks 
on, 2 weeks off. 
Group 3 
(N=2) 
80mg/kg γT3, PO, weekly on 5 consecutive days, 4 weeks. 
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Group  Treatment/dose 
Group 4 
(N=2) 
53mg/kg 13cRA, PO, given together with 80mg/kg γT3, PO, 
weekly on 5 consecutive days; durations as per Groups 2 & 3. 
Group 5 
(N=2) 
53mg/kg 13cRA, PO, followed immediately by 100mg/kg 
ABT-263, PO, weekly on 5 consecutive days; durations as per 
Groups 2 & 3. 
 
13cRA is an orally dosed drug in humans, and γT3 (as well as other tocotrienol-
related substances) is commonly administered via the oral route.  
The dose of 13cRA used here was calculated based on the human dose of 
160mg/m2/day for 2 weeks on, 2 weeks off (Veal et al., 2013). Using the 
estimated body surface area (BSA) of a 20g mouse at 0.0066m2 (Reagan-Shaw, 
Nihal & Ahmad, 2008; Animal Care and Use Committee, 2015),  
160mg x 0.0066m2 = 1.056 mg/day 
= 1.056 mg per 20g mouse 
As 1kg = 1000g, which is 20g x 50,  
1.056 mg x 50 = 52.8 mg /kg/day, which was rounded up to a dose of 
53mg/kg/day. 
There is so far insufficient evidence to clearly establish a dose for γT3. The IC50 
calculated of γT3 alone on SH-SY5Y cells in our in vitro studies was around 
20µM. However, the pharmacokinetics of γT3 are still unclear and it is difficult 
to predict the behaviour of γT3 in a mouse. So far, intravenous (iv) and 
intraperitoneal (ip) routes have shown low bioavailability and considerable work 
is currently being carried out to investigate formulations including liposomes 
and nanoparticles (Fu et al., 2014). Doses in other studies vary greatly: 1mg/kg, 
ip for ectopic gastric cancer xenografts (Manu et al., 2012); 80mg/kg, 
intratumoral, currently used by our collaborators for glioblastomas; 125mg/kg, 
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gavage, three times a week to treat ectopic prostate cancer xenografts (Jiang et 
al., 2012); 400mg/kg daily for 4 weeks for orthotopic pancreatic tumour 
xenografts (Kunnumakkara et al., 2010). Eventually we decided to use a dose of 
80mg/kg/day, PO, for 4 weeks in the drug tolerability and optimisation stage. 
The results obtained here would then be used to establish a safe and effective 
dose for the treatment stage. 
The dose of ABT-263 (100mg/kg/day, PO) was the same dose as used in another 
study that treated neuroblastoma tumours in mice (Lamers et al., 2012).  
 
3.3.6.4 Tumour bearing study 
Tumours were induced based on the outcomes of Section 3.3.4.2. As tumour 
induction using only 4 x 106 cells was unsuccessful, ectopic tumours were 
initiated as described in Section 3.3.5.2 using 6 x 106 SH-SY5Y cells per tumour 
and mice dosed according to the groups and numbers described in Table 3.4.  
 
3.3.6.5 Monitoring 
General mouse monitoring was carried out as described in Section 3.3.3. Tumour 
growth monitoring was carried out as described in Section 3.3.5.3, with the 
addition of PET imaging performed thrice per mouse: pre-tumour induction, pre-
treatment initiation and at the end of the study just before termination.  
 
3.3.6.6 Termination 




3.3.7 Main treatment study 
3.3.7.1 Animals 
40 mice were used in this portion of the study. Mice were randomly selected and 
grouped in groups of 8 per group, with treatment groups as described in Table 
3.4.  
 
3.3.7.2 Tumour induction 
Tumours were induced as described in Section 3.3.5.3.  
 
3.3.7.3 Monitoring 
Monitoring was carried out as described in Section 3.3.6.5. 
 
3.3.7.4 Treatment 
Treatment was prepared and administered to mice as described in Section 
3.3.6.2. 
 
3.3.7.5 Termination and tumour collection 





3.3.8 Western Blot 
3.3.8.1 Antibodies 
Antibody dilution ratios were determined as per description in Section 3.2.8.3. 
 








Abcam, UK 42 kDa 1:1000 
Bcl-2 Elabscience, Taiwan 26 kDa 1:1000 
Bcl-xL Elabscience, Taiwan 30 kDa 1:1000 
Caspase 3 Elabscience, Taiwan 35 kDa 1:1000 
Caspase 9 Elabscience, Taiwan 46 kDa 1:1000 
MYCN Elabscience, Taiwan 45 kDa 1:1000 













3.3.8.2 Tumour sample preparation 
Frozen tumours were weighed and then pulverised, on ice, into a fine powder in 
a chilled, autoclaved mortar, using liquid nitrogen and a chilled, autoclaved 
pestle. Powders were then transferred to ice cold RIPA buffer, containing 
10μL/mL each of Halt Protease and Phosphatase Inhibitor Cocktail 100X and 
0.5M EDTA, as described in Section 3.2.8.2. For every 5 mg of tissue, 300 μL 
of RIPA buffer was used. Then, tissue/RIPA buffer mixture was agitated using 
a vortex for 2 hours at 4°C. Following that, mixture was centrifuged at 12000 
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rpm for 20 minutes, at 4°C. Supernatant was collected and aliquots of 20 μL per 
tube were made and the pellet discarded. Aliquots were stored at -80°C.  
 
3.3.8.3 Protein concentration determination 
Protein concentration was determined using Bradford Assay, as described in 
Section 3.2.8.2. 
 
3.3.8.4 Western blot procedure 
Western blot was carried out as described in Section 3.2.8.3, using 25 μg protein 
lysate per sample. For in vivo samples, proteins studied were: BCL-2, BCL-xL, 
p53, caspase-3, caspase-9 and MYCN. β-actin was again used as a loading 
control. Titration of antibody dilutions were performed as described in Section 
3.2.8.3. 
However, a further protein quantification step was carried out after scanning 
membranes with the Chemidoc Imager. 
Membranes were transported in TBS to a dark room. After removal from TBS, 
Pierce™ ECL Western Blotting Substrate was added again for 1 minute, before 
membranes were covered in transparent plastic and exposed to film (Amersham 
Hyperfilm™ ECL, GE Life Sciences, UK) for 15 minutes in an autoradiography 
cassette (Hypercassette, GE Life Sciences, UK). The film was then washed in 
Carestream® Kodak® Autoradiography GBX Developer (Sigma, USA) for 30 
seconds, washed in water for 1 minute, and finally washed in Carestream® 
Kodak® Autoradiography GBX Fixer (Sigma, USA) for 10 seconds. Film was 




3.3.8.5 Densitometry  
Protein bands on films were scanned using the GS-800 Calibrated Imaging 
Densitometer (Bio-Rad, USA) and accompanying software, Quantity One (Bio-
Rad, USA). Prevention of saturated film was accomplished by earlier trial and 
error of film exposure length. Image analysis was performed using the same 
software.  
Next, relative protein expression was calculated. First, the treated protein band 
intensity of interest was divided by its sample control band intensity (β-actin) 
for normalisation (A). Non-treated protein band intensity was also divided by its 
sample control band intensity (β-actin) for a normalised non-treated protein band 
intensity (B). Finally, relative protein expression was calculated:  
 
Relative protein expression =
Normalised treated protein band intensity






3.4 STATISTICAL ANALYSIS 
 
Differences between treated and untreated controls were compared using two-
tailed paired t-test with Dunnett’s post-hoc test, except for tumour reduction 
data, where differences were compared using the Kruskal-Wallis test with 
uncorrected Dunn’s test. Data was presented with error bars to indicate mean ± 
SD, representative of at least 3 independent experiments. Statistical significance 
was set at p < 0.05. All statistical analysis was carried out using GraphPad Prism 




CHAPTER 4  RESULTS 
 
4.1 IN VITRO RESULTS 
 
This section will present the results obtained from cell culture work. First, cell 
viability results on individual and combination treatments of 13cRA, γT3 and 
ABT-263 on SH-SY5Y and SK-N-BE(2) cell lines (Sections 4.1.1.1 and 
4.1.1.2), and comparison of IC50 values in individual and combination treatments 
(Section 4.1.1.2). Next, combination index values obtained from analysis by 
Compusyn software in Section 4.1.2, followed by flow cytometry results from 
treatments on both cell lines to determine effects of the abovementioned 
treatments on apoptosis (Section 4.1.3), and finally protein expression results 





4.1.1  Cell viability 
4.1.1.1 Individual treatments 
Both SH-SY5Y and SK-N-BE(2) cells showed a significant increase in cell 
viability when treated with lower doses of 13cRA (below 10 μM), as seen in 
Figure 4.1. Thereafter, cell viability decreased. SH-SY5Y cells had a slightly 
steeper slope. Both cell lines showed very significant decrease in cell viability 
at 50 μM (p≤0.0001), compared to no treatment control. The IC50 for 13cRA in 
both cell lines was 39 μM.  
Change in cell viability of SH-SY5Y and SK-N-BE(2) cells treated with 0-50M 13cRA



































Figure 4.1: Cell viability of SH-SY5Y and SK-N-BE(2) cells treated 
individually for 24 h with 0 to 50µM 13cRA, as measured by 
MTS assay. Results are represented as mean ± SD from N= ≥3 
(biological replicates); *significant when compared with 




In contrast to 13cRA treatment, treatment with γT3 did not result in significant 
increase in cell viability at low concentrations (Figure 4.2). SH-SY5Y cell lines 
responded to treatment earlier than SK-N-BE(2) cell lines, with significant 
decrease in cell viability at 7.5 μM (p≤0.01), while SK-N-BE(2) cell lines only 
showed the same significant decrease in cell viability at 30 μM. IC50 for γT3 in 
the SH-SY5Y cell line was 20 μM and 26 μM in the SK-N-BE(2) cell line.  
Change in cell viability of SH-SY5Y and SK-N-BE(2) cells treated with 0-30M T3




























Figure 4.2: Cell viability of SH-SY5Y and SK-N-BE(2) cells treated 
individually for 24 h with 0 to 30µM γT3, as measured by MTS 
assay. Results are represented as mean ± SD from N= ≥3 
(biological replicates); *significant when compared with 




In Figure 4.3, treatment with ABT-263 showed a slight, although not significant 
increase in cell viability in SH-SY5Y cell lines followed by a steady decline in 
cell viability which was not significant until 40 μM ABT-263 (p≤0.001). In the 
same graph, SK-N-BE(2) cell lines showed a slight and significant increase in 
cell viability at 12.5 μM (p≤0.001), followed by steady but not significant 
decrease until 50 μM, when the reduction in cell viability compared to no 
treatment became significant (p≤0.001). IC50 for ABT-263 in both cell lines was 
40 μM.  
 

































Figure 4.3: Cell viability of SH-SY5Y and SK-N-BE(2) cells treated 
individually for 24 h with 0 to 80µM or 0 to 100μM of ABT-263, 
respectively, as measured by MTS assay. Results are represented 
as mean ± SD from N= ≥3 (biological replicates); *significant 




4.1.1.2 Combination treatments 
As shown in Figure 3.4 (Section 3.2.3), the sub-optimal concentrations used for 
combination treatment was chosen by calculating IC25 values from the IC50 
values obtained from the individual treatment assay. It should however be noted 
that the sub-optimal concentrations used and the final calculated IC50 values may 
not completely correspond, as later data was added to the IC50 calculations (to 
reduce error bars) after sub-optimal value calculation and subsequent experiment 
was carried out.  
SH-SY5Y cells showed a much more rapid decline in cell viability than SK-N-
BE(2) cell lines when treated in combination with 0 to 40µM 13cRA and either 
8.5μM or 12.5μM γT3, respectively (Figure 4.4).  In the SH-SY5Y cell line, 
addition of 8.5 μM of γT3 caused the IC50 of 13cRA to drop by 74% from 39μM, 






Change in cell viability of SH-SY5Y and SK-N-BE(2) cells treated with 0-40M 13cRA and T3
































Figure 4.4: Cell viability of SH-SY5Y and SK-N-BE(2) cells treated 
individually for 24 h with 0 to 40µM 13cRA and either 8.5μM or 
12.5μM γT3, respectively, as measured by MTS assay. Results 
are represented as mean ± SD from N= ≥3 (biological replicates); 
*significant when compared with untreated cells *p≤0.05, 
**p≤0.01, ***p≤0.001, ****p≤0.0001. 
 
 
Figure 4.5 shows a similar pattern, where SH-SY5Y cell lines showed a more 
rapid decline in cell viability than SK-N-BE(2) cells when treated with 0 to 
25µM γT3 and either 15μM or 20μM 13cRA, respectively.  Addition of 15 μM 
13cRA caused IC50 of γT3 (20 μM) to decrease by 90% in the SH-SY5Y cell 
line, while addition of 20 μM of 13cRA to treat the SK-N-BE(2) cells reduced 
the IC50 by 23%. 
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Figure 4.5: Cell viability of SH-SY5Y and SK-N-BE(2) cells treated 
individually for 24 h with 0 to 25µM γT3 and either 15μM or 
20μM 13cRA, respectively, as measured by MTS assay. Results 
are represented as mean ± SD from N= ≥3 (biological replicates); 
*significant when compared with untreated cells *p≤0.05, 






However, when SH-SY5Y and SK-N-BE(2) cells were exposed to 0 to 40µM 
13cRA and 19.5μM ABT-263, SH-SY5Y only showed a visible and significant 
decline in cell viability at 10 μM 13cRA, and while SK-N-BE(2) showed a drop 
in cell viability at the same 13cRA concentration, significance was only 
observed at 40 μM 13cRA (Figure 4.6). The IC50 of 13cRA dropped by 26% 
from 39 μM in the SH-SY5Y cell line after addition of 19.5 μM ABT-263, while 
in the SK-N-BE(2) cell line, the reduction in IC50 was less, at 15%.  
 
Change in cell viability of SH-SY5Y and SK-N-BE(2) cells treated with 0-40M 13cRA and ABT-263





























Figure 4.6: Cell viability of SH-SY5Y and SK-N-BE(2) cells treated 
individually for 24 h with 0 to 40µM 13cRA and 19.5μM ABT-
263, as measured by MTS assay. Results are represented as mean 
± SD from N= ≥3 (biological replicates); *significant when 





When IC50 figures of combination treatments were compared, a significant 
decrease in IC50 was observed when SH-SY5Y cell lines were treated with 0 to 
25µM γT3 only or 0 to 40µM 13cRA only, compared to combination treatments 
(Figure 4.7).   






























Figure 4.7: Comparison of IC50 in SH-SY5Y cells treated for 24 h with 
individual treatments (0 to 25µM γT3 only or 0 to 40µM 13cRA 
only) compared to combination treatments, as measured by MTS 
assay. Results are represented as mean ± SD from three biological 
replicates and significance between individual and combination 





Figure 4.8 shows a similar, significant difference between IC50 of individual and 
combination treatments in SK-N-BE(2) cell lines.  





























Figure 4.8: Comparison of IC50 in SK-N-BE(2) cells treated for 24 h with 
individual treatments (0 to 25µM γT3 only or 0 to 40µM 13cRA 
only) compared to combination treatments, as measured by MTS 
assay. Results are represented as mean ± SD from three biological 
replicates and significance between individual and combination 




However, no significant change in IC50 was observed when ABT-263 was 
combined with 13cRA to treat either cell line, although the addition of ABT-263 
to 13cRA did result in a slight reduction of IC50 for 13cRA (Figure 4.9).  
 
A. SH-SY5Y 





























Figure 4.9: Comparison of 13cRA IC50 in SH-SY5Y cells (A) and SK-N-
BE(2) cells (B) treated for 24 h with individual treatment (0 to 
40µM 13cRA only) and combination treatment (additional 30µM 
or 40µM ABT-263), as measured by MTS assay. Results are 






Table 4.1: Comparison of IC50 values of individual and combination 13cRA 
or γT3 treatments in SH-SY5Y and SK-N-BE(2) cell lines. Cells 
were exposed to treatment for 24h with individual treatments (0 
to 25µM γT3 only or 0 to 40µM 13cRA only) or combined with 
either 13cRA or γT3, and cell viability was measured by MTS 
assay.  
 IC50 value (µM) 
Treatment group SH-SY5Y SK-N-BE(2) 
13cRA only 39 39 
γT3 only 20 26 
13cRA + 8.5 µM γT3 10 - 
γT3 + 15 µM 13cRA 2 - 
13cRA + 12.5 µM γT3 - 16 






4.1.2 Combination index 
 
Combination index values obtained after processing IC50 values using 
Compusyn software are summarised in Tables 4.2, 4.3 and 4.4.  
The addition of γT3 to 15 μM of 13cRA showed immediate synergy in SH-SY5Y 
cell lines (from the lowest concentration of γT3, 0.975 μM), while in SK-N-
BE(2) cell lines, synergy was only observed at the higher concentration of 7.5 
μM γT3 added to 20 μM 13cRA (Table 4.2).  
Table 4.2: Effect of 0.9375 - 25 µM of γT3 combined with 13cRA on SH-
SY5Y and SK-N-BE(2) cells; n≥3.  If CI is >1: antagonism; <1: 
synergism; = 1: additive effect. Values indicating synergism are 
underlined. 
 Cell line 
γT3 (µM) 

















The addition of 13cRA to 8.5 μM γT3 in SH-SY5Y cell lines only showed 
synergy with 5 μM of 13cRA, while in SK-N-BE(2) cell lines, 10 μM 13cRA 
and 12.5 μM γT3 was needed to show synergy (Table 4.3).  
Table 4.3: Effect of 0.5 - 40 µM of 13cRA combined with γT3 on SH-SY5Y 
and SK-N-BE(2) cells; n≥3. If CI is >1: antagonism; <1: 
synergism; = 1: additive effect. Values indicating synergism are 
underlined. 
 Cell line 
13cRA (µM) 













30467 30468 30470 0.378 0.786 0.125 
 
Interestingly, treatment with ABT-263 and 13cRA in both cell lines had similar 
effects (Table 4.4). Synergy was observed at the same concentration of 13cRA 
(10μM) in both SH-SY5Y and SK-N-BE(2) when 0 to 40 μM 13cRA was added 
to 19.5 μM ABT-263.  
Table 4.4: Effect of 10 - 40 µM of 13cRA combined with ABT-263 on SH-
SY5Y and SK-N-BE(2) cells; n≥3. If CI is >1: antagonism; <1: 
synergism; = 1: additive effect. Values indicating synergism are 
underlined. 
 Cell line 
13cRA (µM) 




( 19.5 µM 
ABT-263) 









4.1.3 Cell cytotoxicity results 
LDH assay was performed on SH-SY5Y and SK-N-BE(2) cell lines, using 
individual and combination γT3 and 13cRA treatments.  
In Figure 4.10, a statistically significant increase in % cytotoxicity was seen at 
the highest concentrations of γT3 (p≤0.01) and 13cRA (p≤0.001) although prior 
to that, % cytotoxicity was calculated at 0% or below.  
LDH assay: SH-SY5Y treated with T3 and 13cRA




















Figure 4.10: Cell death of SH-SY5Y cells treated individually with 0-30µM 
γT3 and 0-50µM 13cRA, as measured by LDH release assay. 
Results are represented as mean ± SD from N= ≥3 (biological 






In Figure 4.11, there was a rise in % cytotoxicity at the highest concentrations 
of γT3 and 13cRA in the SK-N-BE(2) cell line, but no statistically significant 
results were seen.  
LDH assay: T3 + 13cRA treatment on SK-N-BE(2) cells
























Figure 4.11: Cell death of SK-N-BE(2) cells treated individually with 0-30µM 
γT3 and 0-50µM 13cRA, as measured by LDH release assay. 
Results are represented as mean ± SD from N= ≥3 (biological 





The combination treatments on SH-SY5Y cells in Figure 4.12 show a 
concentration dependent rise in % cytotoxicity in the 0 to 25µM γT3 and 15µM 
13cRA group, with a statistically significant increase at 7.5μM γT3 when 15μM 
was added (p≤0.05), with statistical significance increasing at each subsequent 
γT3 concentration p≤0.01 at 15μM and p≤0.001 at 25μM. However, the 0 to 
40µM 13cRA and 8.5µM γT3 treatment group displayed high % cytotoxicity 
throughout, even at 8.5 μM γT3 only (~75% cytotoxicity), with the % 
cytotoxicity remaining at around this level throughout. 
LDH assay: SH-SY5Y + T3 = 8.5m + 13cRA = 0-40M























Figure 4.12: Cell death of SH-SY5Y cells treated in combination with either 
0 to 40µM 13cRA and 8.5µM γT3 or 0 to 25µM γT3 and 15µM 
13cRA, as measured by LDH release assay. Results are 
represented as mean ± SD from N= ≥3 (biological replicates). 






Figure 4.13 shows no statistically significant results from the combination 
treatments on the SK-N-BE(2) cell line, although the 0 to 25µM γT3 and 20µM 
13cRA treatment group does indicate a concentration dependent increase in % 
cytotoxicity. The 0 to 40µM 13cRA and 12.5µM γT3 group starts at about 25% 
cytotoxicity at 0μM 13cRA and 12.5μM γT3 and dips slightly below, only rising 
to about 30% cytotoxicity at 40μM 13cRA.  
LDH assay: SK-N-BE(2) + T3 12.5 M + 13cRA = 0 - 40 M






















0-40M 13cRA + 12.5M T3
 
Figure 4.13: Cell death of SK-N-BE(2) cells treated in combination with either 
0 to 40µM 13cRA and 12.5µM γT3 or 0 to 25µM γT3 and 20µM 
13cRA, as measured by LDH release assay. Results are 





4.1.4 Flow cytometry 
 
Figures 4.14A and 4.15A are dot plots of control cells, 13cRA only-treated cells, 
γT3 only- and γT3/13cRA-treated cells, and ABT-263 only- and ABT-
263/13cRA-treated cells in SH-SY5Y and SK-N-BE(2) cell lines, respectively. 
Figures 4.14B and 4.15B summarise percentage number of the previously 
mentioned cells at each stage of apoptosis, with the values obtained from the dot 
plots shown in Figures 4.14A and 4.15A.  
In the SH-SY5Y cell line none of the changes in viable cells were statistically 
significant when comparing treated to non-treated cell groups (Figure 4.14). 
There was an increase in number of cells in early apoptosis after treatment with 
γT3 combination treatment in the SH-SY5Y cell line, from 3.2% to 5.6%, 
although it was not statistically significant (Figure 4.1A). There was also a slight 
drop to 1.8% and 1.9% respectively for ABT-263 only and ABT-263 
combination groups. In the late apoptosis stage, there was an statistically 
insignificant increase from 5% in vehicle only control cells to 10.3%, 8.8%, 
9.9% and 6.3% in γT3 only, γT3 combination, ABT-263 only and ABT-263 
combination treatment cells, respectively. Necrosis also showed increases, 
although statistically insignificant, in percentage number of cells in γT3 only, 
γT3 combination, ABT-263 only and ABT-263 combination treatments, with 
values of 4.3%, 5%, 3.6% and 3.9%, respectively, up from 0.8% in the control 









Figure 4.14: Comparison of apoptosis in SH-SY5Y cells after individual or 
combinations with 13cRA, γT3 or ABT-263, using flow 
cytometry with Annexin V-FITC/PI assay kit. Dot plots of cells 
with no treatment control, 13cRA only, γT3 only, γT3 and 
13cRA, ABT-263 only and ABT-263 and 13cRA shown in (A). 
Data in (B) shows % number of cells at each stage of apoptosis, 
comparing treatment groups to no treatment control, as well as 
individual compared to combination treatment groups. Results in 
(B) are represented as mean ± SD from N=3 (biological 
replicates). No significant changes found.  
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Samples from the SK-N-BE(2) cell line (Figure 4.15) showed one statistically 
significant change in the late apoptosis stage: from 0.3% of control cells to 1.8% 
of cells in the ABT-263 combination treatment group (Figure 4.15B).  
Otherwise, like the SH-SY5Y cell line, there were some changes in percentages 
of cell distribution but they were not statistically significant. In the early 
apoptosis stage, the ABT-263 combination group once again showed an increase 
compared to the control group cells, 4.5% vs 1.9%, respectively, while the γT3 
combination group in early apoptosis showed an even lesser increase of 3.4%. 
In late apoptosis and necrosis, changes in cell percentage were even more slight, 










Figure 4.15: Comparison of apoptosis in SK-N-BE(2) cells after individual or 
combinations with 13cRA, γT3 or ABT-263, using flow 
cytometry with Annexin V-FITC/PI assay kit. Dot plots of cells 
with no treatment control, 13cRA only, γT3 only, γT3 and 
13cRA, ABT-263 only and ABT-263 and 13cRA shown in (A). 
Data in (B) shows % number of cells at each stage of apoptosis, 
comparing treatment groups to no treatment control, as well as 
individual compared to combination treatment groups. Results in 
(B) are represented as mean ± SD from N=3 (biological 
replicates), *significant when compared with untreated cells 
*p≤0.05.   
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4.1.5 Western blot (in vitro) 
 
A significant decrease in MYCN protein expression was observed in ABT-263 
individual and combination groups in the SH-SY5Y cell line, * p≤0.05 (Figures 
4.16 and 4.17A). While increases in Bcl-2 protein expression were observed in 
the 13cRA and γT3 combination group (Figures 4.16 and 4.17B), they were not 
statistically significant. 
































   
 
Figure 4.16: Effect of 13cRA and γT3, alone and in combination, and ABT-
263 alone and in combination with 13cRA, compared to vehicle 
only control on protein expression of Bcl-2 and MYCN in SH-
SY5Y neuroblastoma cell lines. Beta actin was used as the 
loading control, and results are representative of three 































Figure 4.17: Comparison of relative density profiles obtained from western 
blot protein bands after individual and combination treatment of 
SH-SY5Y cell lines, as seen in Figure 4.16 of A) MYCN and B) 
Bcl-2. Results are represented as mean ± SD from three 
biological replicates and significance between treated and 





In the SK-N-BE(2) cell line, protein expression of MYCN was not significantly 
altered in all treated samples compared to untreated samples (Figures 4.18 and 
4.19A). However, there were significantly elevated Bcl-2 protein expression 
levels in γT3 combination, and ABT-263 individual and combination groups 
(Figures 4.18 and 4.19B). There was also a reduction in Bcl-2 protein expression 
in the 13cRA only treatment group for the SK-N-BE(2) cell line, but this was 
not significant (Figure 4.19B).  
No bands were obtained for samples tested against p53, and therefore no results 
are presented.  
 

































   
 
Figure 4.18: Effect of 13cRA and γT3, alone and in combination, and ABT-
263 alone and in combination with 13cRA, compared to vehicle 
only control on protein expression of Bcl-2 and MYCN in SK-N-
BE(2) neuroblastoma cell lines. Beta actin was used as the 
loading control, and results are representative of three 
































Figure 4.19: Comparison of relative density profiles obtained from western 
blot protein bands after individual and combination treatment of 
SK-N-BE(2) cell lines, as seen in Figure 4.18 of A) MYCN and 
B) Bcl-2. Results are represented as mean ± SD from three 
biological replicates and significance between treated and 





4.2 IN VIVO RESULTS 
 
This section presents results obtained from in vivo experiments. Treatment 
combinations were selected based both on prior in vitro work as well as 
published literature for guidance on dosage and frequency.  
Section 4.2.1 shows results of the effect of individual and combination 
treatments on tumour volume of tumours grown from SH-SY5Y cell lines in 
nude mice (Figure 4.20) and representative PET images to show position of 
tumour growth, as well as relative sizes at the end of treatment (Figure 4.21).  
Western blot results using protein samples extracted from the previously 
mentioned tumours – both the images of representative protein bands, as well as 





4.2.1 Tumour size reduction 
 
Using readings from daily calliper measurements, significantly smaller tumour 
sizes (p ≤ 0.05) were observed in two treatment groups (13cRA only and γT3 
combined with 13cRA), when compared to vehicle only control (Figure 4.20). 
Average final tumour volume of 13cRA only group and γT3 combination group 
were reduced by about half (2.2 cm3), and three quarters (1.1 cm3), respectively, 
compared to the vehicle only control (3.9 cm3). However, all treatment groups 
demonstrated a lower final tumour volume when compared to vehicle only 
control.  
























Figure 4.20: Comparison of treatment effects on tumour volume, vs. vehicle 
only control. N= 4 to 8. * indicates significance, where p ≤ 0.05, 








C: γT3 (80mg/kg) 








Figure 4.21 is a qualitative representation of tumours observed in PET scan 
images. Using the VivoQuant software, each image is built from the combination 
of two scans: one is a CT scan, which provides a direct anatomical image of the 
mouse, while the 18F--FDG PET image visualises the biodistribution and uptake 
of 18F-FDG. Increasing brightness indicates higher uptake of 18F--FDG, i.e. pale 
yellow or white shows high levels of 18F--FDG uptake and blue shows low levels 
of 18F—FDG uptake. The images in Figure 4.21 show high uptake of 18F-FDG 
in the bladders of all images, as well as in the hearts of images A to C, but low 






Figure 4.21: Representative images to show effects of treatments on tumour 
volume. Images were obtained by PET/CT scan and processed 
using Vivoquant software. T indicates position of tumour, H is 
the heart and B is the bladder. Yellow dotted line indicates area 
of tumour. 
Key: A: Vehicle only control; B: 13cRA (53mg/kg); C: γT3 
(80mg/kg); D: γT3 (80mg/kg) and 13cRA (53mg/kg); E: ABT-


















4.2.2 Western blot (in vivo) 
 
When compared to the no treatment group, the only significant change in protein 
expression was observed with an increase in caspase-9 for tumours treated with 
13cRA only (Figures 4.22 and 4.23B).  
MYCN protein bands were not observed from western blots (Figure 4.22).  
Figure 4.23A shows an increase in p53 expression in all treatment groups, 
however, this was statistically not significant (p-value ranged from 0.7 to 0.9). 
Caspase-9 showed a slight reduction in protein expression for γT3 + 13cRA and 
ABT-263 and 13cRA groups, but this was not statistically significant (p=0.98 
and p=0.95, respectively). Caspase-3 expression had the highest, but not 
statistically significant increase in the 13cRA only group (p=0.211) while the 
γT3 only and ABT-263+13cRA combination groups showed lesser and also 
statistically insignificant increases (p=0.464 and p=0.926, respectively) (Figures 
4.22 and 4.23C). Slight increases in Bcl-xL expression was observed for all 
treatment groups (p-value ranging from 0.399 to 0.899) except ABT-
263+13cRA combination, which had a slight decrease (p=0.980) and increase in 
Bcl-2 was observed in all treatment groups, with the γT3 + 13cRA group having 
the highest increase (p=0.268) (Figures 4.22, 4.23D and E); however, all changes 
in expression of both proteins was not statistically significant (Figures 4.23D 
















































   
 
Figure 4.22: Effect of 13cRA and γT3, alone and in combination, and ABT-
263 in combination with 13cRA, compared to vehicle only 
control on protein expression of Bcl-2, Bcl-xL, caspases-3 and -
9, MYCN and p53 in ectopic tumours grown in nude mice from 
an SH-SY5Y neuroblastoma cell line. Beta actin was used as the 
loading control, and results are representative of three 
























































































Figure 4.23: Comparison of relative density profiles obtained from western 
blot protein bands as seen in Figure 4.22 of A) p53, B) caspase-
9, C) caspase-3, D), Bcl-xL, and E) Bcl-2. Results are represented 
as mean ± SD from three biological replicates and significance 







CHAPTER 5  DISCUSSION  
 
Our hypothesis, as mentioned in the introduction, is that γT3 has significant anti-
tumour effects on neuroblastoma, and one possible mechanism is by binding to 
the Bcl-2 protein to initiate the intrinsic apoptosis cascade. We also hypothesised 
that the combination drug treatment of γT3 together with 13cRA will 
demonstrate a synergistic effect.  
In order to investigate our hypothesis, we carried out experiments to determine 
effects of γT3 on cell viability and death in SH-SY5Y and SK-N-BE(2) cell 
lines, and used the obtained IC50 values to calculate the combination index (CI) 
in order to determine if the combinations were synergistic. ABT-263 was also 
used as we wanted to compare the theorised Bcl-2 inhibitory action of γT3 to a 
known selective Bcl-2 inhibitor. Additionally, cytotoxicity was evaluated using 
the LDH assay. 
To investigate apoptotic action of γT3, we carried out in vitro flow cytometry 
experiments with Annexin V-FITC/PI staining as well as protein investigations 
with western blot, using in vitro and in vivo samples. The in vivo protein samples 
themselves were extracted from ectopic tumours grown in nude mice, treated 
with individual or combination treatments of 13cRA, γT3 or ABT-263. Tumour 
growth was monitored using callipers and PET scan in order to ascertain anti-





5.1 EFFECTS ON NEUROBLASTOMA CELL LINES 
 
5.1.1 Gamma-tocotrienol as an individual agent  
So far, several studies have investigated the anti-cancer properties of γT3, 
although not in neuroblastoma. Instead,  studies have primarily focused on using 
tocotrienols to treat the most common cancers such as breast, prostate and liver 
(Sailo et al., 2018; Aggarwal et al., 2019), although one study, by Tan et al. 
(2016) has shown a potential mechanism of action of γT3 in neuroblastoma. Few 
CNS cancers have been studied with tocotrienols, although tocotrienols have 
been shown to cause apoptosis in glioblastoma (Lim et al., 2014; Abubakar et 
al., 2017). Tocotrienols have been found to have many targets including, but not 
limited to inflammatory cytokines, enzymes such as COX-2, transcriptional 
factors such as PPAR-γ and anti-apoptotic proteins such as Bcl-2 and Bcl-xL 
(Kannappan et al., 2012).  
This study investigated the effects of γT3 and 13cRA as individual treatments, 
in the SH-SY5Y and SK-N-BE(2) cell lines. SH-SY5Y, with its single copy of 
MYCN, was chosen to represent lower risk stages of neuroblastoma, while SK-
N-BE(2) represents the high risk group of neuroblastoma patients, as MYCN is 
amplified (over 100 copies) (Baj & Tongiorgi, 2009).  
The IC50 value of 20µM γT3 in SH-SY5Y cells  (Figures 4.2 and 4.7) is the same 
as that found in the study by Tan et al., (2016). The results also show that γT3 
has an earlier effect on SH-SY5Y cells than SK-N-BE(2) cells (Figure 4.2), as 
cell viability begins to drop at 0.975μM (c.f. ≥5μM in SK-N-BE(2) cells). The 
IC50 value of γT3 in SK-N-BE(2) cells is 26µM (Figures 4.2 and 4.8).  
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The higher concentrations required to treat SK-N-BE(2) cell lines compared to 
SH-SY5Y is not completely unexpected, due to the MYCN amplification in SK-
N-BE(2) cells, which is well documented as a cause of resistance to therapy in 
high-risk neuroblastoma (Matthay et al., 1999), compared to a cell line such as 
SH-SY5Y, which only has a single copy MYCN.  Nevertheless, these results 
show that γT3 is able to reduce cell viability in a concentration dependent 
manner in both cell lines. This confirms findings with the SH-SY5Y cell line 
from a previous study (Tan et al., 2016) and gives new information about its 
effects on a resistant neuroblastoma cell line, SK-N-BE(2). The dose dependent 
reduction in cell viability also adds to our knowledge about the action of γT3 in 
cancer cell lines, as it is similar to observations in A549 human lung 
adenocarcinoma and U87MG glioblastoma cell lines (Lim et al., 2014; 
Abubakar et al., 2017).  
Cell lines showed a viability of over 100% when treated with only 13cRA, until 
approximately 20μM, when viability reduced in a dose dependent manner 
(Figure 4.1). The increase in cell viability at low doses can be attributed to the 
known effect of 13cRA to differentiate cancer cells, where changes in apoptosis 
signalling in the cells in order to ensure viability have been observed, such as 
increase in p53 or increases in Bcl-2 family expression in SH-SY5Y cells treated 
with low doses of 13cRA (Waetzig et al., 2019; Hadjidaniel & Reynolds, 2010).  
The current high dose, pulsed frequency of 13cRA administration for the 
maintenance stage of high risk neuroblastoma was based on studies to provide 
optimal 13cRA plasma levels while limiting dose-dependent side effects such as 
mucocutaneous toxicity, skin dryness and cheilitis (Reynolds et al., 2003; 
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Matthay, 2013). Unfortunately, while initial trial results showed that 13cRA was 
a beneficial adjuvant therapy in high risk neuroblastoma (46±6% patients with 
event free survival rate, 3 years post randomisation vs 29±5% patients without, 
p=0.027) (Matthay et al., 1999), a follow up study showed that the 5 year event 
free survival rate for those patients who received the 13cRA intervention was 
not statistically significant against the placebo group (p=0.1219) even though 
the survival rate of the treatment group was still higher than the placebo group 
(Matthay et al., 2009). Furthermore, it is well documented that high risk 
neuroblastoma with MYCN amplification is prone to developing treatment 
resistance (Canete et al., 2009; Cohn et al., 2009; Yalçin et al., 2013). 
5.1.2 Synergy with other treatments 
As the current dosing schedule of 13cRA is limited by toxicity, it is necessary to 
explore ways of improving the efficacy of 13cRA without compromising the 
safety of patients. Many other cancers have developed resistance to drug therapy, 
and one approach to overcome this barrier is by administering a multi-target 
drug, or administering a combination of treatments that will affect multiple 
targets (Cole & Maris, 2012; Lu et al., 2012). Another is by identifying drug 
combinations that are synergistic, where the effects of lower, usually sub-
optimal doses of two drugs are amplified when combined (Han et al., 2017).  
Past studies have shown the synergistic effects of tocotrienols were combined 
with other drugs. Synergy was demonstrated with TRF and tamoxifen in MCF7 
and MDA-MB-435 breast cancer cells (Nesaretnam et al., 2010), γT3 and a plant 
extract, hydroxyl-chavicol in several glioma cell lines (Abdul Rahman et al., 
2014), and γT3 and another plant extract, jerantinine A in U87MG glioblastoma 
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cells (Abubakar et al., 2017). Based on available evidence, we assessed the 
effects of combining γT3 and 13cRA (and ABT-263 and 13cRA) to treat SH-
SY5Y and SK-N-BE(2) cell lines for synergy.  
Compared to individual treatments with 13cRA and γT3, the results of the 
combination treatments show a much larger difference when comparing both cell 
lines. When 8.5μM γT3 was added to 13cRA in the SH-SY5Y cell line, the IC50 
of 13cRA dropped by 74% from 39μM (Figures 4.4 and 4.7), while addition of 
12.5μM γT3 was added to 13cRA in the SK-N-BE(2) cell line, the IC50 of 13cRA 
dropped by a lower degree, by only 23% from 39μM (Figures 4.4 and 4.8). 
Addition of 15μM of 13cRA to γT3 caused a 90% reduction of γT3 IC50 in the 
SH-SY5Y cell line (Figures 4.5 and 4.7) while addition of 20μM 13cRA to the 
SK-N-BE(2) cell line caused γT3 to drop by 53% (Figures 4.5 and 4.8).  
Additionally, in Figure 4.4, the SK-N-BE(2) cell line appears to increase in cell 
viability much more than the SH-SY5Y cell line, where there is an almost 
immediate dose-dependent drop upon initiation of combination treatment. 
Although SK-N-BE(2) cell viability remains below 100% at higher dose than 
10μM, it does not substantially drop until above 20μM and the reduction is not 
significant until 40μM. In Figure 4.5, there is once again a large rise to almost 
150% in cell viability for the SK-N-BE(2) cell line at the 0μM γT3 with 20μM 
13cRA treatment point, compared to the rise to only about 110% SH-SY5Y cell 
line when exposed to 0μM γT3 combined with 15μM 13cRA. Cell viability in 
the SK-N-BE(2) cell line reduces below 100% at a point between 5μM and 
7.5μM (with added 20μM 13cRA), which follows a similar pattern as seen in 
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Figure 4.4 where SK-N-BE(2) cell viability only dropped below 100% at the 
20μM 13cRA point (with added 12.5μM γT3).  
As 13cRA and γT3 both have different targets (Waetzig et al., 2019; Tan et al., 
2016), it is possible that the reduction in IC50 when cells were exposed to a 
combination treatment compared to individual treatment is simply due to the fact 
that the treatment was affecting multiple targets. As a comparison, ABT-737, an 
early generation Bcl-2 inhibitor, was able to antagonise the protective effects of 
low dose 13cRA in pre-treated SMS-KCNR neuroblastoma cells, and re-
sensitise the cells respond to treatment with the cytotoxic agent etoposide, 
resulting in increased apoptosis (from 8% to 52%) (Hadjidaniel & Reynolds, 
2010). ABT-737 is much more specific than γT3 (van Delft et al., 2006; 
Kannappan et al., 2012), and so potentially, there might also be pathways other 
than just Bcl-2 interacting in this combination treatment.  An alternative reason 
for this observation is that the combination was synergistic.  
In order to obtain CI results from the software, average cell viability percentage 
of each concentration in the individual and combination treatment assays 
(Figures 4.1 to 4.6) was keyed into Compusyn software (Chou, 2006). According 
to the Chou-Talalay method for drug combination (Chou, 2010), a synergistic 
effect is seen when combination index (CI) is calculated at less than 1. CI larger 
than 1, indicates antagonism and a CI equal to indicates an additive effect.  
From the results calculated by the software, there is strong synergy between 
8.5μM γT3 and 5μM 13cRA in the SH-SY5Y cell line, CI=0.445, while in the 
SK-N-BE(2) cell line, 12.5μM γT3 and 10μM 13cRA slightly higher doses are 
required for synergy (Table 4.3). This data was obtained from the cell viability 
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results in Figures 4.1, 4.2 and 4.4. We also performed the CI calculation based 
on data from Figures 4.1, 4.2 and 4.5. Table 4.2 shows synergy between 15μM 
13cRA and 0.975μM γT3 in the SH-SY5Y cell lines (CI=0.091) as well as 
between 20μM 13cRA and 7.5μM γT3 in the SK-N-BE(2) cell line (CI=0.239).  
For comparison, we were also interested in the CI value between 13cRA and the 
selective Bcl-2 inhibitor, ABT-263. Using cell viability results from Figures 4.1, 
4.3 and 4.6, we found synergy at 19.5μM ABT-263 and 10μM 13cRA in SH-
SY5Y and SK-N-BE(2) cell lines (CI=0.230 and CI=0.472 respectively).  
From these results, it is clear that the combination of γT3 and 13cRA is 
synergistic. Furthermore, despite the non-significant reduction in cell viability, 
the addition of ABT-263 to 13cRA is also synergistic. Similarities between the 
mechanism of action of γT3 and ABT-263 have been observed, as they have both 
been shown to bind to the Bcl-2 protein (Tan et al., 2016; Tse et al., 2008). 
According to in vitro results published by Reynolds et al., (2003), 5 to 10μM 
13cRA therapy over 2 weeks is sufficient to show sustained growth arrest in 
neuroblastoma cell lines without toxicity. This was the in vitro work that lead to 
the currently prescribed high dose, pulsed frequency of 13cRA therapy as 
maintenance in high risk neuroblastoma (Matthay, 2013). However, that alone 
is still prone to treatment failure and recurrent disease, and clinically, does not 
show a statistically significant improvement in 5 year survival rate (Yalçin et al., 
2013).  
A synergistic effect was observed by the addition of 12.5μM γT3 to 10μM 
13cRA in the MYCN amplified cell line, SK-N-BE(2), which was chosen as the 
model for high risk neuroblastoma. This a similar level of 13cRA that was found 
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to be ideal for sustained growth arrest, with as little side effects as possible 
(Reynolds et al., 2003). Furthermore, this dose of γT3 is well below what has 
been found to be toxic to normal cells, as only doses above 100μM were found 
to be neurotoxic in primary cultures of cerebellar neurons from rats (Then et al., 
2009).  
In our cell viability assays, the dose of only 10μM 13cRA in SK-N-BE(2) cell 
lines did not decrease cell viability, but rather increased it to well above 100%  
(Figure 4.1), and in combination, there was still no significant dose dependent 
reduction in cell viability until 13cRA reached 40μM (Figure 4.4). However, as 
previously discussed, the SK-N-BE(2) cell line is overall more resistant to 
treatment than the SH-SY5Y, and while the dose reduction at concentrations of 
more than 10μM 13cRA with combined γT3 did not significantly reduce the cell 
viability, it did prevent cell viability rising above 100%.  
Low dose 13cRA is commonly used to differentiate cancer cell lines, which is 
the principle behind the usage of 13-cis retinoic acid as an adjuvant treatment 
(Reynolds et al., 2003). Unfortunately, as this is only effective in about 50% of 
high risk neuroblastoma patients (Matthay et al., 2009), this approach needs to 
be improved. With the addition of a non-toxic dose of γT3 to 10μM 13cRA in 
SK-N-BE(2) cells, cell viability dropped below 100% (Figure 4.4), unlike in the 
individual treatment where cell viability at the 10μM 13cRA treatment point 
remained at nearly 120% and only dropped below 100% at more than twice the 
dose. This finding, if replicated in a clinical setting, can potentially enhance the 
potency of 13cRA adjuvant treatment in high risk neuroblastoma without the 
additional side effects that come with increasing the dose.  
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In addition to this potential benefit to 13cRA treatment in high risk 
neuroblastoma adjuvant therapy, these observations add weight to the evidence 
that γT3 can act synergistically with other drugs. This is important, as when drug 
combinations are synergistic, lower concentrations of drugs would be needed, 
meaning enhanced action but with less risk of dose-dependent toxicity. 
Furthermore, as anti-cancer therapies work more effectively when targeting 
multiple mechanisms, this is a logical approach to improving the efficacy of high 





5.2 MECHANISM OF ACTION 
 
The Bcl-2 protein family is made up of over 20 proteins that are responsible for 
regulating the intrinsic apoptosis pathway. Their functions can be broadly split 
into 3 groups: BH3-only proteins, pro-survival proteins and pro-apoptosis 
proteins. The BH3-only proteins are either responsible for directly activating 
pro-apoptotic proteins, or neutralising pro-survival Bcl-2 family proteins; i.e. the 
BH3-family proteins work towards initiating apoptosis. If there were an excess 
of pro-survival Bcl-2 family proteins, then apoptosis, or natural cell death, would 
be hindered (Ashkenazi et al., 2017).  
Deregulation of Bcl-2, either by amplification of the BCL2 gene or 
overexpression of pro-survival Bcl-2 protein family members, such as Bcl-2 and 
Bcl-xL, has been linked to cancers as diverse as breast cancer (Schott et al., 
1995), large B cell lymphoma (Monni et al., 1997), small lung carcinoma 
(Olejniczak et al., 2007), and of course, neuroblastoma (Dole et al., 1995; Tanos 
et al., 2016). In all these cancers, the Bcl-2 deregulation contributes directly or 
indirectly to the development of the initial cancer or to its resistance to treatment, 
or both.  Delbridge et al., (2016) reviewed small molecules that have been 
developed over the past 30 years with the Bcl-2 regulated apoptotic pathway 
(intrinsic pathway) as a target, with the aim to “directly activate apoptosis of 
malignant cells”, and all these small molecules have been developed as BH3-
mimetics. One of the most common actions of natural BH3-only proteins is to 
bind to pro-survival Bcl-2 proteins in order to neutralise them, and thus allow 
normal apoptosis to resume (Doerflinger, Glab & Puthalakath, 2015).  
131 
 
Tan et al., (2016) concluded from evidence seen in their in silico docking 
analysis that γT3 binds to the hydrophobic groove of the pro-survival Bcl-2 
protein, acting very much like a BH3-only protein. Therefore, an assessment of 
the action of γT3 should include an apoptosis assay. In their paper, the 
researchers showed, using the LDH assay, that γT3 significantly induced cell 
death compared to an untreated control (p<0.05). Additionally, they evaluated 
depolarised mitochondrial membrane potential (using JC-1 staining) and found 
a significant increase (p<0.05) in % cells containing green JC-1 monomer (an 
indication of apoptosis) between the no treatment control and SH-SY5Y cells 
treated with 15μM γT3 cells.  
In this study, the potential of combination treatments of γT3 and 13cRA to cause 
apoptosis over individual treatments was investigated. Also, as our hypothesis is 
that γT3 acts on neuroblastoma cells by binding to the BH3 domain of the Bcl-2 
protein to initiate the intrinsic apoptosis cascade (Tan et al., 2016), a direct 
comparison with a Bcl-2 inhibitor was required. The Bcl-2 inhibitor ABT-263 
was used as a comparison to γT3 due to a higher affinity to Bcl-2 than Bcl-XL 
and Bcl-w compared to its predecessor, ABT-737 (Oltersdorf et al., 2005; Tse 
et al., 2008).  
 
5.2.1 Gamma-tocotrienol and apoptosis 
In the SH-SY5Y cell line, individual treatment with both 13cRA and γT3 lead 
to statistically significant increases in cytotoxicity at the highest doses of 
treatment, at 50μM (p≤0.001) and 30μM (p≤0.01), respectively (Figure 4.10). In 
the SK-N-BE(2) cell line, although sharp rises in cytotoxicity were seen at the 
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highest concentrations (30μM γT3 and 50μM 13cRA), these increases were not 
statistically significant (Figure 4.11).  
Adding 15μM of 13cRA to γT3 in the SH-SY5Y cell line resulted in the first 
statistically significant increase in cytotoxicity, recorded at 7.5μM (p≤0.05), 
showing an obvious dose-dependent trend in cytotoxicity. The next two 
concentrations are also statistically significant: 15μM (p≤0.01) and 25μM 
(p≤0.001). A similar combination (20μM 13cRA added to γT3) in the SK-N-
BE(2) cell line shows a similar dose-dependent trend, although there are no 
statistically significant changes in cytotoxicity (Figure 4.13).  
The more significant response of the SH-SY5Y when compared to the SK-N-
BE(2) cell lines in both individual and combination treatments mirrors that of 
the cell viability assay results discussed in Section 5.1. As previously stated, the 
SK-N-BE(2) cell line is known to be more resistant to treatment due to its 
overexpression of the MYCN gene, while SH-SY5Y has only a single copy of 
MYCN and is therefore much more susceptible to treatment (Baj & Tongiorgi, 
2009).  
The lactate dehydrogenase (LDH) assay was performed on in vitro cell cultures: 
SH-SY5Y and SK-N-BE(2). The LDH assay measures LDH activity in the 
supernatant, or leakage of LDH from the cell into the culture medium, which 
then reacts with the assay reagents to form a red formazan product which can be 
measured, as the amount of formazan is directly correlated to the amount of LDH 
released because of cell membrane damage, which indicates irreversible cell 
death (Fotakis & Timbrell, 2006). While the MTS assay only measures changes 
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in overall cell proliferation, the LDH assay is able to differentiate between cell 
cycle inhibition and cell death (Smith et al., 2011).   
Compared to cell viability results, the cell cytotoxicity (cell death) results show 
a sudden spike in cytotoxicity at higher concentrations, as opposed to the more 
gradual decline in cell viability seen in the MTS assay. It should be noted that 
the LDH assay can be considered to be a measure of the extent of plasma 
membrane breakdown (a sign of cell death), as LDH is normally confined to the 
inside of the cell (Fotakis & Timbrell, 2006; Galluzzi et al., 2009) while the MTS 
assay for cell viability measures metabolically active cells, by measuring the 
amount of formazan formed by conversion of the tetrazolium compound using 
NADPH or NADH (Promega, 2012). However, these metabolic alterations 
might be caused by factors other than cell death (Galluzzi et al., 2009). Thus, it 
is possible that while cell cycle inhibition occurred at lower drug concentrations 
and was detected with the MTS assay, the cell plasma membrane did not break 
down sufficiently to release LDH and cause irreversible cell death until higher 
drug doses were administered to the cells.  
Interestingly, when γT3 was added to 13cRA (8.5μM in the SH-SY5Y and 
12.5μM in the SK-N-BE(2) cell lines), instead of a dose-dependent increase in 
cytotoxicity, the cells started at a heightened level of cytotoxicity (when exposed 
to either 8.5μM or 12.5μM γT3 only) and stayed mostly at that same level as the 
dose of 13cRA increased (Figures 4.12 and 4.13). In the SH-SY5Y cell line, the 
cells were mostly at about 75% cytotoxicity throughout, while in the SK-N-
BE(2) cell line, the cells stayed level at about 30% cytotoxicity.  
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This observation might be explained by other parameters not covered by the 
LDH assay (and might be answered if another cytotoxic assay, e.g. neutral red) 
was also used to confirm), as the equivalent γT3 dose in the individual 
cytotoxicity assays did not show a similar rise in cytotoxicity (Figures 4.10 and 
4.11). In the SK-N-BE(2) cell line (Figure 4.11), there is no statistically 
significant change, although cytotoxicity levels do drop very slightly when 
13cRA is added at low concentration, before rising again at the highest dose, 
40μM. This somewhat ties in with the MTS assay results seen in Figure 4.4, 
where the same treatment group and cell line showed increase in cell viability at 
low doses of 13cRA (with added 12.5μM γT3) before dropping as the 13cRA 
concentration increased.  
 
5.2.2 Flow cytometry 
While the LDH assay, along with the MTS assay are acceptable as preliminary 
screening assays in order to evaluate the anti-cancer effects of γT3 on 
neuroblastoma cells, a more specific apoptosis assay was required in order to 
specifically determine how γT3 (individually and in combination) caused cell 
death. Based on the evidence of past work, as discussed earlier, we hypothesised 
that one possible mechanism of γT3 was apoptosis.  
Annexin V-FITC/PI and flow cytometry was used to assess the degree of 
apoptosis in both cell lines after either individual or combination treatments. 
Annexin V is a protein that binds preferentially to phosphatidylserine (PS), 
which is usually expressed on the inner surface of the plasma membrane, but in 
early apoptosis, is exposed to the outer surface, although the plasma membrane 
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is still intact. FITC is a fluorochrome attached to Annexin V that allows the 
detection and quantification of the Annexin V. PI only stains nucleic acids of 
dead cells with compromised cell membranes as intact cell membranes exclude 
it (Riccardi & Nicoletti, 2006; Wilkins, Kutzner, Truong, Sanchez-Dardon, & 
McLean, 2002). Thus, unlike the LDH assay which quantifies LDH released 
from cells where the membrane is damaged, Annexin V-FITC can differentiate 
between different stages of cell death.  
We measured and then compared the apoptotic changes of the plasma membrane 
of treated to untreated SH-SY5Y and SK-N-BE(2) cells after staining with 
Annexin V-FITC/PI and analysis with the flow cytometer. There was only one 
statistically significant change in number of cells (Figure 4.15B: ABT263 
combination group had a significant increase compared to control). This could 
be due to a large variability in values within each group between repeats. Despite 
the lack of statistical significance, there was still a visible qualitative shift in cell 
populations when comparing the no treatment control cells to treatment cell 
populations, which will be discussed.  
While generally, treatment groups for both the SK-N-BE(2) and the SH-SY5Y 
cell lines showed a shift in the cell population towards apoptosis, the overall shift 
in cell population for all treatment groups was far less drastic in SK-N-BE(2) 
cells compared to SH-SY5Y. The results here echo those of the cell viability and 
cell cytotoxicity assays, where IC50 of γT3 in SH-SY5Y cells was lower than in 
SK-N-BE(2) cells (20μM vs 26μM). Additionally, the amount of cells 
undergoing late apoptosis in the individual 13cRA and γT3 treatment groups was 
very similar to that of the no treatment control group, unlike in the SH-SY5Y 
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cell line (Figure 4.14 A and B) where about twice as many late apoptotic cells 
as viable cells are visible. In the cell viability assays, especially in combination 
treatment, the SH-SY5Y cell lines were far more responsive to treatment than 
SK-N-BE(2) cells (Figures 4.4 and 4.5), and the same can be said of the cell 
cytotoxicity results, where treatments were more cytotoxic in SH-SY5Y cells 
than SK-N-BE(2) cells (Figures 4.10 to 4.13). The overall lesser response of SK-
N-BE(2) cells to treatment compared to SH-SY5Y cells can be easily explained 
by the treatment resistance that is common in cells with amplified MYCN 
expression, which is a feature of the SK-N-BE(2) cells. As the SK-N-BE(2) cell 
line was selected as a model for high risk neuroblastoma, the observations here 
are supported by literature and clinical observations that high risk neuroblastoma 
has more treatment resistance than lower risk groups of neuroblastoma (Baj & 
Tongiorgi, 2009; Park et al., 2013). 
When comparing the no treatment control cells to the five treatment groups in 
Figure 4.14A, there is a visible increase in the number of double- and PI-only 
stained SH-SY5Y cells, which indicates late apoptotic and necrotic cell death, 
respectively, with the exception of the 13cRA only group. Interestingly, in the 
SK-N-BE(2) cell line, 13cRA  showed a slight, although not statistically 
significant increase in apoptotic cells compared to control. However the 
percentage of cells undergoing necrosis in the SK-N-BE(2) cell line was very 
low – the highest was just over 1% (Figure 4.15B) while in SH-SY5Y cells, the 
highest was around 5% (Figure 4.14B).  
These observations could be attributed to the fact that the dose of 13cRA used 
here was well below its IC50, according to our cell viability assay, and low dose 
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13cRA has been shown to augment survival signalling in SH-SY5Y cell lines 
(Waetzig et al., 2019) and even antagonise the action of cytotoxic drugs such as 
etoposide (Hadjidaniel & Reynolds, 2010) in SH-SY5Y cell lines. In a TUNEL 
assay, (which assesses proportion of cells with sub-G1 DNA content in response 
to treatment, as a measure of apoptotic cell death), addition of 13cRA to a cell 
population treated with etoposide reduced apoptosis from 68% to 4.5% 
(Hadjidaniel & Reynolds, 2010), while Waetzig et al., (2019) found that cell 
viability was increased due to reduction in p53 protein levels in SH-SY5Y cells 
after treatment with low dose 13cRA. While the SK-N-BE(2) cell line is less 
commonly studied than the SH-SY5Y cell line, a study investigating the effect 
of ATRA on SK-N-BE(2) and SH-SY5Y cells by analysing morphological 
changes and cell cycle, found that low dose (10μM) caused more differentiation 
in SK-N-BE(2) cells than in SH-SY5Y cells (Redova et al., 2010). In a study 
investigating the role of MYCN in neuroblastoma cell differentiation, researchers 
found that overexpressing MYCN in a normally poorly differentiating 
neuroblastoma cell line, SK-N-AS, increased number of cells with neurite 
outgrowth (measure of differentiation) by approximately 90% compared to wild 
type, single copy MYCN cells after exposure to 10μM ATRA (Guglielmi et al., 
2014). The MYCN overexpression of the single copy MYCN SK-N-AS cell line 
mimics that of the SK-N-BE(2) and SH-SY5Y cell lines used here, respectively. 
They also showed, using BrdU/PI staining and flow cytometry, that after 
treatment with ATRA, more LAN-5 neuroblastoma cells (overexpressed MYCN) 
were arrested in the G0/G1 phase of the cell cycle (indicating differentiation) 
than control cells (71.5% vs 50.4%). These observations are also supported by 
the cell viability data in Figure 4.1, where there is a significant increase in cell 
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viability of SH-SY5Y and SK-N-BE(2) cells to over 100% at low doses of 
13cRA (<10μM). Additionally, from the slope of the curve, cell viability 
continues to remain above 100% in SH-SY5Y and SK-N-BE(2) up till 
approximately 20 and 25μM, respectively, which means the sub-optimal doses 
of 13cRA used here (15μM and 20μM) was within the dose range where cell 
viability was higher than no treatment control cells.  
Compared to the other treatment groups, there were more Annexin V stained 
cells, i.e. apoptotic cells, in both the γT3 individual and combination treatment 
groups in the SH-SY5Y cell line (Figures 4.14A and B) and in the SK-N-BE(2) 
cell line, there were more apoptotic cells in the γT3 combination treatment group 
than the other groups apart from ABT-263 (Figures 4.15A and B). There were 
also more necrotic cells in the PI positive quadrant (necrosis) of the γT3 
treatment groups in the SH-SY5Y cells than in the other groups Figure 4.14B).  
Tocotrienols, and specifically γT3, have been shown to cause apoptosis in other 
cancer cell lines, as well as the SH-SY5Y cell line. In a mitochondrial membrane 
potential measurement, a significant increase (p<0.05) in % cells containing 
green JC-1 monomer (an indication of apoptosis) was seen in SH-SY5Y cells 
treated with 15μM γT3 compared to the no treatment control (Tan et al., 2016). 
In another study, using Annexin V-FITC/PI, Abdul Rahman et al., (2014) found 
significantly more (p<0.05) SW1783 and LN18 glioma cells in early apoptosis 
when treated with γT3 compared to no treatment control. Additionally, they 
found a significant increase (p<0.05) in necrotic cells for the γT3 treatment group 
in the SW1783 cells compared to the control. In another study on the effect of 
γT3 on cancer cells, 67.7% (p<0.001) of U87MG glioblastoma cells showed 
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induction of G0/G1 cell cycle arrest  (apoptosis) after treatment with γT3 for 24 
hours, compared to control treatment (Abubakar, Lim, Kam, & Loh, 2017).  
This study therefore reflects previous work on the apoptotic effect of γT3. 
13cRA alone, especially at a low dose did not lead to apoptosis compared to γT3 
alone or in combination (Figures 4.14 and 4.15). The fact that the γT3 
combination group had a higher number of cells in the apoptosis stages than 
individual 13cRA and γT3 groups in both cell lines (Figures 4.14 and 4.15) is 
encouraging, as it lends support to the idea of enhancing the effects of 13cRA 
without increasing the dose, and with it, the side effects, by adding a low dose 
of γT3, many times lower than levels known to be toxic (Then, Mazlan, Mat 
Top, & Wan Ngah, 2009).  
There was also more apoptotic effect in the γT3 groups than in the ABT-263 
individual and combination groups in the SH-SY5Y cell line (Figure 4.14B), 
while in the SK-N-BE(2) cell line, the ABT-263 combination group showed a 
significant increase in late apoptotic cells compared to control (Figure 4.15B). 
While the SH-SY5Y cell line is not a cell line normally associated to treatment 
resistance, it is, as discussed in Section 4.1, uniquely non-sensitive to specific 
Bcl-2 antagonists such as ABT-263, due to its relatively (compared to primary 
tumours) low level of Bcl-2 expression (Lamers et al., 2012). Thus, while other 
treatments showed a more drastic shift in SH-SY5Y cell populations towards the 
apoptotic quadrants (Figure 4.14A), both ABT-263 treatment groups had more 
muted responses. In the SK-N-BE(2) cell line, the ABT-263 groups had more 
apoptotic cells than in the γT3 groups (Figure 4.15B). Comparing this to the 
lower numbers of apoptotic cells for the ABT-263 groups against the γT3 groups 
140 
 
in the SH-SY5Y cell line, it highlights the insensitivity of the SH-SY5Y cell line 
to Bcl-2 antagonists such as ABT-263. This insensitivity will be examined at a 
later point in the discussion. Despite the specific insensitivity of SH-SY5Y to 
Bcl-2 antagonists, ABT-263 has been shown to cause apoptosis in 
neuroblastoma cells with PI staining and analysis by flow cytometry showing an 
increase in sub-G1 fraction compared to control (Lamers et al., 2012).  
From the observations made in this study, it is clear that γT3 causes cell death in 
both neuroblastoma cell lines. Furthermore, when used in combination with 
13cRA, sub-optimal doses of both drugs can be used for a greater effect than 
when used individually, as seen in the cell cytotoxicity results. Based on the flow 
cytometry results, is not conclusive whether apoptosis is the definite mechanism 
of action of γT3 in neuroblastoma cells, due to statistical insignificance. 
However, using the observations here, as well as other studies (Abdul Rahman 
et al., 2014; Tan et al., 2016; Abubakar et al., 2017), there is good evidence to 
indicate that apoptosis is at least one of the mechanisms used by γT3 to kill 
neuroblastoma cell lines, and this should be further studied in additional 
experiments for confirmation, using different assays and more variety of cell 
lines.  
Although the experiments using Annexin V-FITC/PI and flow cytometry were 
used to confirm apoptosis as a possible mechanism of γT3 in neuroblastoma cell 
lines, that method would not give further details on the precise pathway 
involved. In order to do that, the effects of γT3 on protein expression were 
investigated, in vitro as well as in vivo.  
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The proteins of interest were chosen based on several factors, including past 
evidence that indicated that γT3 caused apoptosis in SH-SY5Y cell lines via the 
intrinsic apoptosis pathway, specifically as a BH3 mimetic that bound to the Bcl-
2 anti-apoptosis protein (Tan et al., 2016). Thus, we used Bcl-2 and caspases-9 
and -3. The activation of caspase-3 by caspase-9 in the intrinsic pathway is 
considered the initiation of apoptosis (Würstle et al., 2012). We also chose 
MYCN as its overexpression, and that of its gene, MYCN, is used as a clinical 
definition of high risk neuroblastoma (Cohn et al., 2009). The p53 protein was 
chosen because p53 is known to activate apoptosis due to external stress, and be 
involved in regulation of various components of the apoptosis cascade (Aubrey 
et al., 2018). Finally, Bcl-xL was used because ABT-263, used in this study as 
a Bcl-2 inhibitor, is also known to (to a lesser degree) affect the Bcl-xL protein 
(Mérino et al., 2012).  
In this investigation, the effects of γT3 and 13cRA, used alone and together, on 
those proteins, were assessed. Protein samples were obtained from both in vitro 
and in vivo sources and the changes or lack of changes were evaluated in order 
to further elucidate the mode of action of γT3 in neuroblastoma.  
 
5.2.3 Expression of apoptosis proteins 
5.2.3.1 MYCN 
In this study, we compared the expression of MYCN protein in two cell lines, 
SH-SY5Y and SK-N-BE(2), after individual and combination treatments of 
13cRA, γT3 and ABT-263. Like the study by Tan et al. (2016), we found that 
24 hours treatment of γT3 reduced MYCN expression in SH-SY5Y cells 
142 
 
compared to control (Figure 4.17A). However, unlike that study, the reduction 
here was slight and not statistically significant. In the SK-N-BE(2) cell line, there 
was a slight, statistically insignificant increase in MYCN expression after 
treatment with γT3 individually or in combination with 13cRA (Figures 4.18 and 
4.19A). Further study is required to determine if the difference in response is due 
to normal protein expression of cell lines, as these properties have been shown 
to significantly influence the response to treatments (Ham et al., 2016; Lamers 
et al., 2012). 
We also found that 13cRA, unlike ATRA, does not increase MYCN expression 
in SH-SY5Y cells (Figures 4.16 and 4.17A), which was what was observed by 
Tan et al. (2016). The same lack of change in MYCN expression after 13cRA 
treatment was also observed in SK-N-BE(2) cells (Figures 4.18 and 4.19A). 
Current known actions of retinoic acids on MYCN expression in neuroblastoma 
cells seem to vary. In contrast to the findings by Tan et al. (2016),  another study 
found that treating IMR-32 and Kelly neuroblastoma cells (both overexpress 
MYCN) with 100 nM ATRA for 6 days caused a visible drop in MYCN 
expression compared to no treatment control (Otsuka et al., 2019). The main 
differences between the study by Tan et al. (2016) and Otsuka et al. (2019) is 
that the former used a higher dose, 10 μM (although this dose is still considered 
low) compared to 100 nM, over a shorter time (24 hours vs 6 days), and SH-
SY5Y cells are non-MYCN amplified, unlike IMR-32 and Kelly cells.  
SH-SY5Y cell lines showed a statistically significant drop in MYCN expression 
after 24 hours treatment with ABT-263 (p≤0.05), both as a single agent or in 
combination with 13cRA (Figure 4.17A). There was no corresponding literature 
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that studied the SH-SY5Y cell line and MYCN expression after treatment with 
a Bcl-2 inhibitor such as ABT-263, however, we can extrapolate from a study 
by Ham et al. (2016), where the SK-N-F1 neuroblastoma cell line, which 
possesses wild-type MYCN, as does SH-SY5Y, did not show any visible changes 
in MYCN protein expression after treatment with ABT-199, a Bcl-2 inhibitor, 
of which ABT-263 is a predecessor. Unfortunately, the significant reduction in 
MYCN expression due to ABT-263 treatment cannot be explained at this point 
and more studies are needed to further elucidate the mechanism.  
In comparison, the MYCN amplified neuroblastoma cell line, SK-N-BE(2), used 
in our study did not show a notable change in MYCN expression after 24 hours 
treatment with ABT-263 (Figure 4.19A). This lack of change in MYCN 
expression in the SK-N-BE(2) cell line correlates with findings in the same study 
by Ham et al. (2016), which aimed to enhance the action of ABT-199 by 
combining it with other drugs. SK-N-BE(2) and other MYCN-amplified 
neuroblastoma cell lines were treated with ABT-199, but no significant changes 
in MYCN protein expression were observed with ABT-199 only treatment, 
although addition of other drugs with different targets did reduce MYCN levels. 
This would indicate that drugs that target Bcl-2 do not necessarily affect MYCN 
levels.  
Unfortunately, the in vivo samples did not yield any results for analysis with 
traditional western blot. However, we sent one set of protein samples (five 
treatment groups, including control) for analysis with a Jess capillary protein 
assay (Appendix B). As this assay only used one biological repeat, we cannot 
fully rely on the results. However, it showed no large changes of MYCN 
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expression in all treatment groups compared to control, except γT3 only, which 
almost doubled (Table B2). Chapter 5.4 will discuss future work, including an 
outline for specific investigations involving MYCN expression.   
 
5.2.3.2 Bcl-2  
Bcl-2 was identified as a possible target of the vitamin E isomer, γT3 (Tan et al., 
2016). Using simulated docking analysis, the study found that γT3 binds to the 
hydrophobic groove of Bcl-2, and the researchers proposed that γT3 acts by 
binding to anti-apoptotic Bcl-2, which is highly expressed in many cancers and 
prevents natural cell death. Thus, the Bcl-2 protein, and its expression following 
treatment with γT3, was of great interest to this study.   
In this study, Bcl-2 expression in SH-SY5Y cell lines after treatment with γT3, 
alone or combined with 13cRA did not change significantly when compared to 
control. The same observation was seen in the in vivo study, which used SH-
SY5Y cell lines for ectopic tumour induction. This lack of change in Bcl-2 
expression in the SH-SY5Y cell line was very similar to the observations in the 
study by Tan et al., (2016). In that study, the researchers also found insignificant 
changes in Bcl-2 expression after treating SH-SY5Y cell lines for 24 hours in 
γT3 alone or combined with ATRA. The groups with added retinoic acid for 
both this and the study by Tan et al., (2016) had very slightly higher Bcl-2 
expression than the γT3 only groups. However, the study focused on the binding 
assay results, which showed that γT3 was able to bind preferentially to the BH3 
domain in the Bcl-2 protein compared to αT3, and did not discuss the 
observations in Bcl-2 protein expression.  
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While there were no significant changes to Bcl-2 levels in the SH-SY5Y cell 
line, the ABT-263 alone and combined groups did appear to cause a non-
significant drop in Bcl-2 expression compared to control. It is interesting to note 
that the in vivo study, which used the SH-SY5Y cell line to induce tumour 
growth, also showed an insignificant change, but it was a very slight increase of 
Bcl-2 expression in the ABT-263 with 13cRA group. However, these results are 
supported by observations in the study by Van Goethem et al. (2017), where 
treatment with the similarly Bcl-2-selective drug ABT-199 did not cause any 
downregulation to Bcl-2 protein abundance compared to vehicle control. In fact, 
the Bcl-2 protein expression of SH-SY5Y, treated or untreated, was very low 
compared to several other neuroblastoma cell lines, although higher than many 
cancer cell lines, evidence of which was shown by another study on Bcl-2 
expression in neuroblastoma cell lines (Lamers et al., 2012). 
While the results in the SH-SY5Y cell line and tumours were all insignificant, 
the in vitro results of the SK-N-BE(2) cell line were not. Bcl-2 protein expression 
was significantly increased compared to control when cells were treated for 24 
hours with γT3 and 13cRA (p≤0.05), ABT-263 alone (p≤0.01), and ABT-263 
combined with 13cRA (p≤0.01). Bcl-2 after treatment with γT3 alone rose 
almost two times more than control, although this was insignificant, and 13cRA 
only treatment caused an also insignificant, but visible drop in Bcl-2 expression.  
As previously mentioned, Bcl-2 has an anti-apoptotic role (Czabotar et al., 
2014), and neuroblastoma cell lines with increased BCL2 expression were found 
to be resistant to common cytotoxic treatments (Dole et al., 1994), while 
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silencing BCL2 in neuroblastoma cell lines with high BCL2 expression lead to 
apoptosis (Lamers et al., 2012).  
A study by Lasorella et al., (1995) showed that when neuroblastoma cells are 
treated with low dose (5 μM) ATRA for 6 days, changes in cell Bcl-2 expression 
varies depending on specific cell line. The study showed that SH-SY5Y and SK-
N-SH cells responded with a substantial increase in Bcl-2 expression compared 
to no treatment control, while SMS-KCNR had about half the increase of Bcl-2 
compared to SH-SY5Y and SK-N-SH, and IMR-32 cells did not show a visible 
increase in Bcl-2 expression. While the first 3 cell lines showed evidence of 
differentiation after 6 days ATRA exposure, the IMR-32 cells did not 
differentiate.  
In addition to being used as a differentiating agent, retinoic acid, and in 
particular, 13cRA, is a known cause of apoptosis in many cancer cell lines. For 
example, using cell cycle and DNA analysis experiments, Toma et al. (1997) 
showed that 13cRA was an effective apoptosis-inducing drug in MCF-7 and 
MDA-MB-231 breast cancer cell lines, with cell populations in DNA histograms 
of 13cRA-treated cells showing a reduction of G1/G2 cells in the cell population, 
compared to control. Treatment with 1 μM of 13cRA for 6 days also resulted in 
reduced Bcl-2 protein for 13cRA-treated MCF-7 cells compared to untreated 
when analysed by immunofluorescence flow cytometry. Reduced Bcl-2 is an 
indication of improved apoptosis.  
In this study, the SK-N-BE(2) cell line was treated with 20 μM 13cRA over 24 
hours, which is both a higher dose and a shorter treatment period than for the 
MCF-7 cells in the abovementioned study. The reduction of Bcl-2 protein 
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(Figure 4.19), while not statistically significant, was still more than half of the 
protein expression in the vehicle control, which points towards treatment with 
13cRA alone demonstrating improved apoptosis in SK-N-BE(2), as shown in 
MCF-7 in the study by Toma et al. (1997).  
However, following that logic, the statistically significant increase of Bcl-2 in 
SK-N-BE(2) after treatments with γT3 combination, and ABT-263, alone and in 
combination, indicate that these treatments inhibit apoptosis. However, as seen 
in the cytotoxicity experiments, these treatments clearly reduce cell proliferation 
and while not statistically significant, did demonstrate an increase in apoptotic 
cells from the flow cytometry experiments.  
One factor that was not investigated in this study was the effect of these 
treatments on the protein expression of Bax. While a simple approach is to study 
only Bcl-2 protein expression, apoptosis is regulated by the interactions between 
the proteins, with Bcl-2 being anti-apoptotic and Bax pro-apoptotic. A change in 
the balance of both Bcl-2 and Bax can affect cell apoptosis. Bax is involved in 
the formation of channels in the mitochondrial membrane to allow cytochrome 
c release when apoptosis is triggered; however, this can be inhibited by 
overexpression of Bcl-2 (Teijido & Dejean, 2010). So, further studies should 
also investigate Bax protein expression. While the study by (Tan et al., 2016) 
did not show any conclusive effects on Bax protein expression after treatment of 
γT3 combined with retinoic acid, their retinoic acid of choice was ATRA, which 
has been shown to have different effects compared to the other commonly used 
isomer,  13cRA (Reynolds et al., 2003). Additionally, they only used SH-SY5Y 
cell lines, and as has been demonstrated here, as well as in published studies 
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(Lamers et al., 2012; Ham et al., 2016; Goldsmith et al., 2012) the choice of 
neuroblastoma cell line can vastly change treatment responses.  
An explanation for the statistically significant increased Bcl-2 expression after 
γT3 combination and ABT-263 single and combination treatment groups in the 
SK-N-BE(2) cell line is still unclear. However, binding of γT3 to the 
hydrophobic groove in the Bcl-2 protein was shown by in silico docking, and 
therefore further studies using a greater diversity of cell lines and further protein 
studies are necessary in order to comprehensively investigate the action of γT3 
in neuroblastoma.  
 
5.2.3.3 Other apoptosis proteins 
We evaluated protein expression levels in the tumour samples obtained from the 
in vivo study to investigate the hypothesised apoptosis caused by γT3. The 
proteins we chose to study were all proteins associated with apoptosis, in 
addition to Bcl-2, which was discussed in the previous section. The proteins 
discussed in this section are: p53, caspases-9 and -3 and Bcl-xL.  
Results from protein extracted from tumour samples showed only one 
statistically significant change in protein expression: caspase-9 in the 13cRA 
treatment group, p≤0.05 (Figures 4.22 and 4.23B). The other in vivo protein 
expression results were not significant, however those findings will nevertheless 
still be discussed in this section. 
Caspase-9 is part of a group of molecules known as “initiator caspases”, known 
as such because they activate the “effector caspases”, such as caspase-3, which 
149 
 
are directly responsible for morphological and biochemical changes that occur 
during apoptosis (Würstle et al., 2012). Precursor caspase-9 exists as a 46kDa 
protein, which is activated when Apaf-1 oligomerises (with cytochrome c and 
dATP) to form a large apoptosome complex. At the apoptosome complex, the 
activated caspase-9 activates procaspase-3, which goes on to execute apoptotic 
cell death. When caspase-9 dissociates from the apoptosome, it is deactivated 
(Kuida, 2000; Fesik, 2005; Würstle et al., 2012). In short, release of caspase-3 
is an indicator of the initiation of apoptosis, and activated caspase-9 is required 
in order to activate caspase-3. In this study, we observed the protein expressions 
of caspases-9 and -3 as markers of apoptosis. Both are common proteins used in 
apoptosis studies.  
In a study that used LA1-55n and SH-SY5Y neuroblastoma cells to examine the 
ability of the small molecule tolfenamic acid to improve the action of 13cRA on 
neuroblastoma, 20 μM of 13cRA alone was shown to cause significant caspase-
3 and -7 activation (p<0.05), when tested with a Caspase-Glo 3/7 kit (Shelake et 
al., 2015). As previously mentioned, caspase-3 is a downstream or effector 
caspase, activated by caspase-9. Release of caspase-3 is an indicator of the 
initiation of apoptosis, and activated caspase-9 is required in order to activate 
caspase-3 (Fesik, 2005; Würstle et al., 2012). The same study also used Annexin 
V-PE/7-AAD to investigate apoptosis in both cell lines, and found that addition 
of 13cRA caused a shift of the LA1-55n cell population from viable to late 
apoptosis (14.2% in 13cRA treated cells vs 3.2% in control cells).  
In comparison, although the 13cRA treatment group tumour samples in this 
study showed nearly 6 times more caspase-9 protein compared to control 
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(p≤0.05), there was also a slightly elevated, although not significant increase in 
caspase-3 protein (approximately 2 times more compared to control). Based on 
these results, none of the treatments used in this study caused apoptosis in the in 
vivo tumours.  
However, it should be noted that the caspase-3 used in this study was inactive 
(procaspase-3), so perhaps not fully reflective of the induction of apoptosis via 
either the intrinsic or extrinsic apoptosis pathways. As previously mentioned, 
activation of caspase-3 is a clear indicator of apoptosis induction, in addition to 
caspases-6 and -7 (Kepp et al., 2011; Würstle et al., 2012).   
The flow cytometry experiments showed only one statistically significant 
increase in apoptotic cells (late apoptosis, ABT-263 combination group), 
however, there was a visible increase (at least double) of apoptotic cells in the 
γT3 combination group in both SH-SY5Y and SK-N-BE(2) cell lines, compared 
to vehicle control (Figures 4.14 and 4.15). Although not conclusive, the pattern 
shown here suggests that further investigation into the apoptotic action of γT3 is 
necessary. For further evidence, using a caspase kit such as the one used by 
Shelake et al. (2015) for in vitro samples and an activated caspase-3 primary 
antibody to investigate protein expression from in vivo tumour samples may be 
helpful in fully understanding apoptotic action of γT3 in neuroblastoma.  
The tumour suppressor protein p53 is a known activator of apoptosis, and has 
been a focus of past research neuroblastoma (Van Goethem et al., 2017; Zhang 
et al., 2013; Chen et al., 2010). It is present in low levels in an unstressed state 
but accumulates when the cell is stressed, for example, following DNA damage, 
oncogene activation or nutrient suppression (Aubrey et al., 2018). Van Goethem 
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et al. (2017) found that suppressing the natural p53 inhibitor Mdm2 in 
neuroblastoma cell lines and orthotopic tumours led to inhibition of cell 
proliferation, and increased action of caspases-3 and -7 indicated that the mode 
of action was apoptosis.  
In this study, there were no statistically significant changes in p53 protein 
expression, when compared to the control group. However, all the treatment 
groups showed an increase in p53 protein expression compared to the control 
group (Figure 4.22A). Compared to the control group, p53 expression was 
increased by more than 5 times, while the γT3 combination group increased by 
just under 5 times, with a similar result from the ABT-263 combination group. 
γT3 alone showed the lowest increase in p53 expression at about 2.5 times more 
than control.  
In a study investigating retinoic acid treatment resistance, SH-SY5Y cell lines 
treated with 5 μM 13cRA for 72 hours showed increased cell viability by 
reducing p53 protein levels, although 5 μM 13cRA for 24 hours did not 
significantly affect p53 expression (Waetzig et al., 2019). However, lower doses 
of retinoic acid, such as 10 μM ATRA, over several days, have been commonly 
used to differentiate SH-SY5Y cells for investigations that require viable, 
neuron-like cells (Encinas et al., 2000; Jämsä et al., 2004; Dwane et al., 2013). 
The dose used in our study was 3 times higher than that used by Waetzig et al. 
(2019), and our study cells were only exposed to treatment for 24 hours. Perhaps 
the differences found between this study and that by Waetzig et al. (2019) could 
be therefore attributed to different dose and length of exposure to the treatment.  
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Tan et al. (2016) also found a statistically insignificant increase in p53 
expression when they treated SH-SY5Y cell lines with γT3 or γT3 combined 
with ATRA. However, unlike with 13cRA, ATRA alone did not show a change 
in p53 expression, when compared to the control group. Niizuma et al. (2006) 
concluded that neuroblastoma cells possess resistance against ATRA, but that 
study did not use 13cRA as a comparison.  Also, while ATRA and 13cRA are 
both retinoic acid isomers, and therefore have similar chemical properties, 
13cRA has been shown to have better in vitro activity in neuroblastoma cell lines 
than ATRA, because it acts as a prodrug for ATRA. This means more drug can 
be delivered into tumour cells, leading to higher potency (Reynolds et al., 1994). 
Therefore, an increase in p53 expression due to 13cRA treatment, in contrast to 
the lack of change due to ATRA treatment is not unexpected. The results for p53 
expression after treatment with γT3 is similar to the in vitro findings by Tan et 
al. (2016). Expression of p53 was increased in both studies by γT3 alone, as well 
as in combination with retinoic acid - 13cRA here, and ATRA in the study by 
Tan et al. (2016), and this increase was statistically insignificant in both studies 
when compared to untreated control.  
There were no significant changes in Bcl-xL protein expression from treated 
samples compared to vehicle control in this study. Bcl-xL is a member of the 
Bcl-2 protein family and was found to be expressed in most neuroblastoma cell 
lines, although expression levels of both Bcl-xL and Bcl-2 were variable (Dole 
et al., 1995). Additionally, the researchers inserted an expression vector 
containing Bcl-xL into the SHEP-1 neuroblastoma cell line, which normally 
expresses negligible levels of Bcl-xL, and found that sufficient levels of Bcl-xL, 
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like Bcl-2, were able to inhibit chemotherapy-induced apoptosis where the 
SHEP-1 cell line previously could not. 
We chose to study Bcl-xL protein expression because after Bcl-2, it is one of the 
most actively bound targets of ABT-263, although to a much smaller degree than 
Bcl-2 (Mérino et al., 2012).  Kunnumakkara et al. (2010) found that γT3 alone 
did not reduce levels of Bcl-xL in an orthotopic nude mouse model of human 
pancreatic cancer compared to vehicle only control, although neither did 
gemcitabine, which is commonly used in pancreatic cancer treatment. However, 
used together, there was a dramatic reduction in Bcl-xL expression, where the 
combination treatment band on the blot was almost entirely gone, compared to 
thick, visible bands for other treatment groups. The results found by both this 
study and Kunnumakkara et al. (2010) could mean that γT3 does not alter Bcl-
xL protein levels in either neuroblastoma or pancreatic cancer cell lines. Future 
studies investigating the mechanism of action of γT3 in both these cancers could 






5.3 GAMMA-TOCOTRIENOL EFFECTS IN VIVO  
 
One of our objectives was to assess anti-tumour effects of 13cRA and γT3 as 
single agents or in combination in a nude mouse model. We monitored the 
tumour development using both manual callipers as well as PET/CT scan. ABT-
263 combined with 13cRA was used as a selective Bcl-2 antagonist comparison 
to the γT3 combination with 13cRA.  
In this section, the effects of γT3 on the volume of an ectopic neuroblastoma 
tumour in a nude mouse model will be discussed, in addition to an evaluation of 
the non-invasive tumour monitoring methods used here.  
 
5.3.1 Effects on tumour volume 
Pre-clinical, in vivo studies in rodents are commonly used in cancer research and 
can be used to further our understanding of the actions of drugs and other 
substances of interest in a model more complex than a simple in vitro study 
(Workman et al., 2010). The in vitro study on effects of γT3 on the viability of 
neuroblastoma cancer cell lines produced promising results, including results 
that indicated that the addition of γT3 to 13cRA was synergistic, thus requiring 
lower doses of each drug in order to achieve a comparable or improved result. 
Due to this promising data, as well as the promise shown in the study by Tan et 
al. (2016), further experiments were conducted in order to study the effects in 
vivo. It should be noted that apart from the study by Tan et al. (2016), there have 
been no other published studies on the actions of tocotrienols on neuroblastoma, 
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either in vitro or in vivo. However, there are several in vitro and in vivo studies 
of the actions of tocotrienols, whether γT3 or TRFs, in other cancer models.  
The in vivo results showed that the combination of γT3 and 13cRA resulted in a 
significant reduction in tumour volume compared to the vehicle only control 
(p≤0.05), but was not shown by either the γT3 only or ABT-263 combination 
groups. Additionally, while the 13cRA only group also showed a significant 
reduction in tumour volume (p≤0.05), the final tumour volume in this group was 
still twice that of the γT3 combination group.  
While the γT3 only group showed very little reduction in tumour volume 
compared to the vehicle control group, the combination of γT3 and 13cRA had 
the lowest tumour volume out of the 5 groups and was statistically significant 
(p≤0.05). These results appear to confirm the in vitro results that showed a 
drastically improved degree of cytotoxicity of combined γT3 and 13cRA 
compared to individual treatments of both. A  similar study by Manu et al., 
(2012) also found that combining γT3 with another drug substantially improved 
the effects of the drug action compared to individual treatments. 
They treated SNU-5 gastric cancer ectopic tumours in athymic nu/nu mice with 
1mg/kg bodyweight of γT3, dissolved in corn oil and delivered via 
intraperitoneal (i.p.) injection 3 times weekly. This was given either alone or in 
combination with oral capecitabine (60mg/kg, oral). In their study, they found 
much better results with combined drug treatments compared to γT3 only. 
However, unlike in this study, the γT3 only group in the study by Manu et al., 
(2012) significantly reduced the tumour volume compared to control (p<0.001), 
and capecitabine alone was similarly effective compared to control (p<0.001). 
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However, the most dramatic reduction in tumour volume was seen in the γT3 
and capecitabine combination group, where tumour volume was approximately 
20 times smaller than control group (p<0.001), and approximately 5 to 7 times 
smaller than capecitabine only and γT3 only groups (p<0.001). This result was 
reflected in this study, where combining γT3 with the standard clinical treatment 
(13cRA) improved the effects.  
One main point of difference between this study and that by Manu et al., (2012) 
is that this study focuses on the post-consolidation stage of treatment (13cRA), 
while the study by Manu et al., (2012) focused on the induction chemotherapy 
(capecitabine). The post-consolidation stage of high-risk neuroblastoma 
treatment aims to treat any residual disease which was not successfully 
eliminated during earlier intensive treatment stages, with the aim being to 
prevent relapse (Smith & Foster, 2018). Capecitabine, as part of the first-line 
chemotherapy regimen in gastric cancer (Wagner et al., 2017), is normally used 
to target tumours rather than residual disease, and as such has higher efficacy (as 
well as toxicity) than 13cRA. So although the individual treatments in this study 
(γT3 or 13cRA) were not significant, while individual treatments in the study by 
Manu et al., (2012) were (γT3 and capecitabine) were, the relative change in 
tumour size reduction between individual and combination treatments for both 
studies were similar.  
Similar to the study by Manu et al., (2012), luciferase-transfected MIA PaCa-2 
pancreatic cancer cells were treated with either γT3 or a chemotherapy drug, or 
both together (Kunnumakkara et al., 2010). In this study, 400mg/kg/day of oral 
γT3 and the chemotherapeutic agent gemcitabine (25mg/kg, twice weekly, i.p.) 
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were used to treat orthotopic pancreatic cancer tumours, and at the end of the 
study, the researchers found that although the individual drug groups did not 
have any significant effects on the tumour volume, combined γT3 and 
gemcitabine made a significant change (p<0.001). This result, where the action 
of individual drug groups was improved upon combination, is similar to the 
results seen when combining 13cRA and γT3 in this study.  
In our study, all treatments, including γT3, were administered orally only after 
subcutaneous tumours reached a size of approximately 1 cm3, as described in 
Section 3.3.5.3. Our results therefore indicate that only the γT3 and 13cRA 
combination was able to stall further tumour growth, as final tumour volume of 
this treatment group was 1.10 cm3. The 13cRA only treatment group had a 
significantly smaller final tumour volume compared to the vehicle control group 
(2.20 cm3 vs 3.98 cm3, p≤0.05) but treatment with this group did not prevent 
tumour growth. Despite this, it should be noted that our study used solid tumours, 
while in a clinical setting, the use of 13cRA is to prevent relapse of tumour 
growth after chemotherapy and radiotherapy (Peinemann et al., 2015). In a 
clinical setting, 13cRA would only be used when there is minimal tumour 
presence, and the ability of retinoic acid to differentiate cancer cells is a major 
reason that its use was first proposed in trials to improve high risk neuroblastoma 
treatment protocols (Reynolds et al., 2003). Thus, it could be argued that because 
the addition of γT3 to 13cRA was able to reduce the size of a solid tumour, in 
vivo, significantly more than 13cRA alone, this could be a beneficial addition to 
13cRA in the maintenance stage of high risk neuroblastoma. 
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5.3.2 Tumour monitoring methods 
The in vivo protocol here used two methods to measure tumour growth in the 
mouse models: Vernier callipers and PET imaging Sections 3.34 and 3.3.7.3. 
Measurements using callipers were taken daily, while PET imaging was 
performed thrice per mouse – before tumour induction, just before treatment was 
initiated and at the end of the study.    
In the representative PET images in Figure 4.21, which was taken at the end of 
the study, tumours are visible, although the outlines are uncertain. This was a 
problem when calculating tumour volume using the Vivoquant software, as the 
software uses the relative tumour intensity compared to background intensity to 
calculate tumour volume. However, it is possible to visually evaluate the size 
difference, where the tumour in Figure 4.21A is distinctly larger than B, D and 
E, which correlates with calliper measurements used to calculate tumour volume, 
as shown in Figure 4.20. External calliper measurements, while unable to 
account for irregularities in tumour shapes, are currently the standard method for 
measuring tumour volume due to its simplicity, low cost and high throughput 
(Jensen et al., 2008). Therefore, the results of the tumour monitoring can be 






5.4 STUDY LIMITATIONS AND FURTHER WORK 
 
There were several limitations in the study that may have directly contributed to 
the insignificant findings. This section will identify and discuss those factors.  
5.4.1 Cell lines and Bcl-2 
One limitation in this study was the cell lines used. SH-SY5Y and SK-N-BE(2) 
were chosen as wild-type and MYCN amplified neuroblastoma cell lines, 
respectively. However, other characteristics of cell lines that need to be taken 
into consideration were only identified after completing this study.  
As previously discussed, neuroblastoma tumours are known to possess higher 
Bcl-2 expression than healthy tissues as well as other tumours (Goldsmith et al., 
2012). Neuroblastoma cell lines, such as SH-SY5Y were also considered to 
possess higher than normal Bcl-2 expression (Reed et al., 1991). More recent 
research however, has shown that most neuroblastoma cell lines have 
significantly lower Bcl-2 expression than primary neuroblastoma tumours and 
therefore are not accurate disease models (Goldsmith et al., 2012; Lamers et al., 
2012). The Bcl-2 expression most likely had a role in some of the more 
unexpected results.  
13cRA had the same IC50 for both cell lines, unlike γT3, which has a lower IC50 
in the SH-SY5Y cell line than SK-N-BE(2). This was unexpected because the 
SK-N-BE(2) cell line, as the high risk neuroblastoma model, should be more 
resistant to treatment. 
On the other hand, when treated with 13cRA, the complex changes in apoptosis 
signalling and differentiation at lower doses that increase cell viability that were 
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previously discussed in Section 5.1.1 (Waetzig et al., 2019; Hadjidaniel & 
Reynolds, 2010) might also contribute to higher cell viability than predicted in 
SH-SY5Y cell line.  
The effect of ABT-263 on cell viability, alone or combined with 13cRA, is not 
easily distinguishable between the two cell lines (Figures 4.3 and 4.6), unlike 
observations seen during the addition of γT3 to 13cRA (Figures 4.7 and 4.8). 
The calculated IC50 of ABT-263 was the same for both cell lines (40μM), and 
while the addition of ABT-263 to 13cRA treatment of both cell lines reduced the 
IC50 of 13cRA, it was not a significant reduction (Figure 4.9).  
Resistance to ABT-263 was expected in the SK-N-BE(2) cell line because of its 
MYCN amplification, which is a known cause of treatment resistance (Park et 
al., 2013). However, the SH-SY5Y cell line was expected to have a more 
prominent response to a Bcl-2 inhibitor because SH-SY5Y cell lines in particular 
are known to overexpress Bcl-2 (Reed et al., 1991), in addition to neuroblastoma 
tumours having higher Bcl-2 expression compared to other healthy tissues 
(Goldsmith et al., 2012). Therefore, using that logic to target Bcl-2 as a strategy 
to treat neuroblastoma, the theory was extrapolated to expect SH-SY5Y cell lines 
to be more sensitive to ABT-263 treatment than SK-N-BE(2) cell lines.  
Unfortunately, our study shows that while SH-SY5Y cell lines might have a 
higher Bcl-2 expression compared to many other cancer cell lines and healthy 
cells, this Bcl-2 expression may not be sufficiently high enough, a fact that was 
not identified when initially planning this study.  
Using Bcl-2 inhibiting drugs such as ABT-263 to treat neuroblastoma cell lines 
with high Bcl-2 protein expression caused apoptosis but did not have the same 
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effect in neuroblastoma cell lines with low Bcl-2 protein expression (Lamers et 
al., 2012). In their study, a panel of 24 neuroblastoma cell lines and 88 
neuroblastoma primary tumour samples were tested for Bcl-2 gene and protein 
expression. Results showed that while the majority of primary tumours have a 
high Bcl-2 protein expression, most neuroblastoma cell lines have comparatively 
lower Bcl-2 expression and out of the 24 cell lines studied here, including SH-
SY5Y, only two cell lines (KCNR and SJNB12) matched the levels of Bcl-2 
observed in the primary tumours.  
A later study using ABT-199, a newer, more specific Bcl-2 inhibitor than ABT-
263, showed that they could predict sensitivity to ABT-199 drug treatment based 
on Bcl-2 protein levels, as cell lines with lower levels of Bcl-2 were less sensitive 
to ABT-199. Bcl-2 protein expression of SH-SY5Y was significantly lower than 
in the CHP126 neuroblastoma line, which was reflected in the IC50 values of 
ABT-199: in the SH-SY5Y cell line, IC50 was 15.32μM compared to 0.01μM in 
the CHP126 cell line (Bate-Eya et al., 2016).   
ABT-263 alone was found to be ineffective in treating SH-SY5Y cell lines, and 
the hypothesis for this failure in treatment was due to another member of the 
Bcl-2 protein family, Mcl-1, which is also elevated to varying degrees in 
neuroblastoma cell lines and tumours. The researchers tested their theory by 
showing improved action (defined as induction of apoptosis and cell viability 
inhibition) of ABT-263 when paired with an norcantharidin, an anticancer drug 
linked to elevation of the endogenous Mcl-1 inhibitor, Noxa  (Wang et al., 2014). 
Another study that treated lymphoma in vitro and in vivo found that Mcl-1 
overexpression cause resistance to ABT-737 (van Delft et al., 2006).  
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SH-SY5Y cell lines also do express some degree of Mcl-1; the study mentioned 
earlier by Bate-Eya et al., (2016) found relatively higher levels of Mcl-1 
compared to Bcl-2 in SH-SY5Y cells, although this was not quantified. 
However, unlike SH-SY5Y, SK-N-BE(2) cell lines are considered Mcl-1 
dependent (and also overexpress MYCN protein) (Nalluri et al., 2015). Mcl-1 
knockdown in neuroblastoma cell lines that are normally resistant to therapy by 
Bcl-2 inhibitor (ABT-737), as well as other conventional chemotherapy, 
overcame the treatment resistance conferred by Mcl-1 (Lestini et al., 2009). So, 
the combined factors of treatment resistance, due to Mcl-1 dependence, in 
addition to overexpressed MYCN could account for the slightly lower effect of 
the Bcl-2 inhibitor ABT-263 to the IC50 of 13cRA when combined in the SK-N-
BE(2) cell line compared to SH-SY5Y (17.5% reduction in IC50 vs 27.5%) 
(Figure 4.9), while lower sensitivity of SH-SY5Y than predicted to ABT-263 
could be due to a combination of lower Bcl-2 expression than previously 
thought, combined with a possible resistance caused by some Mcl-1 expression.  
Due to protein expression and in silico docking results which showed that γT3 
binds to the hydrophobic groove of Bcl-2 to induce apoptosis via the intrinsic 
pathway (Tan et al., 2016), ABT-263, a selective Bcl-2 inhibitor was chosen as 
a comparison for the Bcl-2 action of γT3. However, once again, the low Bcl-2 
expression of this particular SH-SY5Y cell line, which was used to grow the 
xenografts in this mouse model, most likely contributed to the poor results of 
ABT-263. The results shown in Figure 4.20 reflect the observations documented 
by Lamers et al. (2012), as the final tumour volume from the ABT-263 
combination group was only just slightly higher than the 13cRA only treatment 
group, and both were not significantly less compared to the vehicle control.  
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The importance of Bcl-2 expression to treatments in high risk neuroblastoma 
cannot be conclusively evaluated in this study due to the Bcl-2 levels in the 
chosen cell lines. Ideally, future work would use cell lines grown from primary 
tumours. An alternative plan would be to transfect SH-SY5Y with a Bcl-2 
expression vector, in a similar manner as the low Bcl-xL-expressing SHEP-1 
cell line in the study by Dole et al. (1995), which would then cause SH-SY5Y to 
express higher levels of Bcl-2. On the other hand, neuroblastoma cell lines that 
have Bcl-2 levels comparable to that of neuroblastoma tumours have been 
identified (Lamers et al., 2012). Both SMS-KCNR and SJNB12 cell lines were 
shown to have comparable Bcl-2 expression to tumours, and SMS-KCNR has 
MYCN amplification (Beppu et al., 2005), while SJNB12 does not have MYCN 
amplification (Shapiro et al., 1993). The contrasting MYCN status of the cell 
lines is still important, as MYCN amplification is a commonly recognized 
classification factor for high risk neuroblastoma (Cohn et al., 2009).  
5.4.2 PET/CT imaging and tumours 
Another part of this study that could be improved is the method of tumour growth 
monitoring in the in vivo experiment. While external callipers are the most 
convenient and affordable method to detect ectopic tumours, they are still less 
accurate and reproducible compared to PET imaging (Jensen et al., 2008).  
According to some published work, PET imaging has been successfully used to 
monitor tumour xenograft progression in small animals, including A431 
epidermoid carcinoma and U251 glioblastoma cells in SCID mice (Fueger et al., 
2006), tumour metabolism in genetically engineered mouse lung cancer models 
(Wang et al., 2015), and a combination of orthotopic SK-N-BE(2)c 
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neuroblastoma tumours with patient derived neuroblastoma tumour explants in 
mice (Braekeveldt et al., 2015).  
However, while the study by Braekeveldt et al. (2015) was able to successfully 
produce images of neuroblastoma tumours in mice, the tumour images in this 
study were much fainter than that of other tissues such as heart and other muscles 
(Figure 4.21 and Figure C1)). An important fact to consider is that the tumours 
used by Braekeveldt et al. (2015) were orthotopic. In a study that compared 
MDA-MB-231-H2N breast cancer tumours in mice that were either implanted 
subcutaneously (ectopic) or in the mammary fat pad (orthotopic), investigators 
found that orthotopic tumours grew faster and furthermore, possessed better 
vascular permeability compared to ectopic tumours. FITC-dextran, injected i.v., 
accumulated more in orthotopic tumours compared to similarly sized ectopic 
tumours, and immunostaining also showed better vascular density in orthotopic 
tumours (Ho et al., 2012). As previously described, PET imaging utilises the 
higher glucose uptake of cancer cells compared to normal cells that results in 
accumulation of positron emissions (from 18-FDG) at the tumour, which can be 
detected by a PET scan (Koba, Jelicks & Fine, 2013). 18-FDG is injected (either 
i.v. or i.p.), and therefore a higher number of blood vessels would improve 
glucose uptake, as demonstrated by the FITC-dextran experiment (Ho et al., 
2012). A lower 18-FDG uptake, leading to lower positron emission by tumours 
in this study could therefore simply be explained by inadequate tumour 
vascularisation.  
One potential way to overcome the vascularisation shortcoming would be to use 
bioluminescence imaging. This imaging technique was found to be superior to 
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both PET and ultrasound imaging when used to detect early tumour formation 
and growth in a rat liver carcinoma in vivo model (Hwang et al., 2015) and . This 
method has been used successfully to monitor tumour growth in mouse models 
of a variety of cancers, using cell lines that were stably transfected with 
luciferase reporter gene: acute myeloid leukaemia (Konopleva et al., 2006), 
pancreatic (Kunnumakkara et al., 2010) and colorectal (Prasad et al., 2016). 
Bioluminescence imaging also carries lower health and safety risks than PET 
imaging as it does not require use of radioactive substances such as 18-FDG, and 
is superior to external calliper measurements as this imaging method is suitable 
for use in both ectopic and orthotopic tumours (Koba et al., 2011). Additionally, 
future experiments could also consider the use of orthotopic tumours instead of 
ectopic, as this would provide better clinical representation (Huynh et al., 2011). 
We were unable to use orthotopic tumours for several reasons, including a lack 
of facilities and expertise to induce orthotopic tumours, as well as regulations by 
The University of Nottingham Animal Ethic Committee that require orthotopic 
studies to be preceded by ectopic studies.  
5.4.3 Cell death assays 
The cell death experiments, LDH assay and flow cytometry, could be better 
supported with expanded protein expression studies, or an additional apoptosis 
assay such as the TUNEL (terminal deoxynucleotidyl transferase-mediated 
dUTP nick-end labelling) assay. Due to higher sensitivity than other methods, it 
is considered the gold standard to detect apoptosis in situ, although drawbacks 
include false positives from necrosis and sample handling (Galluzzi et al., 2009). 
It would work well as an additional assay as it is not recommended to rely on it 
as the sole apoptosis assay (Kepp et al., 2011). Further evidence for presence or 
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absence of apoptosis can be collected with other methods, such as protein 
expression studies, i.e. Western blot.  Due to factors such as human error, relying 
on just one or two methods may not be sufficient, resulting in statistically 
insignificant results and/or  large error bars (Figures 4.10 to 4.13).  
Protein expression studies here were not completely conclusive, and the scope 
of proteins studied requires expansion. One way to overcome this limitation 
would be to include Bax, in order to calculate a Bcl-2/Bax ratio, as a better 
representation of cell survival after γT3 treatments, as demonstrated in past 
research (Then et al., 2009; Tan et al., 2016). The complex relationship between 
Bcl-2 and Bax was also described Cory and Adams (2005), and how 
understanding the interaction and balance of both these proteins played a role in 
establishing Bcl-2 as a valid target in cancer therapy. In addition to different 
proteins assayed, transferring the protein from the gel to the membrane in wet 
conditions rather than semi-dry is considered more reliable (Yang & Mahmood, 
2012), and could be the preferred future method. We also trialled a protein 
capillary assay called Jess (Appendix B), which is another potential method for 
protein assay. 
For more efficient identification of caspase alterations, a caspase assay kit such 
as that used by Tan et al. (2016) could be used. However, for results that are 
more conclusive than those presented in this study, both the activate and inactive 
forms of caspase-3 should be studied, as the trigger for apoptosis is the activation 
of inactive procaspase-3 (Würstle et al., 2012). This approach was used in a 
study investigating effects of cytotoxic drug treatments against neuroblastoma 
cell lines, and the vehicle only control cells did not express cleaved caspases, 
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unlike the treated cell lines (Fang et al., 2011). The incorrectly used caspases 
here was simply due to oversight when planning the experiment.  
Apart from caspases, cytochrome c can also be studied as an indicator of 
initiation of apoptosis. Furthermore, as cytochrome c must be released from the 
mitochondria in order to continue the intrinsic apoptosis cascade, samples could 
be separated into cytoplasmic and organelle fractions in order to compare 
different treatment effects (Lamers et al., 2012). 
Other proteins from the Bcl-2 protein family could be included in a future study. 
Mcl-1 is also found to be overexpressed in various neuroblastoma cell lines, and 
was shown to be linked to some treatment resistance (van Delft et al., 2006; 
Lestini et al., 2009). It would be interesting to study not only the protein 
expression of Mcl-1 in neuroblastoma after treatment with γT3 but also to 
investigate possible affinity of γT3 for Mcl-1. As γT3 is known to have multiple 
targets (Kannappan et al., 2012; Tham et al., 2019), a future in silico docking 
study to investigate its binding affinity should be conducted with more proteins, 
such as Mcl-1 and Bcl-xL, both of which have similar actions as Bcl-2, and have 
already been studied together as therapeutic targets of the Bcl-2 antagonist, 
ABT-199 (Bate-Eya et al., 2016).  
In addition to traditional qualitative and quantitative methods of evaluating 
protein expression, a possible future experiment would be to study interactions 
between Bcl-2 pro-survival and BH3-only proteins to compare the effects of 
different treatments. The quantitative, high-throughput method uses fluorescent 
fusion proteins of the proteins of interest, and their interactions are viewed using 
confocal microscopy. According to the researchers, they were able to view the 
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movements of proteins in the cytoplasm and mitochondria, as well as quantify 
fluorescent intensity from each cell compartment (Wong et al., 2012a).  
Finally, future studies should consider the use of ABT-199 instead of ABT-263, 
as not only has it been shown to be the most selective of Bcl-2 compared to ABT-
263 and ABT-737 (Souers et al., 2013), it has recently been approved for use in 
several types of leukaemia, making it more relevant clinically (Bohl, Bullinger 
& Rücker, 2019; Wei et al., 2019). ABT-199 was developed from ABT-263, and 
stocks of ABT-263 had already been purchased and in vitro studies began when 






CHAPTER 6  CONCLUSION 
At the beginning of this study, a list of aims and objectives was made that had to 
be fulfilled in order to investigate our hypothesis. This hypothesis was composed 
of several parts. First, we hypothesised that γT3 has significant anti-tumour 
effects on neuroblastoma, and that combining it with a current drug treatment 
for high risk neuroblastoma would have a synergistic effect. Finally, we 
hypothesised that γT3 binds to the hydrophobic groove of Bcl-2 in order to 
initiate the intrinsic apoptosis cascade, and that due to this binding, γT3 would 
show similar, although less significant anti-tumour effects when compared to the 
Bcl-2 inhibitor ABT-263.  
The addition of γT3 to 13cRA adjuvant therapy in high risk neuroblastoma may 
be beneficial, based on the in vitro and in vivo results obtained in this study. In 
vitro results showed very significant improvements when treating both SH-
SY5Y and SK-N-BE(2) cell lines with combined γT3 and 13cRA compared to 
individual treatments, as seen in raw MTS and LDH assay results. Additionally, 
combination index analysis proved that the combination of γT3 and 13cRA was 
clearly synergistic. Furthermore, the in vivo results showed that addition of γT3 
was able to significantly reduce tumour volume compared to vehicle only and 
individual treatments, as well as compared to the Bcl-2 inhibitor, ABT-263.   
While in silico docking evidence (Tan et al., 2016) may have indicated that Bcl-
2 alone was a clear lead towards determining the mode of action of γT3 in its 
anticancer properties for treating neuroblastoma, the evidence here is less clear. 
The investigation here focused on the intrinsic apoptosis pathway, due to 
evidence from past research. Flow cytometry with Annexin V-FITC/PI staining 
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showed that the combined γT3 and 13cRA treatments in both SH-SY5Y and SK-
N-BE(2) cell lines increased the number of apoptotic cells slightly more than 
other treatment groups, but this increase was not statistically significant. When 
comparing single treatments against combination, combined γT3 and 13cRA in 
both cell lines caused a greater level of apoptosis than single agents, although 
once again, this was not statistically significant. Western blot of tumours 
obtained from the in vivo experiment also did not show conclusive results 
regarding caspase-9, caspase-3 or p53 protein expression after treatment with 
γT3. There were also no conclusive results for Bcl-2 and Bcl-xL protein 
expression for γT3 treatments in either in vitro or in vivo samples, although the 
combination γT3 treatment did significantly increase Bcl-2 expression compared 
to untreated control in the SK-N-BE(2) cell line.  Overall, these results are 
indicative of γT3 possibly using apoptosis to kill neuroblastoma cells, as 
although flow cytometry analysis showed a visual increase in apoptotic cells, 
this was not statistically significant. And while protein expression results were 
inconclusive for all proteins studied, using the activated forms of caspase-9 and 
-3 could potentially give clearer results than what was obtained here.  
Due to the importance of the role of overexpressed MYCN in high risk 
neuroblastoma, MYCN protein was investigated using Western blot in both in 
vitro and in vivo samples. There was a slight and statistically insignificant 
decrease in both single and combination γT3 treatment groups in the SH-SY5Y 
cell line but a statistically significant increase for the same groups in the SK-N-




As a final conclusion, γT3 could potentially be used in combination with 13cRA, 
as part of the high risk neuroblastoma maintenance therapy, as it has shown 
significant anti-tumour effects on neuroblastoma, both in vitro and in vivo. This 
γT3 combination treatment had a synergistic effect and showed more significant 
anti-tumour effects on neuroblastoma cell lines and an in vivo tumour model than 
the selective Bcl-2 inhibitor ABT-263. However, based on the current evidence, 
it is not possible to conclusively identify the mechanism of action of γT3 as 
binding to the Bcl-2 protein in the intrinsic apoptosis pathway. Although these 
results were still indicative of apoptosis, further work is required to further 




Figure 6.1: Summary of study findings: γT3 and 13cRA has anti-cancer 
effects in vitro and in vivo. However, the mechanism of action 
cannot yet be confirmed based on the results of this study and 
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Table A1:  Signs of pain and distress in laboratory rodents and lagomorphs (Baumans et al., 1994) and additional note from The University 






Reduced weight gain or weight loss of up to 
10% 
 
Weight loss of up to 20% 
Weight loss greater than 25% 
 
Food and water consumption 40-70% of 
normal for 72hrs 
Food and water consumption <40% of normal 
for 72hrs 
Food and water consumption less than 40% 
for 7 days 
Partial piloerection 
 
Staring coat and marked piloerection 
Anorexia (total inappetence) for 72 hrs 
 
Subdued but responsive, animal shows 
normal provoked patterns of behaviour 
Subdued animal shows subdued behaviour 
patterns even when provoked 
Staring coat –marked piloerection with other 
signs of dehydration such as skin tenting 
Interacts with peers 
 
Little peer  interaction  
Unresponsive to extraneous activity and 
provocation 
 
Transiently hunched especially after dosing 
 
Hunched intermittently 




Intermittent vocalisation when provoked 







Oculo-nasal discharge transient (typical 
signs of chromorhinodacryorrhoea in 
rodents) 
Oculo-nasal discharge persistent 

















No prostration Transient prostration  (<1hr) 
Prolonged prostration (>1hr) 
 




Note: Action required at the University of Nottingham: 
The clinical signs listed represent the upper limit of severity in each category. 
Observation of a combination of signs of moderate severity should result in immediate action such as cessation of dosing, amelioration of the signs 
by treatment, euthanasia. The Named Persons or their nominees should be informed. 
Observation of a single clinical sign from the substantial severity limit should result in immediate action (usually euthanasia). The Named Persons 







JESS PROTEIN ASSAY  
Jess protein analysis is an automated western blotting process that uses a 
capillary based system to reduce time and reagents compared to traditional 
western blot. Furthermore, the automation reduces many steps that may cause 
errors, as well as reduces the amount of protein sample required (Lück, Haitjema 
& Heger, 2021).  
The western blot results from the tissue samples were not very conclusive 
(Figure 4.22). However, we still had a small amount of protein from the tumour 
tissues. Additionally, we wanted to attempt using activated caspases instead of 
the procaspases. Due to the limited time and tissue samples, we chose to consult 
a professional service (Biomed Global) that would carry out the Jess assay for 
us. This assay was carried out in order to both assess the usefulness of the Jess 
system in our lab, as well as to add to the current data we obtained from 
traditional western blot.  
 
Method 
Protein samples from ectopic tumours were extracted and protein concentration 
determined as described in Sections 3.3.8.2 and 3.3.8.3, respectively.   All five 
treatment groups from the in vivo study were assessed: no vehicle control, 
13cRA only, γT3 only, γT3 and 13cRA, and ABT-263 and 13cRA (Section 3.3). 
The following polyclonal antibodies were used: 
Table B1: Details of primary antibodies used in Jess Protein Assay  
Antibody Cat. No. Manufacturer Dilution 
Factor 
MW 
Caspase-9 E-AB-63242 Elabscience 1:10 37kDa/47kDa 
Cleaved-
CASP3 p17 
E-AB-30004 Elabscience 1:10 20-32kDa 
p53 E-AB-32469 Elabscience 1:10 43-44 kDa 




The amount of protein required for each sample was 3µg, and each sample was 
diluted in 0.1X sample buffer and then denatured at 95°C for 5 minutes, and then 
vortexed and spun down.  and the ProteinSimple Jess system (Bio‐Techne, USA) 
was loaded according to the microplate layout in Figure B1, as provided by 







Figure B1: Layout of Jess automated system microplate. The microplate was laid out with wells from A1 to F25, with reagents and/or samples 
transferred to each well as per the manufacturer’s protocol. Samples, each containing 3µg of protein each were added to wells in 
row A2-21. Rows 22 to 25 were no lysate controls for each antibody. Protein normalization reagent was added to row B for automatic 
normalisation when the software analyses the bands. Row C contained antibody diluent (10µL/well). Four antibodies were used at 
a 1:10 dilution (row D), while secondary anti-rabbit antibodies provided in the kit) were added to row E. Row F contained the 
luminol. Finally, A1 contained 5µL of the biotinylated ladder (12-230kDa) and E1 had 10µL Streptavidin-NIR, a fluorescence biotin 




After the microplate was filled as per Figure B1, the plate was centrifuged for 5 
minutes at 1000xg at room temperature before being placed into the Jess 
automated system. The microplate was read using the fluorescence 
immunoassay setting with Compass Software (Bio‐Techne, USA) and after the 
run was complete, image analysis was also performed using Compass Software. 
Protein normalisation is automatically calculated by the software. Biomed 









Figure B2: Effect of 13cRA and γT3, alone and in combination, and ABT-263 
in combination with 13cRA, compared to vehicle only control on protein 
expression of (i) caspase-9, (ii)cleaved caspase-3 p-17, (iii) p53 and (iv) MYCN, 
in ectopic tumours grown in nude mice from an SH-SY5Y neuroblastoma cell 





Table B2: Summary of relative density values, obtained from Jess protein 
assay. Samples were obtained from ectopic mouse tumours 
(grown from SH-SY5Y  cell lines) and subjected to 5 treatment 
groups, including untreated control. No statistical test performed 
as n=1. 
 
Density (relative units) 
  








1.00 1.28 1.39 1.09 1.53 
caspase-9 
(47kDa) 
1.00 1.03 0.98 0.88 1.00 
caspase-3 1.00 0.73 1.26 0.80 0.71 
p53 1.00 0.87 1.50 0.82 1.09 














Figure C1: Representative images obtained from PET/CT scan and 
processed by Vivoquant software to show signal intensity. From 
left to right: whole mouse (viewed from above), then sagittal, 
coronal and transversal slices. Tumour is indicated by yellow 
dashes. The colour bars on the right show intensity of 18-FDG: 
blue indicates no signal while yellow/white show high signal 
intensity. Treatment group: (i) vehicle only control; (ii) 13cRA 
(53mg/kg); (iii) γT3 (80mg/kg); (iv) γT3 (80mg/kg) and 13cRA 
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